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ABSTRACT OF THE DISSERTATION 
OVERWEIGHT/OBESITY AND HIV DISEASE PROGRESSION IN HIV+ ADULTS IN 
BOTSWANA 
by 
Sabrina Sales Martinez 
Florida International University, 2015 
Miami, Florida 
Professor Adriana Campa, Major Professor 
Studies indicate that overweight and obesity protect against HIV-disease 
progression in antiretroviral therapy (ART)-naïve patients. We examined retrospectively 
the relationship of overweight/obesity with HIV-disease progression in ART-naïve HIV+ 
adults in Botswana in a case-control study with 18-month follow-up, which included 217 
participants, 139 with BMI 18.0-24.9 kg/m2 and 78 with BMI ≥25 kg/m2.   Archived 
plasma samples were used to determine inflammatory markers: leptin and bacterial 
endotoxin lipopolysaccharide (LPS), and genotype single nucleotide polymorphisms 
(SNPs) of the Fat Mass and Obesity Associated Gene (FTO).  
 At baseline, BMI was inversely associated with risk for AIDS-defining conditions 
(HR=0.218; 95%CI=0.068, 0.701, P=0.011), and higher fat mass was associated with 
reduced risk of the combined outcome of CD4+cell count ≤250/µL and AIDS-defining 
conditions, whichever occurred earlier (HR=0.918; 95%CI=0.847, 0.994, P=0.036) over 
18 months, adjusting for age, gender, marriage, children, and baseline CD4+cell count 
and HIV-viral load.    
FTO-SNP rs17817449 was associated with BMI (OR=1.082; 95%CI=1.001, 
1.169; P=0.047). Fat mass was associated with the risk alleles of rs1121980 (OR=1.065; 
95%CI=1.009, 1.125, P=0.021), rs8050136 (OR=1.078; 95%CI=1.021, 1.140; P=0.007), 
 vi 
and rs17817449 (OR=1.086; 95%CI=1.031, 1.145; P=0.002), controlling for age, gender, 
tribe, total energy intake, and activity. There were no associations of SNPs with markers 
of disease progression.  
 Leptin levels were positively associated with BMI (β=1.764; 95%CI=0.788, 2.739; 
P=0.022) and fat mass (β=0.112; 95%CI=0.090, 0.135; P<0.001), but inversely with viral 
load (β=-0.305; 95%CI=-0.579, -.031; P=0.030). LPS levels were inversely associated 
with BMI (OR=0.790, 95%CI=0.630, 0.990; P=0.041), and fat mass (OR=0.852, 
95%CI=0.757, 0.958; P=0.007) and directly with viral load (OR=2.608, 95%CI=1.111, 
6.124; P=0.028), adjusting for age, gender, smoking and %fat mass. 
  In this cohort, overweight/obesity predicted slower HIV-disease progression. 
Obesity may confer an advantage in maintaining fat stores to support the overactive 
immune system.  FTO-SNPs may contribute to the variation in fat mass; however, they 
were not associated with HIV-disease progression.  Our findings suggest that the obesity 
paradox may be explained by the association of increased LPS with lower BMI and 
higher viral load; while viral load decreased with increasing leptin levels.  Studies in 
African populations are needed to clarify whether genetic variation and inflammation 
mediate the obesity paradox in HIV-disease progression.  
 vii 
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CHAPTER I: INTRODUCTION 
Statement of Problem 
The prevalence of obesity is increasing worldwide, including developing African 
nations.1,2  Botswana is experiencing an increase in obesity, which is also observed 
among the HIV+ adults.3  At the same time, Botswana is experiencing one of the worst 
epidemics of HIV with a prevalence rate of 23.0% among those between the ages 15 to 
49 years.4 An obesity paradox has been documented in many conditions including HIV, 
where those who are obese may have a survival advantage or improved disease 
outcomes.5  It is described as paradox in HIV since obesity has been associated with 
higher CD4 cell counts and delayed time to AIDS defining conditions.6-9  Studies on HIV 
and obesity are mainly conducted in settings where the patients are treated with 
antiretroviral therapy (ART), and where being or becoming obese is a disadvantage for 
physical and mental reasons, as obesity increases the risk for comorbidities with 
confounding findings and interpretations.10,11  In addition, inflammation accompanies 
both obesity and HIV disease, and its role in HIV disease progression has not been 
described in the ART naïve population, specifically as related to markers of inflammation 
such as Leptin, C-reactive protein and immune activation and bacterial 
lipopolysaccharide (LPS) endotoxin.  
Genetics has a strong influence on obesity12 which has been estimated to 
account for 40-70% of the variation in human adiposity.13 The association of the Fat 
Mass and Obesity Associated (FTO) gene has been reported to be strong with obesity, 
however, it has not been replicated in all populations and currently there are no 
published studies on the FTO gene variants in HIV disease or in a population in 
Botswana.  
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The objective of this study was to examine the relationship between 
overweight/obesity and HIV disease progression, inflammatory markers, and SNPs of 
the FTO gene in HIV+ adults who are not on ART in Botswana.   
 
Significance of Study 
The proposed research is important since there are several studies in the literature 
indicating that overweight or obesity provides some protection from accelerated HIV 
disease progression,6-9  but the potential mechanisms for such relationships are lacking. 
This study design allows for the examination of the effects of HIV before ART initiation to 
obtain a better understanding of how obesity and genetic factors are interrelated and 
affect HIV disease progression.  In addition, as HIV becomes a chronic disease with the 
advent of more effective and accessible treatments, and the risks for obesity and its 
comorbidities increase, recognizing genetic susceptibility for obesity will help design 
interventions that are tailored to an individual’s genetic variations.14   
The evidence from the literature generates the following questions:  
• Is the “obesity advantage” related to the genetically acquired energy efficiency, 
regardless of fat accumulation, or it is associated with fat accumulation that 
provides a protection to rapid wasting, which is one of the most powerful signs of 
HIV-disease progression and associated with shorter time to death?  
• Could it be the result of both factors?  
• How does the interaction of obesity and HIV affect inflammation and the immune 
response? 
• Could those without a genetic risk for obesity benefit from early aggressive 
nutrition intervention and ART to prevent wasting?  
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Botswana is one of the first resource-limited countries to provide ART on a sizeable 
scale,15 however, many countries, especially in sub-Saharan Africa, still have challenges 
in providing ART and maintaining adherence.16  Of the 21.2 million people in Africa 
eligible for ART under the 2013 WHO guidelines, only 7.6 million are receiving ART.17 
Therefore, acquiring information on factors that may delay disease progression and 
possible mechanisms related to these risks is significant and timely.  Moreover, the 
findings from this study could be translated and contribute towards clinically relevant 
recommendations.  
 
Innovation 
This is the first study exploring the role of genetic susceptibility to obesity as a positive 
factor to delay HIV disease progression in ART naïve patients.   
In the following three studies, hypotheses were tested and results presented as research 
papers.  
 
Specific Aims and Hypothesis 
CHAPTER III: EFFECT OF BMI AND BODY COMPOSITION ON HIV DISEASE 
PROGRESSION IN HIV INFECTED ART NAÏVE ADULTS IN BOTSWANA 
Specific Aim 1:  To determine the relationship between being overweight/obese (BMI ≥ 
25 kg/m2)  and HIV disease progression (CD4 cell count, HIV viral load and AIDS 
defining conditions) in HIV+ asymptomatic adults in Botswana not on antiretroviral 
therapy (ART) over 18 months.  
Hypothesis 1a:  (Primary outcome) The overweight/obese group will present 
less clinically significant CD4 cell count decline from Baseline (≥ 25%) over 18 
months than the normal weight group. 
Hypothesis 1b: The overweight/obese will have significantly lower levels of HIV 
viral load over 18 months than the normal weight group. 
Hypothesis 1c:  Significantly less AIDS defining conditions will occur over 18 
months in the overweight/obese group compared to the normal weight group. 
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CHAPTER IV:  PRELIMINARY ASSOCIATION STUDY OF THE FAT MASS 
AND OBESITY GENE POLYMORPHISMS WITH HIV DISEASE 
PROGRESSION 
 
Specific Aim 2: To determine the interrelationships among being overweight/obese, 
markers of genetic propensity for obesity (single nucleotide polymorphisms (SNPs) in 
FTO) and HIV disease progression (CD4 cell count, HIV viral load and AIDS defining 
conditions) in HIV+ asymptomatic adults in Botswana not on ART over 18 months.  
Hypothesis 2a: The FTO gene SNPs will be associated with being 
overweight/obese. 
Hypothesis 2b: The FTO gene SNPs will be associated with delayed HIV 
disease progression over 18 months. 
Hypothesis 2b1: The FTO gene SNPs will be associated with 
significantly higher CD4 cell count. 
Hypothesis 2b2: The FTO gene SNPs will be associated with 
significantly lower HIV viral load. 
Hypothesis 2b3: The FTO gene SNPs will be associated with 
significantly less AIDS-defining conditions.  
 
CHAPTER V: ASSOCIATION OF INFLAMMATORY MARKERS WITH BODY 
COMPOSITION AND HIV DISEASE PROGRESSION IN ART NAÏVE HIV+ 
ADULTS IN BOTSWANA 
 
Specific Aim 3: To evaluate the relationship between the inflammatory markers (leptin, 
C-reactive protein and bacterial lipopolysaccharide) and HIV disease progression in 
HIV+ asymptomatic adults not on ART in Botswana over 18 months. 
Hypothesis 3a:  Higher levels of leptin, C-reactive protein and bacterial 
lipopolysaccharide will be associated with significantly faster HIV disease 
progression. 
Hypothesis 3a1: Higher levels of inflammatory markers will be 
associated with lower levels of CD4 cell count.  
Hypothesis 3a2: Higher levels of inflammatory markers will be 
associated with higher HIV viral load.  
Hypothesis 3a3: Higher levels of inflammatory markers will be 
associated with greater AIDS-defining conditions. 
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Table 1: Statistical Analysis of Hypotheses  
Hypothesis Dependent 
Variable 
(Outcome 
Variable) 
Measurement 
of Dependent 
Variable 
Type of 
Dependent 
Variable 
Independent 
Variable 
Measurement 
of 
Independent 
Variable 
Type of 
Independent 
Variable 
Statistical Analysis
1a CD4 cell 
count 
(decrease of 
≥ 25%) 
CD4 cell count 
in blood 
Dichotomous 
variable (0=no 
decrease ≥ 25% 
and 1=yes 
decrease       
≥ 25%) 
Body Mass 
Index (BMI) 
BMI measured 
as weight in 
kg/ height in 
meters 
squared 
Dichotomous 
variable (0=BMI 
18.0-24.9kg/m2 
and 1=BMI ≥ 25 
kg/m2) 
Proportional Hazard 
Survival Model will be 
performed to compare 
hazard ratios on time to 
event (CD4 cell count 
decrease ≥ 25%) over 18 
months.  
1b HIV viral load HIV viral load in 
blood 
Continuous 
variable 
Body Mass 
Index (BMI) 
BMI measured 
as weight in 
kg/ height in 
meters 
squared 
Dichotomous 
variable (0=BMI 
18.0-24.9kg/m2 
and 1=BMI ≥ 25 
kg/m2) 
Pearson and Spearman 
correlations, as deemed 
appropriate and 
scatterplots will be 
performed to evaluate the 
relationship between HIV 
viral load and BMI groups.  
Linear regression will be 
used to examine the 
relationship between HIV 
viral load, at baseline and 
18 months, and BMI 
groups  
1c AIDS 
Defining 
Conditions 
Presence of 
AIDS Defining 
Condition 
Recorded by 
Study Physician 
Dichotomous 
variable (0=no 
and 1=yes) 
Body Mass 
Index (BMI) 
BMI measured 
as weight in 
kg/ height in 
meters 
squared 
Dichotomous 
variable (0=BMI 
18.0-24.9kg/m2 
and 1=BMI ≥ 25 
kg/m2) 
Proportional Hazard 
Survival Model will be 
performed to compare 
hazard ratios on time to 
event (AIDS defining 
conditions) over 18 
months.  
2a Body Mass 
Index (BMI) 
BMI measured 
as weight in kg/ 
height in meters 
Dichotomous 
variable (0=BMI 
18.0-24.9kg/m2 
and 1=BMI ≥ 25 
Genotypes 
for FTO 
SNPs 
5 Genotypes 
for FTO SNPs 
determined by 
TaqMan 
Dichotomous 
variable (0=non-
risk alleles and 
Logistic Regression will 
be performed to see the 
relationship between FTO 
SNPs and BMI groups. 
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squared kg/m2) Discrimination 
Assay 
1=risk allele) Cox Proportional Hazard 
Survival Model will be 
performed to compare 
hazard ratios on time to 
event (BMI ≥ 25 kg/m2) 
over 18 months. 
2b1 CD4 cell 
count  
CD4 cell count 
in blood  
Continuous 
variable  
Genotypes 
for FTO 
SNPs 
5 Genotypes 
for FTO SNPs 
determined by 
TaqMan 
Discrimination 
Assay 
Dichotomous 
variable (0=non-
risk alleles and 
1=risk allele) 
Pearson and Spearman 
correlations, as deemed 
appropriate, will be 
performed to evaluate the 
relationship between 
markers of disease 
progression (CD4 cell 
count and HIV viral load) 
and FTO SNPs. Logistic 
regression will be used to 
examine the relationship 
between markers of 
disease progression and 
FTO SNPs over 18 
months. 
2b2 HIV viral load HIV viral load in 
blood 
Continuous 
Variable 
Genotypes 
for FTO 
SNPs 
5 Genotypes 
for FTO SNPs 
determined by 
TaqMan 
Discrimination 
Assay 
Dichotomous 
variable (0=non-
risk alleles and 
1=risk allele) 
Pearson and Spearman 
correlations, as deemed 
appropriate, will be 
performed to evaluate the 
relationship between 
markers of disease 
progression (CD4 cell 
count and HIV viral load) 
and FTO SNPs. Logistic 
regression will be used to 
examine the relationship 
between markers of 
disease progression and 
FTO SNPs over 18 
months. 
2b3 AIDS Presence of Dichotomous Genotypes 5 Genotypes Dichotomous Logistic Regression will 
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Defining 
Conditions 
AIDS defining 
conditions 
recorded by 
study physician 
variable (0=no 
and 1=yes) 
for FTO 
SNPs 
for FTO SNPs 
determined by 
TaqMan 
Discrimination 
Assay 
variable (0=non-
risk alleles and 
1=risk allele) 
be performed to see the 
relationship between 
AIDS defining conditions 
and FTO SNPs. Cox 
Proportional Hazard 
Survival Model will be 
performed to compare 
hazard ratios on time to 
event (AIDS defining 
condition) over 18 
months. 
3 Leptin, CRP 
and LPS 
Plasma leptin 
and LPS 
measured with 
ELISA and 
plasma high 
sensitivity CRP 
provided from 
parent grant  
Continuous 
Variable 
CD4 cell 
count, HIV 
viral load 
and AIDS 
Defining 
Conditions 
CD4 cell count 
and HIV viral 
load in blood 
and presence 
of AIDS 
defining 
conditions 
recorded by 
study 
physician 
Continuous 
variable for CD4 
cell count and 
HIV viral load 
Dichotomous 
variable for AIDS 
Defining 
Conditions (0=no 
and 1=yes) 
Pearson and Spearman 
correlations, as deemed 
appropriate, will be 
performed to evaluate the 
relationship between 
inflammatory markers and 
markers of disease 
progression (CD4 cell 
count and HIV viral load).  
Student’s t-test will be 
performed to compare the 
differences in 
inflammatory markers and 
presence of AIDS defining 
conditions. Linear and 
logistic regressions will be 
used to examine the 
relationship between 
inflammatory markers and 
markers of disease 
progression over 18 
months.  
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Potential Mechanisms for the Obesity Paradox 
BMI does not differentiate between fat and lean body mass and cannot account for 
the quantity of adiposity of an individual.5  Some investigators have suggested the use of 
waist circumference as a measurement of body fat distribution instead of BMI since it 
has been shown to be associated with all-cause mortality6 and inflammatory markers7,8 
independent of BMI.  Visceral or abdominal adiposity has been shown to be associated 
with an inflammatory state,9 however, BMI does not indicate fat distribution in visceral, 
peripheral or lower body. Therefore, the positive outcomes in the overweight/obese 
populations that have been observed may be due to variations of body fat mass and 
presence of a higher proportion of lean body mass.  
Bacterial lipopolysaccharide or LPS is an endotoxin and a stimulator of inflammatory 
cytokine production and lipoproteins can bind LPS.  Models of endotoxaemia in mice 
and rats have shown that lipoproteins such as LDL, VLDL, HDL, triglycerides and 
chylomicrons can affect LPS bioactivity.10-13  Although obesity is associated with an 
increase in inflammation, there may be an obesity paradox present in some conditions 
where a reduced inflammatory response is observed.  This hypothesis has been coined 
the “endotoxin-lipoprotein hypothesis.” 14  The theory is that LPS binds to lipoproteins 
through the generation of micelles, therefore reducing cytokine proliferation and 
inflammation.15   Rauchhaus et al.10 proposed that higher levels of cholesterol may be 
beneficial since lipoproteins can moderate the inflammatory immune response.  
 Valentijn et al.,4  also considers genetics as a possible explanation for the survival 
advantage in overweight/obese.  Genetic polymorphisms may have variable effects on 
body composition through its effect on food intake, energy expenditure and BMI.16  
These variable effects may produce differing survival effects in the overweight/obese 
populations. 
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 This study examined the obesity paradox in a Botswana population with HIV and 
ART naïve.  The impact of obesity on HIV disease progression over time were explored.  
The relationship between being overweight/obese and HIV disease progression and its 
interrelationship between genetic propensity for obesity and inflammatory markers was 
investigated.   
 
Obesity in Botswana 
Growth in economy, urbanization, and diminished physical activity is contributing to a 
rise in obesity in African countries, such as Botswana.17 The prevalence of overweight 
and obesity in 2011 were different throughout sub-Saharan Africa and generally was 
higher in women compared to men.17 Botswana has the following rates of overweight 
(18.5-24.9 kg/m2): 53.5% in women and 41.6% in men, and obesity (>25 kg/m2) 17.7% in 
women and 6.9% in men.18   A nationally representative study19 showed that 
approximately 23.3% of women were overweight compared to 12.9% in men, and 15.7% 
of women compared to 3.2% of men were obese. The mean BMI for women and men 
were 24.4 kg/m2 and 21.7 kg/m2 respectively.  Increasing age and education was 
associated with higher BMI.  BMI increased in women with high parity and remained 
constant for men.  Data on overweight and obese and its relationship to health outcomes 
are lacking in the general and HIV populations in Botswana.  
 
HIV and Obesity 
In 2008, an estimated 1.4 billion people around the world were obese and about 
65% of the population in the world live in countries where more people die from being 
overweight and obese than from being underweight.20   An increase of obesity has also 
been observed in HIV+ adults, especially when on antiretroviral treatment (ART),21 and 
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rates of obesity are more common now than the occurrence of wasting in developed 
countries.22,23  It’s been estimated that in sub-Saharan Africa 10% of women had a BMI 
of less than 18.5 kg/m2 with wasting still prevalent in some areas.24  However, sub-
Saharan Africa is experiencing a nutrition transition with a rapid rise in overweight and 
obesity.25 Studies conducted to investigate obesity and its effect on HIV disease 
progression have so far been inconclusive, with some studies reporting an association 
and others reporting no association between CD4 cell counts, a measure of HIV disease 
progression, and obesity. 21, 26-29 
 
HIV Disease Progression and Obesity 
Studies have shown that obesity may be protective of further HIV disease 
progression before initiation of ART.  Jones et al.27 showed in 871 women who were 
recruited from a multicenter prospective cohort in the United States (US) that a higher 
baseline BMI was associated with a lower chance of reaching CD4 cell count <200 
cells/µL for the first time.  All women were ART naïve at baseline.  A higher BMI was 
also negatively associated with experiencing HIV-related events, with a 3.1 times greater 
odds of HIV-related death in the lowest BMI category compared to those in the highest 
category (95% CI, 1.2–8.1).  An average change in CD4 cell count of 1.65 cells/µL per 
unit change in BMI (95% CI, 0.05–3.25) was experienced and the authors indicated that, 
positive changes in BMI tended to be associated with positive changes in CD4 cell 
count, even controlling for previous CD4 cell count and BMI, albeit not significant.  Shor-
Posner and colleagues26 studied 125 HIV+ ART naïve adults in Miami, Florida. They 
followed over 18 months HIV+ obese (BMI >27kg/m2) adults.  Patients had proportionally 
lower clinically significant decrease in CD4 cell count (decrease of > 25% cells from 
baseline) in obese than nonobese HIV+ adults (18.8% vs.60.5%, p=0.004).  In addition, 
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BMI during the 18 months was negatively associated with death, even after adjusting for 
CD4 cell count of < 200 cells/µL at baseline.  Shuter et al.28 through a retrospective 
review of 189 medical records from New York, showed that being overweight was 
independently associated with lack of an AIDS diagnosis before clinic enrollment 
(OR=3.16; CI: 1.44, 6.96).  In addition, lower baseline BMI and decreasing BMI during 
follow-up were independently predictive of advancement to AIDS.  
Currently, only one study has shown that immune markers (CD3, CD8, and total 
lymphocyte counts) were associated with obesity in HIV+ ART treated adults with 
undetectable viral loads.  Adeyemi et al.29 conducted a study with 216 HIV+ patients with 
diabetes in Chicago and  demonstrated that obese patients (BMI 30-39.9kg/m2)  had 
CD3 counts 26% higher than patients with normal BMI (p=0.004) and CD8 counts 28% 
higher (p=0.01), after controlling for age, sex, ethnicity, renal function, A1C, and duration 
since HIV diagnosis. The result may also be evaluated in a dose-response manner as an 
absolute increase in CD3 counts of 27 and CD8 of 16 for every increase of 1 kg/m2 in 
BMI. There was also a 17% higher total lymphocyte count among the obese patients due 
to the higher CD3 and CD8 cells after controlling for the same covariates (p=0.04). 
Availability of longitudinal studies on BMI and HIV disease progression are 
lacking. A study conducted by Crum-Cianflone et al.30 compared immune cell counts and 
BMI in 1,097 HIV+ patients in seven centers throughout the US in the pre-ART and ART 
eras. They showed that, at the time of HIV diagnosis, white blood cell count and immune 
counts (CD4, CD8, CD4/CD8 ratio, CD3, CD19 and CD56) were not statistically 
significant by BMI categories.  In a longitudinal analysis those diagnosed in the pre-ART 
era had less mean postdiagnosis decreases in white blood cell count, total lymphocyte 
count, CD4 cell count, CD4%, and CD4/CD8 ratio as BMI category increased (all with 
P<0.05). Obese participants who were diagnosed in the ART era had significantly higher 
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increases in CD4 cell counts, CD4% and CD4/CD8 ratio (all with P<0.05) compared to 
normal weight participants. A longitudinal retrospective study in HIV+ ART naïve 
individuals in South Carolina who were starting ART was conducted by Johnson et al.31 
They demonstrated that when comparing normal weight individuals, those who were 
obese had larger increases in CD4 cell count (5.5 cells/uL, P<0.001).  Mean CD4 cell 
count in the obese group was higher at diagnosis (611.2 cells/µL) than the normal weight 
group (550.5 cells/µL, P<0.019).  Excess weight in the pre-ART era and even after 
initiation of ART seems protective of disease progression and contributes to immune 
recuperation, possibly by preserving energy and nutritional stores in order to deal with 
HIV and AIDS-related illnesses.  
Factors associated with weight gain were investigated in a study conducted by 
Tate et al.32 The participants included in the study were from Alabama, ART naïve and 
initiating ART. Over two years, the prevalence of overweight/obesity increased from 45% 
to 56%. Those with a BMI of <18.5 kg/m2 had lower CD4 cell counts and higher viral 
load at baseline (P<0.05) at baseline than the rest.   Greater increases in BMI were 
observed in patients with baseline CD4 count <50 cells/µL and boosted protease 
inhibitor use, but did not account for all of the variation observed in weight change.  
Obesity was highly prevalent, however, and the study did not examine how weight gain 
affected disease progression.  
The protective effect provided by obesity has been hypothesized to be related to 
extra available energy in the form of fat available for use in time of crisis during the HIV 
disease that would spare protein’s use33 and also help to preserve the immune system, 
especially innate immunity that is not directly affected by the infection.28,34  HIV and its 
secondary infections are known to generate a hypermetabolic state that is sustained 
throughout the disease.35 The HIV patient is susceptible to infections, in which the body 
 16 
 
will require energy to battle continuous infections and immune activation.  Those who 
are obese may also have a genetic advantage in maintaining fat stores and utilizing 
energy more efficiently to fuel the immune system.  Mechanistic studies in this area are 
needed.  
 
HIV Disease Progression and Body Composition 
 Although BMI can provide a simple measure of obesity, its association with body 
fat mass can vary by age, gender, race/ethnicity, and degree of fitness.36,37  Measuring 
body composition to be able to differentiate between body compartments such as lean 
body mass and fat mass can provide useful information and can be easily completed 
with the use of bioelectrical impedance (BIA). A safe electric current can be sent through 
the body to measure resistance and body fat will provide more resistance than lean 
mass.  With the use of equations body fat can be estimated.38 In addition, BIA can 
provide an estimate of the amount of intracellular and extracellular water and 
metabolically active tissues, known as body cell mass. In HIV, BIA has been shown to 
be an effective approach to detect total and area specific fat mass.39 While alterations in 
body composition, also known as HIV associated lipodystrophy syndrome (HALS)40, 
have been well-documented in patients taking ART, alterations in body composition and 
its association to HIV disease progression in ART naïve patients are not as well known.  
 Some studies have shown significant associations between body composition 
measurements and HIV disease progression in ART naïve adults.  In a study conducted 
by Swanson et al.,41 in 56 HIV infected women in Chicago, bioelectrical impedance was 
used to characterize body composition and examine its relationship with measures of 
HIV disease. Correlations were found with positive associations with CD4 cell count and 
fat-mass adjusted for height (r=0.32, P=0.01). Body cell mass adjusted for height was 
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also correlated with viral load (r=0.32, P=0.05).  Visnegarwala and colleagues42 
analyzed gender differences in body composition and stage of HIV disease in 422 HIV+ 
ART naïve adults from patients recruited in 15 US cities.   In men, body cell mass was 
inversely associated with prior AIDS defining conditions (coefficient -1.7kg, P<0.005) and 
HIV viral load (-0.92 kg, P=0.02).  In women, those with prior AIDS defining conditions 
had lower total body fat (-9.54 kg, P<0.005) and total body fat was also associated with 
CD4 cell count (+1.64 kg, P=0.02). Hamill et al.43 compared body composition in South 
African women with CD4 cell count >350 cells/µL (n=74) and low CD4 cell count (~200 
cells/µL) (n=74).  Those with CD4 cell count >350 cells/µL had significantly higher fat-
mass in kg (P<0.001) and lean body mass in kg (P=0.005).  In addition, the group with 
higher CD4 cell count had a higher fat mass squared/lean body mass squared ratio 
(P=0.002).   They concluded that biological variations between men and women may 
have contributed to the different findings with the different body compartments and 
disease progression parameters.  The studies conducted on body composition in ART 
naïve HIV infected adults had a cross-sectional design and included populations in the 
US.  Changes may occur through time in body composition that may ultimately have an 
effect on HIV disease progression.  
 
The Fat Mass and Obesity Associated (FTO) Gene in African Populations 
 The Fat Mass and Obesity Associated (FTO) gene was first identified in 200744 
and has been associated with obesity and obesity related traits.45,46 The gene was 
originally found in mice and was responsible for the fused toe (Ft) phenotype and also 
provided the gene its name.47 The hypothalamus is the site where the FTO gene is 
mainly expressed48 and may be involved in energy homeostasis,49 and fat cell lipolysis 
which may regulate body fat.50 Specifically, the single nucleotide polymorphism (SNP) of 
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the FTO gene rs9939609 A allele is most commonly associated with obesity. 44,46,51  Five 
of the SNPs previously shown to be associated with BMI were included in this study 
(rs9939609, rs1421085, rs8050136, rs17817449, and rs1121980). Currently, there are 
no published studies on the FTO gene and its association to obesity and adipokines in 
HIV+ patients or in a population in Botswana.   
 Henning and colleagues52 were the first to investigate the polymorphisms of the 
FTO gene in an African population.  The effect of the FTO gene on BMI was assessed in 
2208 slender Gambian children and adults.  In adults, BMI and weight for height was not 
associated with any of the genotypes of the FTO gene.  In addition, the 95% confidence 
interval of the effect size for variant rs9939609 did not correspond to that of Europeans 
reported in other research studies.  The findings of this study may not be relevant to 
other populations where obesity is prevalent or an abundance of food is available.  
 Adeyemo et al. 53 conducted a study that assessed the genetic variation in the 
FTO gene in 517 West Africans and 968 African Americans and its association to 
obesity as measured by BMI, waist circumference and fat mass percentage.  The variant 
of the FTO gene rs9939609 did not show any associations with obesity in the two 
populations, however two other gene variants rs1121980 and rs7204609 were 
associated with obesity in the West African participants (p<0.05). 
 A genetic association study completed by Lombard et al,54 assessed the 
association of SNPs from FTO and other obesity related genes with BMI in 990 black 
adolescent South Africans.  Seven FTO SNPs were included; rs9939973, rs9940128, 
rs1421085, rs1121980, rs17817449, rs8050136, and rs9939609. The FTO SNP 
rs1781749, the minor allele or G, was associated with increased BMI (effect size 1.9, 
p<0.05) after adjusting for sex, age, and pubertal age.  Sex specific associations were 
not found with SNPs of the FTO gene. In a model that included the SNPs for FTO 
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rs1781749, LEP (leptin) rs10954174, LEP rs6966536, and MCAR (melanocortin 4 
receptor) rs17782313 the effect size for the FTO SNP was 2.2, p=0.007. This finding 
was adjusted for age, sex and sex-specific pubertal age.  The effect corresponded to the 
estimated percent change in BMI of each allele independent of the covariates.  Based on 
the available data from studies on FTO, the most common SNP rs9939609 was not 
associated with BMI in the African populations but concluded that more studies are 
needed to investigate these relationships in other African populations. The results from 
this study are relevant to Botswana, who are closely related culturally and genetically to 
South Africans, with whom they share borders, language and ancestors.55  However, 
Botswana and other African nations are known to be a heterogeneous population with 
many ethnic groups.56    Replication studies in diverse African populaces are need to 
identify the SNPs that may cause the variations seen in obesity relevant to the pertaining 
population.  GWAS studies in African populations are lacking to identify novel SNPs that 
are appropriate to the population is of importance.     
 
The Fat Mass and Obesity Associated (FTO) Gene and HIV Disease Progression  
 Currently, in the literature there are no know studies evaluating markers of HIV 
disease progression and SNPs of the FTO gene in an HIV mono-infected population. 
Recently, Pineda-Tenor et al.57 carried out a cross-sectional study in 261 HIV/HCV co-
infected participants in Spain.  Those with the rs9939609 AA genotype had higher levels 
of BMI (p=0.016) when compared to the AT/TT genotypes remained significant after 
adjusting for age, gender, markers of HIV disease progression, markers of HCV disease 
progression, liver fibrosis and ART.  However, the genotypes for rs9939609 were not 
associated with CD4 cell count or HIV viral load.   
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Obesity and Inflammation 
 Inflammation is a condition in which the homeostasis between pro and anti-
inflammatory markers in the body are out of balance and may lead to a prolonged stage 
of inflammation which in turn may affect the progression or outcomes of many conditions 
and/or diseases.58  Obesity is known to be associated with a chronic state of low grade 
inflammation. Inflammation in obesity is due to many mechanisms which include 
disordered secretion of adipokines within adipose tissue resulting in insulin resistance 
and metabolic disorders.59  Adipokines can affect many processes in the body such as 
metabolism, growth, blood pressure, vascularization, coagulation and inflammation and 
a variation in fat mass can change their production.60 It has also been shown that an 
accumulation of macrophages occurs in obesity and this affects the increased release of 
TNF-α, a pro-inflammatory cytokine.61  TNF-α release, mainly derived from 
macrophages, initiates a pro-inflammatory cascade of events and can block insulin 
activity leading to insulin resistance.62  Obesity may also reduce the production of other 
inflammatory products as a result of the “endotoxin-lipoprotein hypothesis.”14   Higher 
levels of lipoproteins are usually found in obesity which can bind bacterial endotoxin 
such as LPS therefore affecting the release of pro-inflammatory cytokines.   There is 
conflicting information in the literature regarding obesity and inflammation, which 
requires further research.   
 
HIV Disease Progression and Inflammation 
 Diminishing CD4 cells is one of the main features of HIV progression and 
eventually the diagnosis of AIDS. There are many mechanisms described as to why a 
loss of immune related cells occur in HIV and inflammation is a key culprit. Loss of 
immune function in HIV may be due to a persistent immune activation.  Inflammation is 
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involved in the depletion of T-cells, and chronic immune activation drives the general 
and HIV-specific losses of immune function.63   Continuous inflammation induces pro-
inflammatory cytokines which has been shown to produce thymic and T cell progenitor 
dysfunction.64  It has also been shown that triggered or activated CD4 cells are a favored 
target for viral infection and replication.  Inflammation may also set up non-infected CD4 
cells and other immune cells for death by programmed cell death or apoptosis.65 This 
constant state of inflammation also predisposes the patients to the occurrence of non-
HIV related complications such as cardiovascular disease.66  The role of obesity in 
inflammation in HIV infection is not clear and the literature is contradictory, therefore, it is 
important to examine the interrelationships that exist between inflammation, obesity, and 
HIV disease progression to elucidate the potential mechanisms involved and how it 
could later be translated into clinically relevant recommendations.  
 
Pro-Inflammatory Markers  
Leptin 
 Adipocytokines or adipokines are biologically active molecules that are secreted 
by adipocytes.67 Adipose tissue, now deemed to be an endocrine organ,68 secretes 
hormones such as leptin that may play an important role in body weight regulation.69  
Leptin was the first adipokine to be isolated and it is involved in weight, inflammatory, 
and immune regulation. Leptin is considered to be pro-inflammatory and can increase T 
cell activation and cytokine release proliferation thereby promoting a Th1 response.69   
Leptin levels are increased in obesity and have been shown to also act upon monocytes 
and prompt the release of cytokines such as TNF-α or IL-6.70 Serum levels of leptin are 
proportional to body fat mass.71  Females tend to have higher levels of leptin due to 
higher body fat mass, and sex steroids may also increase leptin mRNA levels72,73  The 
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adipose tissue of obese individuals contain a larger amount of macrophages that when 
activated will secrete cytokines such as TNF-α and IL-6.74  
 Leptin as a proinflammatory cytokine may have effects on the innate and 
adaptive immune responses. It has been suggested that leptin does not begin an 
immune response but instead may impact the outcome by inducing proinflammatory 
cytokines from different cell types, such as T cells.75 Inflammatory stimuli such as 
lipolysaccharide (LPS), a bacterial endotoxin, increases leptin gene expression and its 
concentration rapidly increases after the first stimulus.  LPS binds to a Toll-like receptor 
on adipose cells and expression of other toll-like receptors occurs, which then increases 
the release of leptin and other inflammatory cytokines.76 Leptin also binds to CRP during 
an immune response.77  Leptin deficient mice have shown impaired responses to 
microbial pathogens such as tuberculosis.75,78  Therefore, leptin plays an important role 
in the immune system and may respond differently depending on the stimuli.  
 Leptin is considered to be a pleiotropic molecule with not only metabolic roles but 
also endocrine and immune regulation.79   Higher levels of leptin in some studies have 
been shown during infection and inflammation, however the results in human studies 
have been inconsistent in various diseases, including HIV.79   Leptin is involved in the 
proliferation of T- cells including CD4 and CD8 cells.80  In addition, leptin has anti-
apoptotic properties for many cell types including lymphocytes.81  Higher levels of leptin 
found in obese individuals82 may enhance the immunity through its role in proliferation 
and anti-apoptotic effects on lymphocytes.  The interplay between leptin and the immune 
response is an area of importance in HIV as it may assist in determining possible 
mechanisms for the protective effect of obesity often seen in HIV.  
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HIV Disease Progression and Leptin in HIV ART Naïve  
 Most of the research on adipokines, like leptin, and HIV have been conducted in 
ART treated patients and information on how leptin affects HIV disease progression in 
HIV ART naïve is lacking.   Below are a few of the studies conducted on ART naïve 
participants, however, some of the findings still remain inconclusive.  
Changes in body fat distribution such as, lipodystrophy, is common in ART 
treated HIV+ persons.  This side effect is closely associated with the use of Protease 
Inhibitors (PIs).83 Leptin levels are decreased in HIV associated lipodystrophy and the 
metabolic or immunological effect is only shown once the patients become 
hypolipidemic.84 The action of leptin is affected by ART.83   
 Prabha and colleagues85 investigated the role of leptin levels in the coinfection of 
HIV and tuberculosis (TB) in 20 HIV infected ART naïve participants, 20 HIV and TB 
infected ART naïve participants and 20 healthy controls in India. Mean serum levels of 
leptin in the group with HIV and TB was significantly lower than that of the control HIV 
group and healthy control group (p<0.01). Women had higher levels of leptin than men 
in all groups, which included the HIV control group (14±4 vs. 5±1, p<0.01).  In all groups 
leptin increased consistently with BMI and in all groups combined for every unit increase 
in BMI a 1.8 fold increase was observed in leptin.   CD4 cell counts and leptin were not 
statistically correlated in any group, even after adjusting for BMI.  
 A study conducted in Nigeria by Onyemelukwe et al.86 examined serum leptin 
levels in ART naïve HIV infected adults in relation to BMI, CD4 cell count, asymptomatic 
and symptomatic HIV and AIDS.  Groups for this study included 26 healthy HIV negative 
controls, 20 normal weight participants, and 20 underweight participants. The median 
serum leptin levels was lower in the normal weight group and underweight group 
compared to the control group (Z=-2.26, p=0.024 and Z=-2.56, p=0.009 respectively). 
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The median leptin level of symptomatic participants were lower compared to 
asymptomatic participants (27.9 ng/mL IQR=4.9-36.4 vs. 43.7 ng/mL IQR=11.8-48.2, Z=-
2.07, p=0.038). Leptin levels were lower in the AIDS cases compared to the non-AIDS 
cases (22 ng/mL, IQR=3.8-40 vs. 35 ng/mL, IQR=25.9-45.6) but was not statistically 
significant.  Female HIV+ participants had lower median leptin levels as compared to 
male HIV+ participants (7.42 ng/mL IQR=3.2-44.3 vs. 35.6 ng/mL IQR=27.7-43.2, 
p=0.05). In this study, HIV+ participants with normal weight had similar leptin levels as 
the healthy HIV negative controls unless there was a difference in weight or symptomatic 
HIV related conditions.  
Azzoni et al,87 investigated the association between HIV viral load, cellular 
activation, and adipose tissue related measures in 83 HIV infected ART naïve South 
African women with a CD4+ cell count of 200-350 cells/µL.  The results showed that 
women with high viral load (> study median) had a higher BMI, waist circumference, 
subcutaneous abdominal fat, and trunk fat mass. Leptin levels were associated with BMI 
(r = 0.699, p<0.001), visceral abdominal fat (r = 0.542, p<0.0001) and total fat mass, (r = 
0.764, p<0.001). In a multivariate regression model the relationship between leptin levels 
and log10 viral load remained (effect estimate = -0.0186653, p = 0.03), even after 
controlling for subcutaneous abdominal fat area.  These results support a direct 
association between leptin levels and HIV viral replication, independent of the amount of 
adipose tissue.  Since these women were ART naïve, they may have been newly 
infected which would explain the higher viral load and the reason they may be healthier 
suggested by the higher BMI and fat mass. The data may also suggest that the cytokine 
dysregulation produced by obesity and related to inflammation might not be the source 
of the protective effect of obesity previous to ART.  Instead, the energy advantage may 
delay wasting and maintain an active innate immune response.  The studies discussed 
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above have limitations that warrant further research, including small sample sizes, 
inconsistent findings, and cross-sectional design.  Although, some studies include 
African populations, heterogeneity in Africans is present and including other nations 
would provide relevant information to their respective regions.  
 
The Fat Mass and Obesity Associated (FTO) Gene and Leptin  
 Obesity affects the release of adipokines such as adiponectin, leptin, cytokines 
IL-6 and TNF-α from adipose tissue which may further lead to fat deposits.88   
Contradictory evidence of an association with the FTO gene and adipokines and 
inflammatory markers exists in the literature.  Zimmermann and colleagues89 did not 
show an association across FTO gene SNP rs9939609 genotypes and inflammatory 
markers including TNF-α, IL-6 and leptin in healthy Danish middle-aged men. A study by 
Zabena et al,90 investigated the association of rs9939609 SNP of the FTO gene with 
obesity-related measures, to assess the FTO gene expression in subcutaneous and 
visceral adipose fat in morbidly obese patients in Spain and the relationship with 
adipocytokine gene expressions.  The rs9939609 A allele was more frequent in the 
morbidly obese patients as compared to the control group, who had no diabetes and 
were not obese, (0.52 and 0.34), even after controlling for age and sex (OR 2.26; 95% 
CI 1.19–4.30, p=0.013). FTO mRNA expression was associated with leptin (r=0.695, 
p<0.001).  Qi et al, 91 investigated the longitudinal relationships of the FTO gene variant 
rs9939609 with obesity and plasma adiponectin and leptin levels in men and women 
from prospective studies, The Nurses’ Health Study and the Health Professional Follow-
Up Study.  The AA genotype of the SNP rs9939609 was associated with BMI in a 26-
year follow-up in women (p<0.05) and 16-year follow-up in men (p<0.05) after adjusting 
for age and diabetes status and correlated with greater obesity risk during follow-up in 
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both women and men in contrast to genotypes TA and TT. A trend was shown in the 
allele A between higher leptin levels when adjusted for age (p=0.06).  No significant 
associations were seen in men with the FTO gene polymorphism and leptin levels.  
Terra et al.92 demonstrated that the FTO gene is associated with an anti-inflammatory 
profile in adipose tissue of morbidly obese (BMI >40 kg/m2) women. Adiponectin 
expression was greater than any other cytokine measured in both subcutaneous and 
visceral fat and decreased when comparing morbidly obese women to a control group 
(BMI<25 kg/m2) (4.03±0.47 vs.10.50±1.74, p=0.019). In subcutaneous fat, FTO 
expression was negatively associated with BMI (r=-0.457, p=0.004) and leptin (r=-0.475, 
p=0.026).  Inconsistent findings were present in the studies on FTO and leptin and 
between genders.  The FTO SNP rs9939609 was most commonly researched in the 
above studies. Studies with African populations on possible relationships between FTO 
and leptin are currently not available.   
 
C-Reactive Protein 
 C-reactive protein or CRP is considered a sensitive systemic marker of 
inflammation and an acute phase reactant.    CRP is produced and released mainly by 
hepatocytes in response to proinflammatory cytokines, such as IL-1 and IL-6.93,94  Within 
adipose tissue, adipocytes and monocyte-derived macrophages may release 
proinflammatory cytokines boosting hepatic production of CRP.95  Higher levels of CRP 
have also been associated with obesity and specifically abdominal obesity.96  High 
sensitivity CRP (hsCRP) allows for a lower limit of detection and a value of > 10 mg/L 
may indicate the presence of a subclinical infection or inflammation.97  CRP is currently 
used in many diagnostic, clinical, and research settings as an acute and chronic 
measure of inflammation.98  CRP is considered to be a stable molecule to measure and 
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many inexpensive methodologies are available to determine CRP.99  Such measures are 
attractive for resource limited settings, like many countries in Africa.  A recent study 
showed that CRP >1.2 mg/L had a specificity of 68.87% for predicting CD4 cell counts of 
<200 cell/µL in HIV adults, which shows that CRP may be a sensitive biomarker beyond 
cardiovascular disease.100   
 
HIV Disease Progression and C-Reactive Protein in HIV ART Naïve  
 Lau et al.101 examined the association between CRP and immune suppression 
and progression to AIDS in 513 HIV-infected men recruited into a multicenter cohort in 6 
US cities who were ART naïve at baseline.  CRP was negatively correlated with CD4 cell 
count (r=-0.17, p<0.001) and positively correlated with HIV RNA levels (r=0.20, 
p<0.001).  Those with higher concentrations of CRP had shorter times to AIDS (overall 
log-rank test, P<0.001).  Median times to AIDS were 5.07 years (95% CI: 4.15-7.26 
years) for those with CRP levels of 1.3 – 2.3 mg/L and 4.48 years (95% CI: 3.17, 5.61) 
for those with CRP levels more than 2.3 mg/L.  Accelerated progression to AIDS was 
only seen in those with CRP levels of >1.2 mg/L. Using Cox proportional hazard models, 
it was observed that increased hazards for the development of AIDS in those with higher 
levels of CRP remained after adjusting for CD4 cell counts and log10 HIV viral load. CRP 
increased over time for participants with and without AIDS, however, those who 
progressed to AIDS had more of a rapid increase in CRP concentrations than those 
without progression to AIDS.  Using a random-effects model, those that progressed to 
AIDS had 8.5% change per year in CRP concentrations compared to those that did not 
progress to AIDS, which had a 4.5% change per year. This study demonstrated a steady 
increase in CRP concentrations before participants’ progress to AIDS.  
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 Guimarães et al.102 compared hsCRP between 42 HIV+ ART naïve patients and 
129 HIV treated patients in Brazil. They investigated the relationship between hsCRP 
and cardiovascular risk factors with HIV disease progression. ART treated participants 
had higher levels of hsCRP compared to ART naïve participants (1.14±1.17 mg/l vs. 
0.3±1.16 mg/L; p<0.001). The ART treated participants had a higher percentage with 
values >3 mg/dL, associated with a higher cardiovascular risk, compared to the ART 
naive group (56% vs. 26%: OR=3.56; 95% CI: 1.55-8.29, p=0.001).  There were no 
statistically significant correlations between CRP and measures of HIV disease 
progression, CD4 cell counts and HIV viral load.  
 Chaudhary and colleagues103 explored possible associations of CRP with CD4 
cell counts and survival in 119 HIV infected ART naïve adults and 33 healthy individuals 
in India.  CRP was negatively correlated with CD4 cell counts (r=-0.148, p=0.045). Using 
a Cox proportional hazard model, higher CRP category (>12mg/dL) was associated with 
AIDS related mortality (RH=1.23, 95% CI: 1.12, 1.25, p=0.0047) after 1 year, albeit only 
8 participants were included in this analysis. CRP was suggested by the authors as 
another measure of disease progression in a resource limited setting.  
 A retrospective study by Baker et al. 104 compared markers of inflammation and 
coagulation in 254 ART naïve or not receiving ART for 6 months to 128 patients who 
initiated ART from various centers in the US during a 6 months follow-up.   At baseline 
there were no statistical differences in CRP between the ART naïve or the ART initiated 
group.  In addition, CRP was not associated with baseline CD4 count or HIV RNA level. 
After initiating ART, CRP did not significantly change from baseline. 
 A published study of inflammatory markers in 546 HIV pre-ART participants by 
Ledwaba and colleagues105 looked at whether elevated levels of inflammatory markers 
would be associated with increased risk of death after initiation of ART in South African 
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participants.  Prior to commencing ART, median hsCRP was significantly higher in the 
case group that included those who died during a median follow-up period of 24 months 
compared to a control group containing 80 uninfected adults (11.25 IQR=2.90-51.90 vs. 
3.6 IQR=1.50-11.30, P=<0.001).  At baseline participants with advanced HIV infection 
had lower levels of hsCRP compared to patients with early HIV (3.05 IQR=1.2-6.2 vs. 
4.30 IQR=1.95-12.3, P=0.002).  Advanced disease, which was accompanied by higher 
levels of CRP, was related to death after starting ART.  The studies investigating the 
relationship between CRP and HIV disease progression have inconsistent results as 
some did not show significant findings.  Since CRP is affected by ART, studies that 
include ART naïve are of importance to see the true associations with HIV disease 
progression.  Studies among African populations are limited in this area of research.  
 
The Fat Mass and Obesity Associated (FTO) Gene, and CRP 
 Adipose tissue may also determine levels of circulating CRP through IL-6, as its 
presence in adipose tissue affects production of CRP by the liver.106 FTO seems to 
affect the amount of adipose tissue and therefore levels of CRP. In a recent study 
completed by Fall et al.,107 over ninety-one thousand adults of European descent 
contributed to an analysis used to confirm causal effects of adiposity, the FTO gene 
variant rs9939609 and cardiometabolic traits, including CRP.  Both BMI and FTO SNP 
were associated with CRP (P<0.05).    Fisher et al.108 studied the association of the FTO 
rs9939609 SNP and CRP levels in 2,415 adult men and women in Germany and found 
that using a regression model that FTO SNP was associated with higher CRP levels in 
men (~14% higher) and women (~12%, P=0.02) for the A allele.  This model was 
adjusted for age, BMI, waist-to-hip ratio, common diseases (myocardial infarction, 
stroke, and diabetes), education, engagement in sports, and smoking.  Zimmerman and 
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colleagues89 also looked at the association of CRP and FTO rs9939609 SNP.  No 
statistically significant results analyzing CRP were observed.  Studies on FTO SNPs and 
its relationships with adipokines and markers of inflammation such as CRP that were 
discussed above have been mainly conducted using European populations. Studies with 
African populations are lacking.  Overall, studies in this subject are limited and more 
research is warranted to examine possible pleiotropic effects of FTO.  
 
Lipopolysaccharide (LPS) 
 Microbial translocation or the movement of bacterial products from the intestinal 
lumen into systemic circulation is measured by bacterial products such as 
lipopolysaccharide (LPS).109  Microbial translocation may have a role in persistent 
immune activation and can provoke pro-inflammatory reactions.110  During HIV, microbial 
translocations may occur due to epithelial damage to the intestine, loss of T-helper-17 
cells and a reduced removal of microbial products by phagocytes are observed.110  
Increased secretion of pro-inflammatory cytokines can also contribute to increased T cell 
activation and specifically can increase CD8 T cell activation and depletion of CD4 T 
cells.111 Conversely, a theory for the obesity paradox includes the endotoxin-lipoprotein 
hypothesis.14  This theory states that during obesity there are a large number of 
lipoproteins circulating and LPS binds to lipoproteins through the formation of micelles in 
the gut.  Lower circulating LPS would reduce the inflammatory response.  This 
hypothesis merits investigation in a HIV infected population that is ART naïve that may 
be protective of further disease progression by obesity.  
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HIV Disease Progression and Lipopolyssacharide (LPS) in HIV Infection without 
ART 
 Redd et al.112 observed in 107 HIV+ ART naïve adults the longitudinal 
relationship between microbial translocation, which included LPS, and inflammatory 
cytokine response in a cohort with varying rates of HIV disease progression in Uganda. 
Markers of microbial translocation were also compared to 24 HIV uninfected adults in the 
US.  At baseline there were no statistical differences in the levels of LPS between the 
HIV infected group in Uganda and the US uninfected group.  When comparing groups 
stratified by HIV disease progression there were still no differences at baseline or over 
time in LPS. The authors proposed that the different levels of microbial translocation 
markers such as LPS, may be a symptom but not a direct cause of HIV disease 
progression.  
 Marchetti and authors113 investigated microbial translocation, as measured by 
LPS, in 379 HIV ART naïve participants in Italy. Participants were recent seroconverters 
with high CD4 cell counts, and who were followed for an average of 3 years. Participants 
were separated into two groups based on the median LPS level (110 pg/mL) and there 
were no differences at baseline in CD4 cell counts and HIV viral load between the 
groups. In a subset that included 17 participants, LPS did not change significantly over 
time (13-25 months).  The group above the LPS median had a shorter median time to 
event (AIDS defining condition, death, CD4 cell count <200 cells/µL or start of ART, 
whichever happened first) of 1.5 years (95% CI: 1.0, 2.0) as compared to those below 
the median who had an average time to event of 4 years (95% CI: 3.1, 5.6), P=0.0002.  
This association remained significant after controlling for proinflammatory cytokines, 
age, CD4, viral load, HCV, HBV and duration of HIV (RH=1.85, 95% CI: 1.32, 2.58, 
p<0.001).  In this study LPS was a strong predictor of HIV disease progression 
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independent of CD4 cell count and HIV viral load.  In summary, the evidence points 
towards an association between LPS levels and disease progression, but is weak in 
elucidating whether the relationship is of cause-and-effect or mediated by other factors. 
Additionally, few studies are available on LPS in HIV ART naïve participants and the 
sample size over time quite small.   Currently, there are no published literature 
examining the relationship between FTO SNPs and LPS in humans.  
 
Summary 
        There is evidence in the literature of an obesity paradox, where higher BMI seems 
to be protective of mortality and disease-related outcomes in several conditions, 
including HIV.3 Obesity may boost the innate immune system even in ART, which is 
probably why it is protective before ART.  Fat available for use in time of crisis in HIV 
disease may spare protein’s use.33 However, factors generating this paradox are not well 
understood and the mechanism for the associated benefits of higher BMI are lacking.  
The prevalence of overweight and obesity are increasing globally, including sub-Saharan 
countries like Botswana.17 Botswana also has the second highest prevalence rate of HIV 
in the world.114 Before the initiation of ART, BMI and body composition measures such 
as fat mass and body cell mass seem to be protective of HIV disease progression, 
however, longitudinal studies in African populations are lacking.    
  Studies that examine the relationships between being overweight/obese and HIV 
disease progression and its interrelationship between genetic propensity for obesity and 
inflammatory markers, such as the study reported in this dissertation, are needed.  The 
studies conducted on body composition in HIV infected, ART naïve patient populations 
were cross-sectional and included populations in the US.  Changes may occur through 
time in body composition that may ultimately have an effect on HIV disease progression. 
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Replication studies in diverse African populations are needed to identify the SNPs that 
may cause the variations seen in obesity that is relevant pertaining to the population.  
Most of the studies discussed above have limitations that warrant further research, 
including small sample sizes, inconsistent findings, and cross-sectional design.  In 
addition, studies that include ART naïve patients are of importance in determining the 
true associations with HIV disease progression.  Although, some studies include African 
populations, heterogeneity among Africans is present and including other ethnicities is 
likely to provide relevant information. The role of obesity in inflammation in HIV infection 
is not clear and the literature is contradictory, therefore, it is important to examine the 
interrelationships that exist between inflammation, overweight/obesity, and HIV disease 
progression to elucidate the potential mechanisms involved and how it could later be 
translated into clinically relevant recommendations.   
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Table 1:  Studies Conducted in Obesity and HIV Disease Progression  
Author/Study 
Design 
Study Purpose Population Main 
Outcome(s) 
Study Findings 
Johnson et al, 
2014 
 
Retrospective 
Longitudinal 
Cohort Study 
To investigate the longitudinal 
association of BMI at HIV 
diagnosis with disease 
progression as evaluated by 
CD4 cell counts obtained 
during routine medical care.  
396 ART naïve 
and had one 
follow-up visit  
CD4 cell 
counts 
Longitudinally, the mean CD4 count was 
611.2 cells/mm3 for obese individuals, 598.1 
cells/mm3 for overweight individuals and 
550.5 cells/mm3 for normal weight individuals. 
When compared to the normal weight 
category, the obese category had significantly 
larger increases in CD4 count (5.5 cells/mm3, 
P < 0.001) versus the overweight category (-
2.1 cells/mm3, P < 0.001). 
Tate et al., 2012 
 
Prospective 
Longitudinal 
Cohort Study 
To evaluate factors associated 
with change among patients 
receiving ART. 
681 ART 
treatment naïve 
patients who 
maintained ART 
therapy for 2 
years.  
BMI At 24 months, 20% of patients moved from 
normal to overweight/obese or overweight to 
obese BMI categories.  Underweight 
participants had lower CD4 counts and Higher 
viral load at ART initiation. Greater increases 
in BMI were observed in patients with 
baseline CD4 count <50 cells/µL and boosted 
protease inhibitor use, but did not account for 
all of the variation observed in weight change. 
Crum-Cianflone 
et al., 2011 
 
Retrospective 
Longitudinal 
Cohort Study 
To investigate relationship 
between body weight and a 
variety of immune cell counts 
at diagnosis and over the 
course HIV infection among a 
cohort of documented HIV 
seroconverters who had serial 
immune cell measurements 
and longitudinal weight data.  
1097 HIV 
seroconverters 
who were 
participants in 
the US Military 
HIV Natural 
History Study 
(NHS) (96% 
male). 
Immune cell 
counts 
Immune cell counts at HIV diagnosis did not 
significantly differ by BMI category. In the 
longitudinal models for those diagnosed 
before the advent of the highly active 
antiretroviral therapy (HAART) era, mean 
postdiagnosis decreases in the white cell 
count, total lymphocyte count, CD4 count, 
CD4 percentage, and CD4/CD8 ratio were 
less as the BMI category increased (all with P 
values of <0.05). Among HIV seroconverters 
diagnosed in the HAART era, obese 
compared to normal-weight patients had 
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significantly smaller increases in CD4 counts, 
CD4 percentages, and the CD4/CD8 ratio (all 
with P values of <0.05). Similar findings were 
also noted among underweight versus 
normal-weight patients.  
Adeyemi et al., 
2009 
 
Cross-sectional 
Study 
 
 
To explore the effects of 
obesity on lymphocyte 
subsets in HIV-positive 
patients with diabetes. 
216 HIV+ 
patients with 
Diabetes on 
HAART and 
undetectable 
viral load. 
White blood 
cell count and 
the following 
lymphocyte 
subgroups, 
defined by 
surface 
antigens: CD3 
(T cells), CD4 
(helper T cells), 
CD8 (cytotoxic 
or suppressor 
T cells), CD19 
(B cells), and 
CD56 (natural 
killer cells). 
As BMI increased, there were significant 
increases in CD3, CD8, and total lymphocyte 
counts. For total white blood cell count and 
the other lymphocyte subgroups (CD4, CD19, 
and CD56), the relationship with BMI was not 
significant. Obese patients had CD3 counts 
26% higher than patients with normal weight 
and CD8 counts 28% higher, controlling for 
age, sex, ethnicity, renal function, HbA1c, and 
duration since HIV diagnosis. 
Jones et al., 
2003 
 
Longitudinal 
Prospective 
Cohort Study 
 
To examine the association of 
BMI with HIV disease 
outcomes. 
871 HIV+ 
women 16-55 
years of age 
with history of 
IDU or high-risk 
sexual contact 
without prior 
AIDS-defining 
clinical illness 
and ART naïve 
at baseline 
Time to first 
CD4 cell count 
<200 
cells/mm3, first 
CD4 cell count 
<100 
cells/mm3, 
opportunistic 
infection and 
HIV-related 
death 
Mean CD4 cell count at baseline 
progressively higher and mean log viral load 
progressively lower as BMI increased. A 
higher baseline BMI was associated with a 
lower rate of occurrence of the first CD4 <200 
cells/mm3. In analysis using time-varying 
BMI, underweight and normal women had 
increased risk of clinical AIDS and 
underweight women had increased risk of 
HIV-related death, compared with obese 
women.  
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Shuter et al., 
2001 
 
Retrospective 
Case-Control 
Study 
 
To determine the prevalence 
and predictive value of 
overweight in an urban HIV 
clinic.  
189 HIV+ 
patients from 
Jacobi Medical 
Center HIV 
Clinic 
Progression to 
AIDS and CD4 
cell count 
Female gender and lack of AIDS diagnosis 
were independently associated with 
overweight. Among patients without AIDS, 
there was a trend towards slower disease 
progression and lower viral load in overweight 
patients, despite similar baseline CD4 cell 
count and similar time to initiation of HAART. 
In multivariate proportional hazards analyses, 
lower baseline BMI and falling BMI during 
follow-up were independently predictive of 
progression to AIDS.  
Shor-Posner et 
al, 2000 
 
Longitudinal 
Prospective 
Cohort Study 
 
To compare immune 
measures and disease 
progression in obese and 
nonobese HIV-1– 
seropositive men and women 
in the pre-HAART era.  
 
125 HIV-1–
infected and 
148 
seronegative 
male and 
female drug.  
HIV-1 related 
mortality, CD4 
cell count <200 
cells/µL and 
25% decline in 
CD4 cell count 
Over an 18-month period, 60.5% of the 
nonobese HIV-1–seropositive patients 
exhibited a 25% decline in CD4 cell count, 
compared with 18% of the obese patients. 
During the follow-up period, 38% of the lean 
and 13% of the nonobese study subjects died 
of HIV-1–related causes. Measurements of 
BMI were inversely associated with 
progression to death, independent of CD4 
count <200 cells/mm3. 
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Table 2:  Genetic Association Studies on the FTO Gene in African Populations 
Author/Study 
Design 
Study Purpose Population FTO SNPs 
Analyzed 
FTO Results with BMI Other Results 
Lombard et al., 
2012 
 
Genetic 
Association Study 
(Cross-sectional) 
To assess the 
association of 
candidate loci with 
BMI in black South 
Africans. The 
authors focused on 
SNPs in the FTO, 
LEP, LEPR, MC4R, 
NPY2R and POMC 
genes. 
990 randomly 
selected adolescents 
from 
the larger Birth to 
Twenty cohort (a 
longitudinal birth 
cohort study of health 
and development in 
Africans) born in the 
metropolitan area of 
Soweto, 
Johannesburg, 
rs9939973 
rs9940128 
rs1421085 
rs1121980 
rs17817449 
rs8050136 
rs9939609 
 
FTO rs17817449, the minor 
allele (G in both cases) is 
associated with increased 
BMI. The seven FTO SNPs in 
this study explain 0.6% of 
variation in log(BMI) after 
adjusting for age-, gender- 
and sex-specific pubertal 
stage and 1.4% unadjusted.  
FTO rs17817449 (p=0.022) 
associated with BMI after 
adjustment for above factors. 
Sex, sex-specific 
pubertal stage and 
exact age together 
explain 14.3% of 
variation in log(BMI).  
Each risk allele was 
associated with an 
estimated average 
increase of 2.5% BMI.  
Adeyemo et al., 
2010 
 
Genetic 
Association Study 
(Cross-sectional) 
To evaluate genetic 
variation in the FTO 
gene and 
investigate 
associations with 
obesity in West 
Africans and African 
Americans. 
Two independent 
subsets:  
1) 968 unrelated 
African Americans in 
Washington, D.C., 
and  
2) 517 unrelated West 
Africans enrolled as 
control subjects as 
part of the Africa-
America Diabetes 
Mellitus (AADM) 
Study. 
262 tag single 
nucleotide 
polymorphisms 
(SNPs) across 
the entire gene. 
The combined effect size for 
BMI for the top SNPs from 
meta-analysis was 0.77 kg/m2 
(P = 0.009, rs9932411) and 
0.70 kg/m2 (P =0.006, 
rs7191513). Two previously 
reported associations with 
intron 1 SNPs (rs1121980 
and rs7204609, r2 = 0.001) 
were replicated among the 
West Africans. 
Both African-ancestry 
samples showed 
weaker linkage 
disequilibrium (LD) 
patterns compared to 
other continental (e.g., 
European) populations. 
Several intron 8 SNPs, 
in addition to intron 1 
SNPs, showed 
significant associations 
in both study samples. 
Hennig et al., 2009 To assess the effect 
of 16 FTO SNPs on 
2208 Lean Gambians 
(Children and Adults) 
rs6499642 FTO SNPs not associated 
with birth weight (BWT), early 
Not Applicable  
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Genetic 
Association Study 
(Cross-sectional) 
body mass in a 
large population of 
predominantly lean 
Gambians 
participating in a 
long-term 
surveillance 
program providing 
contemporary and 
early-life 
anthropometric 
measurements. 
rs6499643 
rs7206790 
rs9940646 
rs12447107 
rs17817288 
rs16945088 
rs17817449 
rs8063946 
rs8063946 
rs3751812 
rs3751813 
rs9939609 
rs9931494 
rs7190492 
rs72046609 
rs9935403 
weight gain in 1–2 year olds, 
BMI in adults (≥ 18 y), or 
weight-for-height (WFH) z-
score across all ages. No 
association was seen 
between genotype and WFH 
z-score or other measures of 
body mass. 
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Table 3:  Studies Conducted on Leptin and HIV Disease Progression in ART Naïve  
Author/Study 
Design 
Study Purpose Population Main 
Outcome(s) 
Study Findings 
Azzoni et al., 
2010 
 
Cross-sectional 
Study 
To assess the 
relationship of fat or 
markers related to 
glucose and lipid 
metabolism with 
viral load in a cross-
sectional sample of 
83 ART-naïve HIV-1 
infected South 
African women.  
83 ART naïve South African 
women 
Cell activation, 
innate 
immunity 
effector levels 
and adipose 
tissue-related 
measures 
including 
leptin 
Women with viral load greater than the 
population median had lower serum leptin. 
Leptin levels were inversely associated with 
viral replication, independent of the amount of 
adipose tissue.  
Onyemelukwe 
et al., 2009 
 
Cross-sectional 
Study 
To determine serum 
leptin levels in ART 
naïve HIV-1 infected 
adults in relation to 
BMI, CD4 cell count 
and presence or 
absence of 
symptomatic HIV 
disease or features 
of AIDS. 
40 consecutive matched, 
HIV infected adults (20 
normal weight and 20 
underweight) and 26 sex 
matched HIV negative, 
healthy normal weight 
controls in Nigeria 
Leptin Female patients tended to have lower leptin 
than males. Median leptin was lower in 
underweight when compared to normal weight 
patients and also lower in symptomatic 
patients when compared to asymptomatic 
patients but not significantly different between 
AIDS and non-AIDS cases. Among healthy 
controls, leptin levels positively correlated with 
CD4 T counts but in HIV/AIDS patients the 
correlation was not significant. 
Prabha et al., 
2005 
 
Cross-sectional 
Study 
To determine the 
leptin levels in HIV 
and HIV with active 
pulmonary TB and 
to see whether leptin 
levels are altered 
with co-infection. 
20 asymptomatic, ART 
naïve HIV infected patients, 
20 asymptomatic ART 
naïve HIV infected patients 
with TB,  
20 healthy control subjects 
(All participants from India) 
Leptin Serum leptin levels and BMI were significantly 
lower in the patients with HIV-TB than control 
and HIV subjects. Multivariate regression 
analysis showed that serum leptin was 
significantly dependent on BMI and sex but 
not on age and the disease groups. Leptin did 
not correlated with either with CD4 cell count 
so with any of the serum cytokines in HIV and 
HIV-TB patients.  
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Table 4:  Studies Conducted on C-Reactive Protein and HIV Disease Progression in ART Naïve  
Author/Study 
Design 
Study Purpose Population Main 
Outcome(s) 
Study Findings 
Ledwaba L et al., 
2012 
 
Nested Case-
Control Substudy 
To assess in an ART naïve 
group of patients with 
advanced HIV infection 
whether pre-ART levels of 
inflammatory and coagulation 
biomarkers are associated 
with mortality.  In addition, to 
assess whether initiation of 
ART lowered levels of these 
biomarkers, and compared 
pre-ART biomarker levels 
among patients with early 
versus late HIV infection and 
HIV uninfected patients.   
187 HIV infected 
ART-naïve 
patients with 
CD4 cell count 
<200 cells/µL 
who died 
359 HIV infected 
ART-naïve 
patients with 
CD4 cell count 
<200 cells/µL 
matched controls
80 uninfected 
(South African 
Cohort) 
Mortality Median baseline biomarkers levels for cases 
and controls, respectively, were 11.25 vs. 3.6 
mg/L for hsCRP, HIV viral load was 
correlated with hsCRP. Adjusted odds ratios 
for the highest versus lowest quartile of 
baseline biomarker levels were 3.5 (95% CI: 
1.9–6.7) for hsCRP, 2.6 (95%CI 1.4–4.9) for 
D-dimer, and 3.8 (95% CI: 1.8–7.8) for IL-6. 
These associations were stronger for deaths 
that occurred more proximal to the biomarker 
measurements. Levels of D-dimer and IL-6, 
but not hsCRP, were significantly lower at 
month 6 after commencing ART compared to 
baseline. 
Baker et al., 
2011 
 
Retrospective 
Longitudinal 
Study 
To determine whether ART 
initiation in ART naïve or 
those off of ART (≥6 months) 
reduced markers of 
inflammation. 
254 HIV+ ART 
naïve or off of 
ART (≥6 months) 
at baseline (126 
differed initiation 
of ART (DC) and 
128 had 
immediate 
initiation of ART 
(VS) 
D-dimer, IL- 
and CRP 
At month 6, 62% of VS group had HIV RNA 
<400copies/mL and median CD4 count was 
190 cells/mm3 higher than for the DC group 
(590 vs. 400 cells/mm3). Compared with DC, 
the VS group had 32% lower D-dimer levels 
at month; differences were not significant for 
hsCRP or IL-6 levels. 
Chaudhary et al., 
2008 
To elucidate association of 
CRP with CD4 counts and 
survival in HIV-1 infected 
119 HIV-infected 
ART naïve 
patients 
AIDS related 
mortality and 
CD4 cell count 
CRP was correlated with CD4 count and 
mortality at 1 year.  CRP was negatively 
correlated with CD4 counts with levels of 
CRP being highest in the group with CD4 cell 
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Prospective 
Longitudinal 
Study 
individuals 33 healthy 
individuals 
counts below 200 cells/µL.  Higher CRP 
category (>12 mg/dL) was associated with 
AIDS-related deaths in a Cox proportional 
Hazard Model after adjusting for CD4 cell 
count.  
Guimaraes et al., 
2008 
 
Cross-sectional 
Study 
To compare hsCRP in HIV-
infected patients treated or 
not with ART and to correlate 
hsCRP levels with traditional 
cardiovascular risk factors 
and to factors related to the 
HIV infection.  
129 HIV+ ART-
treated 
42 HIV+ ART 
naive 
CRP hsCRP levels were higher in ARV-treated 
compared to ARV-naive patients. Seventy-
two (56%) ARV-treated patients and 
11 (26%) ARV-naıve patients had hsCRP 
concentrations >3 mg/dl (high risk for 
cardiovascular complications). No correlation 
was found between hsCRP levels and CD4 
cell counts and HIV-viral load. Independent 
factors associated with hsCRP levels were 
therapy with current non-nucleoside reverse 
transcriptase inhibitors (NNRTI), waist-to-hip 
ratio, fasting glucose  and glucose levels 2 h 
after load in multivariate analysis model 1 
and current NNRTI therapy, protease 
inhibitor therapy and cardiometabolic 
syndrome in multivariate analysis model. 
Lau et al., 2006 
 
Retrospective 
Longitudinal 
Cohort Study 
To elucidate the relationship 
between HIV disease and the 
concentration of CRP. 
513 HIV 
serpopostive 
men randomly 
chosen MACS 
participatns ART 
naïve at baseline 
Time to AIDS The cross-sectional associations between 
log10 
CRP were correlated inversely with CD4 
lymphocyte counts and directly with log10 
HIV RNA levels. Levels of CRP of more than 
2.3 mg/L were associated with a decreased 
time to the development of AIDS (relative 
time to AIDS,  compared with individuals with 
CRP levels of 1.2 mg/L or less, which 
remained significant after adjustment for 
CD4 lymphocyte counts and HIV RNA and 
hemoglobin concentrations. Levels of CRP 
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significantly increased over time with mean 
slopes of 8.5% and 4.5% per year for 
individuals with and without progression to 
AIDS, respectively. Individuals had a 
geometric mean CRP level of 2.5 mg/L in the 
6-month interval before progression to AIDS, 
which was an increase from a nadir of 1.0 
mg/L at 6.5 years before progression to 
AIDS. 
 
 
Table 5:  Studies Conducted on LPS and HIV Disease Progression in ART Naïve  
Author/Study 
Design 
Study Purpose Population Main Outcome(s) Study Findings 
Marchetti et al., 
2011 
 
Retrospective 
Longitudinal 
Study 
To evaluate the role of 
immune activation and 
microbial translocation in HIV 
infected ART naïve patients 
with high CD4 cell count in the 
first years of chronic infection 
in predicting HIV disease 
progression.  Also, to cross-
sectionally evaluate the 
correlations between markers 
of immune activation, 
microbial translocation, and 
CD4 cell count and HIV 
viraemia and their 
modifications during untreated 
infection.  
379 HIV+ 
patients ART 
naive with 
CD4>200 cells/ 
µL 
AIDS defining 
condition, death, 
CD4 cell count of 
<200 cells/µL or 
start of ART 
A median of 3.1 years after the estimated 
serconversion date median LPS marker 110 
pg/mL (IQR 75-215). LPS was the only 
biomarker associated with primary composite 
outcome independently of age, HIV-RNA and 
CD4 RR=1.04 per loge higher, 95% CI: 1.18-
1.66, p<0.001).    
Redd et al., 2009 To examine the longitudinal 107 HIV+ ART LPS, soluble Multiple markers for microbial translocation 
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Retrospective 
Longitudinal 
Study 
relationship between microbial 
translocation and circulatory 
inflammatory cytokine 
responses in a cohort of 
people with varying rates of 
HIV-1 disease progression in 
Rakai, Uganda.  
naïve Ugandan 
patients and 24 
HIV uninfected 
US adults 
 
CD14, LPS, 
EndoCAb, LPS 
binding protein 
and inflammatory 
cytokines 
(lipopolysaccharide, endotoxin antibody, and 
sCD14) did not change significantly during 
HIV-1 disease progression. Moreover, 
circulating immunoreactive cytokine levels 
either decreased or remained virtually 
unchanged throughout disease progression. 
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CHAPTER III:  EFFECT OF BMI AND BODY COMPOSITION ON HIV DISEASE 
PROGRESSION IN HIV INFECTED ART NAÏVE ADULTS IN BOTSWANA 
Abstract 
Background:  An obesity paradox has been documented in many conditions including 
HIV. Several studies indicate that overweight or obesity provides some protection from 
accelerated HIV disease progression in patients not receiving antiretroviral therapy 
(ART). Studies conducted to investigate obesity and its effect on HIV disease 
progression have been inconclusive and are lacking in African settings. This research 
investigates the relationship between overweight and obesity and HIV disease 
progression in HIV+ asymptomatic adults not on ART in Botswana over a period of 18 
months.   
Methods:  A retrospective, cohort study in asymptomatic, ART naïve, HIV+ adults was 
conducted that included 217 participants, 139 with BMI 18.0-24.9 kg/m2 and 78 
participants with BMI ≥ 25 kg/m2.  The primary outcome was time to event (25% or 
greater decrease in CD4 cell count) during 18 months of follow-up and secondary 
outcomes were time to event of CD4 cell count <250 cells/µL, and AIDS defining 
conditions. Proportional survival hazard models were used to compare hazard ratios on 
time to events of HIV disease progression between BMI groups and BMI and body 
composition as continuous variables over 18 months. 
Results: Using Cox Proportional Hazards model, higher baseline BMI was associated 
with significantly lower risk of having an AIDS defining condition over an 18 months 
follow-up (HR, 0.218; 95% CI, 0.068-0.701, P=0.011).  Higher fat mass at baseline was 
also significantly associated with a decreased risk of having AIDS defining conditions 
(HR, 0.855; 95% CI, 0.741-0.987, P=0.033) and the combined outcome of having CD4 
cell count ≤ 250/µL and AIDS defining conditions, whichever occurred earlier (HR, 0.918; 
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95% CI: 0.847-0.994, P=0.036).  All models were adjusted for age, gender, marital 
status, children (yes or no) and baseline CD4 cell count and baseline HIV viral load.  
There was no significant effect of BMI on HIV viral load over 18 months. 
Conclusions: Higher BMI and fat mass were associated with slower disease 
progression in HIV infected ART naive adults in Botswana. Mechanistic research is 
needed to evaluate the association of obesity and HIV disease progression. 
 
Keywords: HIV infection, ART naïve, BMI, disease progression, body composition, BIA  
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Introduction 
 The importance of good nutrition in maintaining good health and delaying 
disease progression for the HIV patient has been well documented in the literature.1,2  At 
the beginning of the HIV epidemic, wasting was one of the main nutritionally related 
concerns, however, today rates of obesity are more common than the occurrence of 
wasting, particularly in developed countries,3-5 especially with antiretroviral treatment 
(ART).6   
An obesity paradox has been documented in many conditions including HIV 
infection, where those who are obese may have a survival advantage or improved 
disease outcomes.7 The protective effect of obesity has been hypothesized to be related 
to extra available energy in the form of available fat for use in time of crisis during the 
HIV disease that would spare protein use,8 and also help to preserve the immune 
system response. Studies on HIV and obesity were mainly conducted in settings where 
the patients are treated with ART, which may confound some of the findings and 
interpretations, as ART has been associated with lipodystrophy and obesity.5 Increased 
obesity has been documented in countries with limited resources,9 however, studies 
conducted in African settings on the relationship between HIV and obesity are lacking. It 
has been estimated that in sub-Saharan Africa, 10% of women have a BMI of less than 
18.5 kg/m2, with wasting still prevalent in some areas.10 However, sub-Saharan Africa is 
experiencing a nutrition-related transition with a rapid rise in overweight and obesity.11 
Botswana is also experiencing an increase in obesity.12 Growth in economy, 
urbanization, and diminished physical activity is contributing to the rise in obesity in 
Southern Africa.13 Studies conducted to investigate obesity and its effect on HIV disease 
progression have so far been inconclusive, with some studies reporting an association 
and others reporting no association between CD4 cell counts and obesity.6,14-17 
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Botswana is also experiencing one of the worst epidemics of HIV with a prevalence 
rate of 23.4%, among those in the range between 15 and 49 years of age in men and 
women.18  Botswana has been one of the first developing countries to provide universal 
access to ART.19  Currently, HIV+ adults in Botswana can receive ART once their CD4 
cell counts are less than 500 cells/µL. Countries especially in sub-Saharan Africa are still 
having many challenges in providing ART and maintaining adherence.20  Therefore, 
having information on delaying disease progression, and its relationships to nutrition-
related measures, in those regions where the two epidemics are co-occuring, is timely. 
The objective of this study was to examine the relationship between overweight 
and obesity and HIV disease progression in HIV+ asymptomatic adults not on ART in 
Botswana over 18 months.  The primary outcome was time to the first occurrence of a 
25% or greater decrease in CD4 cell count during the course of the study and the 
secondary outcomes were time to reaching CD4 cell count <250 cells/µL, AIDS defining 
conditions, and changes in HIV viral load. This study was conducted in HIV+ adults who 
were ART naïve and had CD4 cell counts >350 cells/µL.   
Methods  
Study Design and Participants 
A retrospective, cohort study analyzing data from 219 HIV+ men and women 
from the placebo group of a clinical trial in Botswana was conducted.  This trial was a 
multifactorial, randomized, double-blinded, placebo-controlled clinical trial which 
investigated whether supplementation with multivitamins and selenium could improve 
immune function and prolong time to AIDS in ART naïve HIV+ adults.21 The study was 
conducted between December 2004 and July 2009. The placebo group was used to 
avoid any confounding effects from the micronutrient supplementation on the outcome 
measures.  Participants were eligible for the parent study with documentation of HIV 
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seropositive test results, CD4 cell count was >350 cells/µL, BMI was >18 kg/m2 for 
women and 18.5 kg/m2 for men, age ≥ 18 years, lack of a past history of AIDS-defining 
conditions, participation in another clinical trial and taking ART. Women were excluded if 
pregnant or had intention to become pregnant.  All participants provided informed 
consent and were recruited from the Botswana-Harvard AIDS Initiative Partnership 
(BHP) in Gaborone, Botswana. The study protocol was approved by the Florida 
International University Institutional Review Board (IRB), the Harvard School of Public 
Health IRB and the Botswana Health Research Unit of the National Ministry of Health. 
Appropriate informed consent was obtained and clinical research was conducted in 
accordance with guidelines for human experimentation as specified by the US 
Department of Health and Human Services, the researchers’ institutions, or both.  
Clinical Data 
At baseline and every three months, physical examination and medical history 
were performed by a trained nurse or a physician.   Anthropometrics were also obtained 
and body mass index (BMI) was calculated by dividing the weight in kilograms by height 
in meters squared. Waist and hip circumference was measured using a tape measure.  
Waist circumference was measured at the narrowest part of the waist between the 
lowest rib and the iliac crest and the hip circumference at the widest portion of the 
buttocks.   Bioelectrical impedance analysis (BIA) using the Biodynamics body 
composition analyzer (model BIA-310; Biodynamics Corp., Seattle, WA), determined 
impedance and calculated body composition. Subjects were measured without shoes 
and socks, and electrodes were placed on the participant’s right hand and wrist and right 
foot and ankle. Blood pressure was measured in the left arm with the elbow flexed to 
heart level. Morbidity information including AIDS-defining conditions, were collected by 
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questionnaires at screening, and at every monthly visit, and confirmed by documentation 
in the medical chart.  
Laboratory Data 
At baseline and every three months blood was drawn for CD4 and CD8 cell 
counts.  Every six months, blood was also drawn to evaluate HIV viral load, lipid panel, 
and blood chemistry. Lymphocyte phenotype was determined with a four-color 
immunophenotyping panel of monoclonal antibodies. Differential counts were 
determined using a Coulter MaxM hematology instrument and corroborated with 
cytocentrifuge smears. HIV-viral load was determined using an in-vitro nucleic acid 
amplification test (Amplicor reagents and protocol, Roche-Diagnostics, Branchburg, NJ).  
The lipid panel was measured using Roche reagent kits (Branchburg, NJ) on a COBAS 
Integra 400 plus auto-analyzer using enzymatic methods according to standard 
operating procedures.   
Nutritional Data 
Twenty-four hour recalls were conducted at baseline and every 3 months by 
trained clinical staff. Macronutrient and fiber intakes were calculated using the NutriBase 
Professional, V.9 (Cybersoft, Phoenix, AZ) program modified by the South Africa 
database, including native foods for which information was available.  An average of at 
least 3 dietary recalls were used to obtain their estimated energy, carbohydrate, protein, 
fat and fiber intakes.  
Statistical Analysis 
BMI was stratified into two groups: 1. normal weight (BMI=18.0-24.9 kg/m2) and 
2. overweight/obese (BMI ≥ 25 kg/m2).  The overweight and obese BMI categories were 
combined to increase the sample size for the analyses.  Laboratory markers of HIV 
infection and disease progression included in the analyses were CD4 cell count, CD4%, 
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CD8 cell count, CD8%, CD4/CD8 ratio and HIV viral load.  Descriptive statistics such as 
frequencies, percentages, medians and interquartile ranges were used to characterize 
the total population, the two groups stratified by BMI and the study variables (primary 
and secondary outcomes) at baseline.  Mann Whitney U and Chi-square tests were used 
to determine differences in HIV disease progression markers and markers of nutritional 
status between the BMI groups and by gender.  Linear and logistic regressions at 
baseline and 18 months were conducted to observe the relationship between BMI and 
HIV disease progression and body composition measures from BIA using BMI as a 
continuous variable and dichotomous variable.  The multiple regression analysis also 
included a measure to check for multicollinearity known as variance inflation factor (VIF).  
All models had a VIF <5, therefore multicollinearity was not a problem. Proportional 
survival hazard models were used to compare hazard ratios on time to events of HIV 
disease progression outcomes with BMI groups, BMI as a continuous variable and body 
composition over 18 months. The primary outcome was time to the first occurrence of a 
25% or greater decrease in CD4 cell count during the course of the study and secondary 
outcomes were time to CD4 cell count <250 cells/µL, and AIDS defining conditions. 
These events were documented from the time of inclusion into the study to the date of 
the visit in which the event was recorded. All models were adjusted for covariates. For all 
analyses, a two sided test was used and P<0.05 was considered statistically significant. 
Statistical analyses were completed using SPSS version 21. 
Results  
Demographics and Clinical Characteristics  
 A total of 219 participants were assigned randomly into a placebo group by the 
parent study.21 Two participants had missing data and were excluded from the final 
analysis.  Seventy-eight participants at baseline had BMI ≥ 25 kg/m2 and 139 had 
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BMI=18.0-24.9 kg/m2.  BMIs were stable throughout the 18 months of follow-up and did 
not statistically change within the normal and overweight/obese groups (Table 1).  Most 
of the participants were female (75.1%) with a median age of 33 years, reflecting the 
characteristics of the epidemic in Botswana.22  Almost half (45.2%) of the participants 
had at least a secondary education level and most had children (85.7%).     
 There were differences in demographic factors among the BMI groups.  Those 
with BMI ≥ 25 kg/m2 were older and more likely female, married and have children (Table 
1).  There were no differences in laboratory markers of HIV infection at baseline between 
the BMI groups.  As shown on Table 2, those with BMI ≥ 25 kg/m2 had a larger waist 
circumference and higher levels of total cholesterol, triglycerides, LDL cholesterol, 
glucose, and blood pressure. Albumin levels were higher in those with BMI 18-24.9 
kg/m2.  Dietary intake was statistically different between the BMI groups.  The 
overweight/obese group had higher basal metabolic rate and fat mass, but lower lean 
body mass, body cell mass and extracellular mass. Physical activity was not statistically 
different between the BMI groups (data not shown).  
Correlations between Laboratory Markers of HIV Infection and Body Composition  
 BMI was significantly correlated with measures of body composition but not with 
the markers of HIV infection (Table 4).  Waist circumference was associated with CD4% 
(r=-.17, P<.05) and CD4/CD8 ratio (r=-.19, P=.05).  Waist-to-hip ratio showed a 
correlation with CD4% (-.33, p<0.01), CD8 cell count (r=.22, P<.01), and CD4/CD8 ratio 
(r=-.26, P<.01). Both fat mass and lean mass were associated with CD4 cell count (r=-
.14, r=.14, P<.05, respectively).  
Effect of BMI on Laboratory Markers of HIV Infection and Disease Progression  
 Table 5 displays the results from logistic regression analysis that compared the 
BMI groups at baseline, 18 months and the change over 18 months in the laboratory 
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markers of HIV infection and disease progression.  No significant associations were 
found with viral load, CD4 cell count, CD4%, CD8 cell count, CD8%, and CD4/CD8 ratio.  
However, there was a trend where CD4% showed those with BMI ≥ 25 kg/m2 to be more 
likely to have a higher change in CD4% over 18 months (OR=1.076, 95% CI=.988,1.166, 
P=.077).  All models were controlled for age, gender, marital status, and children 
(whether they had children, yes or no).  
 Linear regressions using BMI as a continuous variable were also conducted to 
compare with measures of HIV disease progression at baseline, 18 months, and the 
change over 18 months (Table 6). There was a trend in the association between CD8 
cell count and BMI at 18 months (β=.002, 95% CI= .000, .004, P=.082).  The change in 
CD4% between baseline and 18 months was significantly associated with BMI, showing 
that for every unit increase in BMI there was .214 increase in the difference in CD4% 
(β=.214, 95% CI= .051, .376, P=0.011). All models were adjusted for age, gender, 
marriage and children.  No significant differences were found with CD4 cell count, 
CD8%, and CD4/CD8 ratio.  
 Table 7 shows that after controlling for age, gender, marital status, children, 
baseline CD4 cell count and viral load, there were no significant differences between 
BMI groups in the main outcome of 25% decline in CD4 cell count over 18 months (HR= 
.744; 95% CI= .489, 1.131; P=.166).  No significant differences were also observed in 
the secondary outcomes of CD4 cell count ≤ 250/μL, AIDS defining conditions, or the 
combined outcome of CD4 cell count ≤ 250/μL, AIDS defining conditions, whichever 
occurred first.  As shown in Table 8, using continuous baseline BMI, higher BMI was 
associated with a protective effect on the risk of having an AIDS defining condition (HR= 
.218; 95% CI= .068, .781; P=.011) after adjusting for age, gender, marriage, children 
and baseline CD4 cell count and viral load. Significant associations were not found 
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between continuous BMI and CD4 cell count ≤250/μL, AIDS defining conditions and the 
combined outcome of CD4 cell count ≤250/μL, AIDS defining conditions, whichever 
occurred first.  
Effect of Body Composition on Laboratory Markers of HIV Infection and Disease 
Progression  
There were no significant associations using linear regression between 
measures of HIV disease progression and fat mass, lean body mass, and body cell 
mass at baseline, 18 months and the difference between these visits (Table 5).   
A trend towards significance was seen with the outcome of 25% decline in CD4 
cell count and fat mass (HR= .974; 95% CI= .945, 1.003, P=.083) (Table 9). Higher fat 
mass was protective of having an AIDS defining condition (HR= .855; 95% CI= .741, 
.987; P=.033).  Higher fat mass was protective against the combined outcome of CD4 
cell count ≤ 250/μL and AIDS defining conditions, whichever occurred first (HR= .918; 
95% CI= .847, .994; P=.036).  The effect of lean body mass on disease progression was 
similar to fat mass, as shown on Table 10.  As lean body mass increased there was a 
higher risk of having ≥ 25% decline in CD4 cell count during the 18 months of follow-up 
but was trending towards significance (HR= 1.027; 95% CI= .997, 1.059, P=.082).  
Higher lean body mass was associated with higher risk of having an AIDS defining 
condition (HR= 1.169, 95% CI= 1.013, 1.349; P=.033), and higher risk of CD4 cell count 
≤ 250/μL and AIDS defining condition albeit not significant (HR= 1.075; 95% CI= .995, 
1.161; P=.068). These models were also adjusted for age, gender, marital status, having 
children and baseline CD4 count and viral load. 
Discussion  
This study showed that BMI and fat mass were protective by delaying the time to 
the first AIDS defining condition in HIV+ ART naïve adults in Botswana during 18 months 
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of follow-up. The fat stores would have provided the extra energy needed to maintain the 
innate immune system responding to protect against opportunistic infections and 
delaying wasting. There were no significant findings over 18 months when comparing 
the main outcome of a clinically significant decline of CD4 cell count (25%) and BMI 
stratified into two groups, BMI=18.0-24.9 kg/m2 and BMI ≥ 25 kg/m2. This finding 
suggests that the protective effect of fat stores are not enough to counteract the focused 
viral attack to the specific immune response, a suggestion supported by the results that 
show no association between BMI and HIV viral load.  Shor-Posner et al.17 found a 
significant difference between obese and nonobese when comparing clinically significant 
25% decline in CD4 cell count over 18 months.  However, these participants were drug 
users and may have been in worse nutritional status and have had HIV for longer 
duration and were in more advanced stage.  BMI at baseline as a continuous variable 
was associated with 78% lower risk of having an AIDS defining condition for every one 
unit increase in BMI.  Past incidence of >1 AIDS defining condition was associated with 
1.3 fold higher risk of having BMI <20 kg/m2 and AIDS defining conditions were also 
associated with a higher risk of wasting.23  
Higher BMI was also associated with a higher CD4% after 18 months of follow-
up.  CD4% is considered to be more steady than absolute CD4 cell counts and provide a 
better prognostic information before ART is initiated.24,25  Recently, it was shown to be a 
good predictor of disease progression for those starting ART with a CD4 cell count of 
>350 cells/µL.26  Other investigators have also found that immune counts are affected by 
weight and/or BMI in HIV.14,27   In a cross-sectional study14 with patients on ART, an 
absolute increase of 16 units of CD8 cell count was seen for every 1kg/m2 increase of in 
BMI.  Crum-Cianflone and colleagues27 compared normal weight to obese HIV+ adults at 
diagnosis and through HAART or ART initiation and concluded that those who were 
 64 
 
obese had smaller reductions in CD4% through time, regardless of whether diagnosis 
took place in the pre-HAART era or after. They also found similar results with CD4/CD8 
counts and only significant differences between normal weight and overweight in the 
HAART era with CD8 counts.  Our findings in ART-naïve population, early in HIV 
disease showed that there were no significant effects of BMI with CD4/CD8 or CD8 cell 
count. Interestingly, Crum-Cianflone and colleagues27 also showed that weight did not 
have an effect on immune cells at HIV diagnosis, but instead the effect of weight on 
immune cells was seen as the disease progressed. This study also did not have any 
significant differences at baseline between the normal weight and overweight/obese 
groups, because the great majority started their participation early in the disease at 
diagnosis.  
This is the first study that demonstrated a longitudinal association between 
reduced AIDS defining conditions with higher fat mass.  Higher fat mass was also 
associated with the combined outcome of CD4 cell count ≤ 250/μL and AIDS defining 
conditions.  On the outcome of a decline in the CD4 cell count of 25% or greater, the 
survival analysis showed a positive trend association with fat mass and negative 
association with lean body mass, a finding supported by cross-sectional significant 
findings in our larger (N=878) cohort in Botswana.28 Supporting this relationship over 
time, Visnegarwala and colleagues29 demonstrated in a cross-sectional study that 
women with a prior AIDS defining condition had lower total body fat in kilograms. 
Maintaining a large lean mass has higher energy costs. Stored protein is less available 
than dietary protein and provides less energy than the same weight in fat,30 this might be 
one of the reasons why lean mass was not protective, but might be even 
counterproductive to maintain adequate immune response before ART.  
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Findings from this study indicate that higher fat mass may provide protection 
from advanced HIV disease.  This protective effect has been hypothesized to be related 
to extra available energy for use in times of emergency during the HIV disease that 
would reduce protein’s use8 and also help to preserve the immune system, especially 
the innate immunity that is not directly affected by the infection.16,31  HIV and its 
secondary infections are known to generate a hypermetabolic state that is sustained 
throughout the disease.32 The HIV patient is susceptible to infections, in which the body 
will require energy to battle continuous infections and immune activation.  Those who 
are obese may have a genetic advantage in maintaining fat stores and utilizing that 
energy more efficiently to fuel the immune system. 
Although there seems to be an obesity paradox in HIV, being obese is a risk 
factor for mortality and chronic conditions or diseases such as cardiovascular diseases, 
diabetes, hypertension, and cancer.33-36  The participants of this study in the 
overweight/obese group had higher levels of total cholesterol, triglycerides, glucose, 
although not clinically significant, and higher LDL and blood pressure.  These differences 
could over a period of time potentially increase their risks for chronic conditions.  
Evidence from the literature supports that once a patient receives ART, their 
cardiovascular and liver risks increases, and obesity becomes an adverse factor for 
health and survival.5 Stevens and colleagues37 have stated concerns over providing 
confusing messages when discussing the obesity paradox and the possible harm it will 
have on public health efforts related to reducing obesity rates to lower the risk of chronic 
diseases. Conversely, other researchers38 theorize that our view of normal or optimal 
weight or BMI categories are too strict and may be biologically unsuitable.  They also 
argue that those with an established disease diagnosis may benefit from an emphasis 
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on lifestyle recommendations regarding physical activity and nutrition rather than 
intentional weight loss or gain.  
The limitations of this study include the sample size, not having sufficient 
numbers of participants to be able to examine differences between overweight and 
obese groups separately, and the predominance of women among the participants. The 
exact time since HIV diagnosis was not available, however, it was known that the 
participants were asymptomatic, never had a diagnosis of AIDS and did not qualify for 
ART. The majority were referred from the clinics where they were diagnosed. 
Participants with BMI in the range of underweight category were not included in the 
parent study as those ranges are strong prognostic indicators of AIDS.21 This HIV 
population was in the early stage of the disease in order to study ART naïve individuals 
and the finding cannot be generalized to all HIV seropositive patients.  The early stage of 
disease may be one of the reasons why we did not see a significant decline of CD4 as a 
main outcome. In HIV, bioimpedance (BIA) has been shown to be an effective method 
for detecting fat mass,39 however, BIA have limitations, since its values can be 
influenced by body arrangement, hydration, ingestion of food and drinks, air and body 
temperature and exercise.40  Our BIA measurement protocol provided for these 
limitations by giving detailed instructions to the participants on their preparation for their 
visit, and standardizing the measurement parameters. The strengths of this study 
consists of capturing and analyzing longitudinal data from HIV+ participants in 
Botswana, that we collected from early asymptomatic stage through defined health 
outcomes, and that this type of information is lacking in African populations.  
 In summary, the results of this study demonstrate that higher BMI and fat mass 
were protective in delaying HIV disease progression in this group of HIV+, ART naïve 
adults in Botswana. BMI separated into two groups, normal weight and 
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overweight/obese groups, did not show a significant effect on decline of CD4 cell count 
over 18 months and may have been due to limited sample size and to the participants’ 
early stage of the disease. Mechanistic studies on the relationship between BMI and 
body composition on disease progression are needed to clarify the obesity paradox in 
HIV.  
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Table 1: Change in BMI* from Baseline to 18 Months by BMI Groups 
Groups Baseline BMI 18 Months BMI P-value 
Overall 22.8 (20.7-27.2) 24.1 (20.4-27.2) .511 
Normal BMI 21.2 (19.9-22.6) 20.9 (19.3-22.5) .338 
Overweight/Obese 28.5 (26.6-30.1) 28.1 (26.1-30.4) .466 
*Reported as median (interquartile range); BMI expressed as kg/m2 
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Table 2:  Demographic Characteristics by BMI Group at Baseline 
 
 
Variable 
Total 
(N=217) 
Normal BMI 
(N=139) 
Overweight/ 
Obese BMI 
(N=78) 
 
P-
value 
Age (years)a 33 (28-39) 31 (28-38) 35 (30-43) .005b 
Gender 
     Male 
     Female 
 
54 (24.9) 
163 (75.1) 
 
44 (31.7) 
95 (68.3) 
 
10 (12.8) 
68 (87.2) 
 
.002b 
 
Marital Status 
     Single 
     Married 
     Other 
 
124 (59.0) 
24 (11.4) 
62 (29.5) 
 
86 (65.2) 
9 (6.8) 
37 (28.0) 
 
38 (48.7) 
15 (19.2) 
25 (32.1) 
 
.010b 
 
Education 
     None 
     Primary 
     Secondary 
     Tertiary 
 
13 (6.2) 
83 (39.5) 
95 (45.2) 
19 (9.0) 
 
9 (6.8) 
52 (39.4) 
59 (44.7) 
12 (9.1) 
 
4 (5.1) 
31 (39.7) 
36 (46.2) 
7 (9.0) 
 
.984 
 
Income (pula) 
     None 
    <300  
    300-600  
    601-1000  
    1001-6000 
     >6000  
     Unsure 
 
48 (22.9) 
20 (9.5) 
41 (19.5) 
51 (24.3) 
43 (20.3) 
6 (2.9) 
1 (0.5) 
 
31 (23.5) 
12 (9.1) 
26 (19.7) 
33 (25.0) 
27 (20.5) 
2 (1.5) 
1 (0.8)  
 
17 (21.8) 
8 (10.3) 
15 (19.2) 
18 (23.1) 
16 (20.5) 
4 (5.1) 
0 (0.0) 
 
.849 
 
Electricity 
     Yes 
      No 
 
83 (39.5) 
127 (60.5) 
 
49 (37.1) 
83 (62.9) 
 
34 (43.6) 
44 (56.4) 
 
.354 
 
Children 
     Yes 
     No 
 
180 (85.7) 
      30 (14.3) 
 
107 (81.1) 
25 (18.9) 
 
73 (93.6) 
5 (6.4) 
 
<.001b 
 
BMI (kg/m2)a 22.8 (20.7-27.2) 21.2 (19.9-22.6) 28.5 (26.6-30.1) .012b 
CD4 Cell Count 
(cells/µL)a 
411.3 (326.3-
546.7) 
415.9 (324.7-
548.9) 
401.2 (331.2-
545.2) 
.908 
 
CD8 Cell Count 
(cells/µL)a 
838.6 (617.5-
1194.9) 
804.1 (588.8-
1229.0) 
891.3 (669.0-
1177.8) 
.251 
 
CD4/CD8 Ratioa 0.5 (0.3-0.7) 0.5 (0.4-0.7) 0.5 (0.3-0.7) .375 
HIV Viral Load 
(Log10 copies/mL)a 
4.3 (3.5-4.8) 
 
4.3 (3.6-4.8) 4.2 (3.3-4.8) .525 
aReported as median (interquartile range); all other variables reported as n (%) 
bStatistically significant, P<.05 
 70 
 
Table 3: Nutrition Related Characteristics by BMI Group at Baseline 
 
Variablea 
Total 
(N=217) 
Normal BMI 
(N=139) 
Overweight/Obes
e BMI (N=78) 
P-
value 
Waist (inches) 32.3 (29.9-35.7) 30.7 (29.1-32.3) 37.6 (34.8-39.3) <.001b 
Waist-to-hip Ratio 0.8 (0.8-0.9) 0.8 (0.8-0.9) 0.8 (0.8-0.9) .017b 
Total Cholesterol 
(mmol/L) 
3.7 (3.0-4.3) 
 
3.5 (2.9-4.0) 
 
4.0 (3.5-4.7) 
 
<.001b 
 
Triglycerides 
(mmol/L) 
0.8 (0.6-1.0) 0.7 (0.5-0.9) 
 
0.8 (0.6-1.2) <.001b 
 
HDL (mmol/L) 1.1 (0.9-1.3) 1.1 (0.9-1.4) 1.1 (0.9-1.2) .301 
LDL (mmol/L) 2.4 (2.0-2.9) 2.4 (1.8-2.7) 2.6 (2.2-3.0) .043b 
Glucose (mmol/L) 4.5 (4.3-4.8) 4.5 (4.2-4.7) 4.6 (4.4-5.1) .002b 
Hemoglobin (g/dL) 12.9 (11.8-14.0) 12.7 (11.4-14.1) 13.0 (12.2-14.0) .251 
Hematocrit (%) 39.4 (36.3-42.3) 39.0 (35.4-42.6) 40.0 (37.3-4.9) .359 
Albumin (g/L) 41.0 (39.3-43.4) 41.6 (39.0-44.5) 39.8 (37.7-42.6) .010b 
Iron (µmol/L) 9.3 (6.3-13.0) 9.5 (6.0-13.2) 8.8 (6.6-12.7) .959 
Systolic Blood 
Pressure (mm Hg) 
119 (110-130) 
 
114 (108-128) 
 
122 (111-139) 
 
<.001b 
 
Diastolic Blood 
Pressure (mm Hg) 
76 (69-82) 
 
72 (65-80) 
 
80 (70-88) 
 
<.001b 
 
Total Energy Intake 
(kcal) 
1507.1 (1177.5-
1902) 
1496.4 (1178.6-
1933.2) 
1568.0 (1175.6-
1890.7) 
.749 
 
Protein Intake (%) 16.3 (14.0-19.6) 16.9 (14.1-20.7) 15.9 (14.0-18.6) .959 
Carbohydrate 
Intake (%) 
65.6 (57.1-71.8) 
 
65.6 (57.3-71.4) 
 
65.9 (56.6-72.7) 
 
.202 
 
Fat Intake (%) 17.4 (12.4-22.9) 17.4 (12.1-22.8) 17.4 (12.7-23.2) .524 
Fiber Intake 
(grams) 
 
16.0 (12.0-21.6)
 
16.1 (12.1-21.4)
 
15.6 (11.8-22.2) 
.871 
 
Basal Metabolic 
Rate (kcal) 
1401 (1268-
1564) 
1338 (1209-
1498) 
1532 (1382-1696) 
 
<.001b 
Fat Mass (%) 29.0 (23.9-33.9) 25.1 (19.9-29.3 34.9 (32.5-37.9) <.001b 
Lean Mass (%) 71.0 (66.1-76.1) 74.9 (70.6-80.1) 65.1 (62.1-67.5) <.001b 
Body Cell Mass (%) 34.1 (31.6-37.3) 35.9 (33.4-39.5) 31.2 (30.-33.2) <.001b 
Extracellular Mass 
(%) 
36.8 (33.7-40.0) 38.9 (36.2-41.0) 33.3 (31.8-35.4) <.001b 
aAll variables reported as median (interquartile range) 
bStatistically significant, P<.05 
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Table 4: Spearman Correlation Coefficients at Baseline 
 BMI Waist Waist
-to-
hip 
Fat 
mass 
Lean 
mass 
CD4 
cell 
count 
CD4% CD8 
cell 
count 
CD8
% 
CD4/ 
CD8 
ratio 
Viral 
Load 
BMI 
 
1.00           
Waist 
 
.82** 1.00          
Waist-to-hip 
 
.16* .53** 1.00         
Fat mass 
 
.72** .58** .03 1.00        
Lean mass 
 
-.72** -.58** .03 -1.00** 1.00       
CD4 cell 
count 
-.03 -.08 -.04 -.14* .14* 1.00      
CD4% 
 
-.09 -.24** -.32** -.08 .08 .50** 1.00     
CD8 cell 
count 
.06 .14 .22** -.03 .03 .26** -.61** 1.00    
CD8% 
 
-.05 .04 .11 -.01 .01 .29** .72** .73** 1.00   
CD4/ 
CD8 ratio 
-.05 -.19* -.26** -.06 .06 .44** .94** -.71** -.89** 1.00  
Viral load 
 
-.08 -.06 .10 -.02 .02 -.23** -.40** .29** .42** -.43** 1.00 
*Statistically significant, P<0.05, **Statistically significant, P<0.01 
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Table 5: Logistic Regression at Baseline, 18 Months and the Change Over 18 Months by BMI Groups* 
 Baseline 18 Months Change Over 18 Months 
Variable OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value 
CD4 cell count 1.000 .999, 1.002 .603 1.000 .999,   1.002 .640 1.001 .998,   1.004 .399 
CD4% .984 .946, 1.024 .424 .994 .952,   1.038 .783 1.076 .988,   1.166 .077 
CD8 cell count 1.000 .999, 1001 .966 1.000 1.000, 1.001 .433 1.000 1.000, 1.001 .381 
CD8% .991 .964, 1.019 .536 .993 .962,   1.026 .691 .976 .910,   1.046 .486 
CD4/CD8 ratio  .767 .286, 2.056 .598 .554 .139,   2.215 .554 .781 .308,   1.983 .603 
HIV viral load 1.054 .748, 1.485 .764 .886 .590,   1.330 .558 .900 .519,   1.561 .707 
*Dependent variable = BMI groups; reference category=BMI ≥25kg/m2; Individual models analyzed for each independent variable 
and adjusted for age, gender, marriage, and children.  
 
 
Table 6: Linear Regression at Baseline, 18 Months and the Change Over 18 Months by Continuous BMI*a 
 Baseline 18 Months Change Over 18 Months 
Variable Slope 95% CI P-value Slope 95% CI P-value Slope 95% CI P-value 
CD4 cell count .001 -.002,     .005 .469 .003 -.002,   .008 .240 -.004 -.010,   .002 .165 
CD4% -.036 -.116,     .043 .371 .052 -.063,   .168 .374 .214 .051,    .376 .011b 
CD8 cell count <.001 -.001,     .011 .938 .002 .000,    .004 .082 .001 -.001,   .002 .399 
CD8% -.031 -.087,     .024 .270 -.069 -.155,   .017 .116 -.076 -.225,   .073 .371 
CD4/CD8 ratio  -.818 -2.878, 1.243 .435 -3.258 -7.323, .807 .115 -.673 -2.613,1.266 .494 
HIV viral load .007 -.715,     .728 .986 .204 -.789, 1.196 .686 .625 -.609, 1.859 .318 
*Individual models analyzed for each independent variable and adjusted for age, gender, marriage, and children  
aDependent variable for baseline analysis included continuous BMI at baseline, dependent variable for 18 months analysis 
included continuous BMI at 18 months, and dependent variable for difference between visits analysis included continuous BMI at 
baseline.  
bStatistically significant, P<.05 
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Table 7: Adjusted Hazard Ratios on the Effect of BMI Groups on HIV Disease 
Progression Outcomes in HIV+ Adults in Botswana During a Follow-up Period of 18 
Months*  
Outcome HRb 95% CIc P-value 
≥ 25% decline in CD4 cell count .744 .489, 1.131 .166 
CD4 cell count ≤ 250/μL 1.021 .381, 2.740 .966 
AIDS Defining Conditions .500 .047, 4.465 .500 
CD4 cell count ≤ 250/μL & AIDS 
Defining Conditions   
1.089 .453, 2.619 .849 
*Cox proportional hazards model were used to examine the effect of BMI groups (0=BMI 
18.0-24.9 kg/m2 and 1=BMI ≥25kg/m2) on individual HIV disease progression outcomes. 
All individual HIV disease progression outcomes were analyzed as separate models and 
adjusted for age, gender, marriage, children and baseline CD4 count and viral load.  
aStatistically significant, P<.05 
bHR= Hazard Ratio 
cCI=Confidence Interval 
 
 
Table 8: Adjusted Hazard Ratios on the Effect of Baseline BMI on HIV Disease 
Progression Outcomes in HIV+ Adults in Botswana During a Follow-up Period of 18 
Months* 
Outcome HRb 95% CIc P-value 
≥ 25% decline in CD4 cell count .963 .919, 1.009 .113 
CD4 cell count ≤ 250/μL 1.043 .932, 1.167  .462 
AIDS Defining Conditions** .218 .068, .701 .011a 
CD4 cell count ≤ 250/μL & AIDS 
Defining Conditions   
.904 .796, 1.028 .124 
*Cox proportional hazards model were used to examine the effect of baseline continuous 
BMI on individual HIV disease progression outcomes. All individual HIV disease 
progression outcomes were analyzed as separate models and adjusted for age, gender, 
marriage, children and baseline CD4 count and viral load. 
**Model adjusted for age, gender, children and baseline CD4 cell count and viral load  
aStatistically significant, P<.05 
bHR= Hazard Ratio 
cCI=Confidence Interval 
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Table 9: Adjusted Hazard Ratios on the Effect of Baseline Fat Mass on HIV Disease 
Progression Outcomes in HIV+ Adults in Botswana During a Follow-up Period of 18 
Months* 
Outcome HRb 95% CIc P-value 
≥ 25% decline in CD4 cell count .974 .945, 1.003 .083 
CD4 cell count ≤ 250/μL .984 .909, 1.065 .793 
AIDS Defining Conditions .855 .741, .987 .033a 
CD4 cell count ≤ 250/μL & AIDS 
Defining Conditions   
.918 .847, .994 .036a 
*Cox proportional hazards model were used to examine the effect of baseline continuous 
fat mass % on individual HIV disease progression outcomes. All individual HIV disease 
progression outcomes were analyzed as separate models and adjusted for age, gender, 
marriage, children and baseline CD4 count and viral load. 
aStatistically significant, P<.05 
bHR= Hazard Ratio 
cCI=Confidence Interval 
 
 
 
 
Table 10: Adjusted Hazard Ratios on the Effect of Baseline Lean Mass on HIV Disease 
Progression Outcomes in HIV+ Adults in Botswana During a Follow-up Period of 18 
Months* 
Outcome HRb 95% CIc P-value 
≥ 25% decline in CD4 cell count 1.027 .997, 1.059 .082 
CD4 cell count ≤ 250/μL 1.008 .939, 1.100 .692 
AIDS Defining Conditions 1.169 1.013, 1.349 .033a 
CD4 cell count ≤ 250/μL & AIDS 
Defining Conditions   
1.075 .995, 1.161 .068 
*Cox proportional hazards model were used to examine the effect of baseline continuous 
lean mass % on individual HIV disease progression outcomes. All individual HIV disease 
progression outcomes were analyzed as separate models and adjusted for age, gender, 
marriage, children and baseline CD4 count and viral load. 
aStatistically significant, P<.05 
bHR= Hazard Ratio 
cCI=Confidence Interval 
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CHAPTER IV:  PRELIMINARY ASSOCIATION STUDY OF THE FAT MASS AND 
OBESITY ASSOCIATED GENE POLYMORPHISMS WITH HIV DISEASE 
PROGRESSION 
Abstract 
Objective:  Being overweight or obese in HIV has been shown to be protective in 
delaying disease progression. The objective of this study was to assess whether 
polymorphisms of the fat mass and obesity associated gene (FTO) are associated with 
body composition and HIV disease progression in HIV+, ART naïve adults in Botswana.  
Methods:  A retrospective study was completed with 215 participants from the placebo 
group of a randomized controlled trial previously conducted and published.  Five SNPs 
of the FTO gene were examined for their association with body composition and 
measures of HIV disease progression.  
Results: A total of 137 normal weight and 78 overweight/obese participants were 
studied. Only rs17817449 was associated with BMI in the dominant genetic risk model. 
FTO SNPs were not associated with laboratory markers of HIV infection at baseline. Fat 
mass and lean mass both were associated with rs1121980, rs8050136, and rs17817449 
with the risk alleles having a higher percentage of fat mass and lower lean body mass 
compared to the non-risk homozygous allele. Over 18 months, FTO SNPs were not 
associated with outcomes of HIV disease progression. 
Conclusions: FTO SNPs may contribute to the variation in body fat mass and lean 
mass in adults in Botswana.  FTO SNPs were not associated with a protective effect on 
HIV disease progression.  Further studies including GWAS are needed in African 
populations to clarify whether genetic variation mediates the obesity paradox.  
 
Keywords: HIV infection, ART naïve, BMI, disease progression, FTO gene  
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Introduction  
Studies have shown that obesity may be protective of further HIV disease 
progression before initiation of antiretroviral therapy (ART).1-4 Obesity was even found to 
be protective after initiation of ART.5  Higher CD4 cell counts and delayed diagnosis of 
AIDS have been found in those who were overweight or obese.1-3,6,7 Those who are 
obese may have a genetic advantage in maintaining fat stores and utilizing energy to 
fuel the immune system.  Conversely, obesity may also increase one’s risk for 
developing chronic conditions such as cardiovascular diseases, diabetes and cancer.8-10 
It is also a concern for the HIV patient that is now living longer due to increasing use of 
antiretrovirals.  Information on mechanisms for the potential benefits of obesity in 
delaying HIV disease progression are lacking.  
Obesity has a strong genetic background11 which has been estimated to account 
for 40-70% of the variation in human adiposity.12 The Fat Mass and Obesity Associated 
(FTO) gene was first identified in 200713 and has been associated with obesity and 
obesity related traits.14,15  The hypothalamus is the site where the FTO gene is mainly 
expressed16 and may be involved in energy homeostasis,17 and fat cell lipolysis which 
may regulate body fat.18 Specifically, the single nucleotide polymorphism (SNP) of the 
FTO gene rs9939609 (A allele) is most commonly associated with obesity;13,15,19  
however this relationship has not been replicated in an African population.  Currently, 
there are no published studies on the FTO gene and its association with obesity in HIV+ 
patients or in a population in Botswana.   
Botswana is experiencing one of the worst epidemics of HIV, with a prevalence 
rate of 23.4% among those who are 15 and 49 years of age.20 Botswana has the first 
successfully implemented ART program in Africa and provides universal access to ART 
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when CD4 cell counts reach < 350 cells/µL.21 Botswana, like other African countries, is 
also experiencing a lifestyle transition that includes increasing rates of obesity.22-24  
The aim of this preliminary study was to determine the interrelationships among 
being overweight/obese, markers of genetic propensity for obesity (SNPs in FTO) and 
HIV disease progression in HIV+ asymptomatic adults in Botswana not on ART over 18 
months. 
Methods  
Study Design and Participants 
We completed a retrospective study analyzing frozen laboratory specimens from 
215 HIV-positive men and women from the placebo group of a multifactorial, 
randomized, double-blinded, and placebo-controlled clinical trial in Botswana. 25  This 
parent study originally included 219 participants in the placebo group,  however only 215 
participants had sufficient samples for laboratory analysis.  The parent study 
investigated whether supplementation with multivitamins and selenium can improve 
immune function and prolong time to AIDS in ART naïve HIV infected adults.25  The 
study was performed between December 2004 and July 2009.  Confounding effects from 
the micronutrient supplementation on the outcome measures were avoided by using the 
participants from the placebo group for the current study.  Participants were eligible for 
the parent study with documentation of HIV seropositive test results, CD4 cell count > 
350 cells/µL, BMI  > 18 kg/m2 for women and > 18.5 kg/m2 for men, age ≥ 18 years, lack 
of a past history of AIDS-defining conditions, lack of current participation in another 
blinded clinical trial and still ineligible for receiving ART in Botswana during the study 
period. Women were excluded if pregnant or had intention to become pregnant.  All 
participants provided informed consent and approval to use their stored blood for future 
studies.  Participants were recruited from the Botswana-Harvard AIDS Initiative 
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Partnership (BHP) in Gaborone, Botswana.  We obtained approval to use their stored 
blood for genotyping SNPs from the FTO gene from the Florida International University 
Institutional Review Board (IRB), the Harvard School of Public Health IRB, and the 
Botswana Health Research Unit of the National Ministry of Health.  
Clinical Data 
At baseline and every three months, physical examination and medical history 
were performed by a trained nurse or a physician.   Anthropometrics were also obtained 
and body mass index (BMI) was calculated by dividing the participants’ weight in kg by 
their height in meters2.  
Waist and hip circumference was measured using a non-stretchable tape 
measure.  Waist circumference was measured at the narrowest part of the waist 
between the lowest rib and the iliac crest and the hip circumference at the widest portion 
of the buttocks.   Bioelectrical impedance analysis (BIA) was performed using the 
Biodynamics body composition analyzer (model BIA-310; Biodynamics Corp., Seattle, 
WA), which provides a print-out of measured impedance and calculated body fat and 
lean mass. Subjects were measured fasting, without shoes and socks, and electrodes 
were placed on the participant’s right hand and wrist and right foot and ankle. Medical 
history included intercurrent health events and currently prescribed medications; a 
review of records was used to verify prescriptions and determine changes in health 
status. Morbidity information was collected by questionnaires at screening, and at every 
monthly visit, and confirmed by documentation in the medical chart. Participants were 
followed medically by the research physicians at the same facilities where the research 
was conducted to improve compliance with study visits. 
Twenty-four hour recalls were conducted at baseline and every 3 months by 
trained clinical staff. Macronutrient and fiber intakes were calculated using the NutriBase 
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Professional, V.9 (Cybersoft, Phoenix, AZ) program modified by the South Africa 
database, including native foods for which information was available.  An average of at 
least 3 dietary recalls were used to obtain their estimated energy, carbohydrate, protein, 
fat and fiber intakes.  A questionnaire on activity patterns to obtain data on physical 
activity was completed.  Time spent walking was used a measure of physical activity.   
Laboratory Data 
At baseline and every six months, blood was also drawn to evaluate HIV viral 
load, lipid panel, and blood chemistry. Every three months blood was drawn for CD4 and 
CD8 cell counts.  Lymphocyte phenotype was determined with a four-color 
immunophenotyping panel of monoclonal antibodies. Differential counts were 
determined using a Coulter MaxM hematology instrument and corroborated with 
cytocentrifuge smears. HIV-viral load was determined using an in-vitro nucleic acid 
amplification test (Amplicor reagents and protocol, Roche-Diagnostics, Branchburg, NJ).   
Single Nucleotide Polymorphisms for the FTO gene 
 The Qiagen QIAamp DNA Blood kit was used to isolate total DNA from plasma 
samples stored at -80° C.  The DNA purification procedure was done using a standard 
microcentrifuge and QIAamp Mini spin columns.  A minimum of 200 µL of plasma was 
used to isolate sufficient DNA for analysis. 
 Polymorphism for the SNPs rs9939609, rs1421085, rs8050136, rs17817449, and 
rs1121980 of the FTO gene that have previously been associated with BMI were 
genotyped by TaqMan allelic discrimination assays from Life Technologies Inc. 
(Carlsbad, CA). Fluorescence was visualized through a real-time PCR system, Bio-Rad 
CFX96 real-time PCR machine (Hercules, CA). Bio-Rad SsoFast Supermix was used 
with the TaqMan assay.  PCR amplification was completed using 10 µL volume.  PCR 
thermal cycling included enzyme activation at 95°C for 2 minutes, 49 cycles of 
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denaturation at 95°C for 5 seconds and annealing and extension at 61°C for 5 seconds.  
A random 10% of samples were re-genotyped to assess genotyping reproducibility.   
Statistical Analysis 
BMI was stratified into two groups: 1. normal weight (BMI=18.0-24.9 kg/m2) and 
2. overweight/obese (BMI= ≥ 25 kg/m2).  Laboratory markers of HIV infection and 
disease progression included in the analyses were CD4 cell count, CD4%, CD8 cell 
count, CD8%, CD4/CD8 ratio and HIV viral load. Descriptive statistics such as 
frequencies, percentages, medians and interquartile ranges were used to characterize 
the two stratified BMI groups at baseline and its relation to the FTO SNPs.  Kruskal-
Wallis test was used to determine differences in body composition and HIV disease 
progression markers between the FTO SNP alleles. Chi-square tests were used to 
determine differences in gender, AIDS defining conditions, BMI groups and FTO SNPs. 
Logistic regression was used to assess the associations between the BMI groups and 
the presence of the FTO SNPs.  Logistic regression was also used for the dominant 
genetic risk model in which the subjects homozygous and heterozygous for the variant 
allele were compared to the wild-type homozygous group for measures of body 
composition and HIV disease progression. Proportional survival models were used to 
compare hazard ratios on time to HIV disease progression outcomes between FTO 
alleles, using the dominant model over 18 months.  HIV disease progression outcomes 
included time to ≥ 25% decline in CD4 cell count, CD4 cell count ≤ 250 and/or AIDS 
defining conditions over 18 months.  Models were adjusted for covariates that included 
age, gender, tribes, baseline CD4, baseline HIV viral load, total dietary kcal intake, and 
activity.  For all analyses, a two sided test was used and P<0.05 was considered 
statistically significant. Statistical analyses were completed using SPSS version 21. 
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Results  
Genotype Frequencies and Demographics  
The genotype and allele frequencies of all SNPs are shown in Table 1.  Overall, 
99% of the samples were successfully genotyped. Ten percent of the samples were re-
genotyped with 96% concordance. All of the SNPs, except for rs1421085, were in 
Hardy-Weinberg equilibrium, (P>.01). Further analysis with SNP rs1421085 was not 
performed since the minor allele frequency was less than 5% in this sample and it was 
not in Hardy-Weinberg equilibrium.  
Baseline description of the study participants separated by BMI groups is 
provided in Table 2.  A total of 215 participants, 137 in the normal BMI group and 78 in 
the overweight/obese BMI were included in the analysis, as four participants were 
excluded for having missing data.  The overweight/obese group was older (median 
(IQR)) (35.00 (30.00-43.00)) than the normal BMI group (31.00 (28.00-38.00), P<.004) 
and had a greater proportion of women (87.20% vs. 69.30, P<.001).  There were no 
statistically significant differences between these groups in laboratory markers of HIV 
infection at baseline.  
Association of FTO SNPs, Body Composition and Laboratory Markers of HIV 
Infection 
 SNPs rs1121980, rs8050136, and rs9939609 genotypes were not associated 
with measures of body composition and laboratory markers of HIV infection at baseline 
(Tables 3-6).  As shown in Table 6, the SNP rs17817449 had a marginal additive model 
association with BMI (P=.088), fat mass (P=.088), and lean mass (P=.085) reflecting a 
possible gene-dosage effect.  Subjects with the GG genotype had higher BMI and fat 
mass and lower lean mass compared to the other genotypes, albeit not statistically 
significant.    
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 Regression analysis was completed using the dominant model for all SNPs for 
examination of their relationships with measures of body composition and laboratory 
markers of HIV infection (Tables 7-10).  A significant relationship with rs8050136 was 
seen with fat mass (OR=1.078; 95% CI= 1.021, 1.140; P=.007) and lean mass 
(OR=.928; 95% CI= .878, .981; P=.008).  SNP rs17817449 was the only SNP 
associated with BMI (OR=1.082; 95%CI= 1.001, 1.169; P=.047).  SNP rs17817449 was 
also associated with fat mass (OR=1.086; 95% C=, 1.031, 1.145; P=.002) and lean 
mass (OR=.921; 95% CI= .874, .971; P=.002). Similarly, rs1121980 had significant 
relationships with fat mass (OR=1.065; 95% CI= 1.009, 1.125, P=.021) and lean mass 
(OR=.939; 95% CI= .889, .991; P=.022).   
Separate analyses were conducted by gender using logistic regression models to 
examine relationships between FTO SNPs, body composition and laboratory markers of 
HIV infection.  In females, rs8050136 in the dominant model showed a statistically 
significant association with fat mass (OR=1.102; 95% CI= 1.029, 1.179; P=.005) and 
lean mass (OR=.909; 95% CI= .849, .973; P=.006). The SNP rs17817449 was also 
significantly associated with fat mass (OR=1.099; 95% CI= 1.031, 1.171; P=.008) and 
lean mass (OR=.911; 95% CI =.855, .971; P=.004). No other SNPs had significant 
results for gender-specific associations.  
Although none of the SNPs had significant findings using the dominant model 
with laboratory markers of HIV infection, rs8050136 did have a trend relationship with 
HIV viral load (OR=.705; 95% CI= .481, 1.035; P=.074), showing a protective effect.  As 
shown in Tables 12-15, the FTO SNPs were not associated with HIV disease 
progression outcomes of 25% decline in CD4, CD4 ≤ 250 cells/µL and/or AIDS defining 
conditions over 18 months using Cox proportional hazard models.  
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Discussion  
This study provides preliminary data on the influence of FTO variants on the risk 
of being overweight/obese in HIV+ adults in Botswana. No significant associations were 
found with the SNP variants and waist or waist-to-hip ratio.  The variant rs17817449 
showed a trend towards higher BMI with the risk allele (GG) compared with the non-risk 
allele (TT).   This variant also had a significant association with BMI, showing a greater 
odds of having higher BMI when the risk allele is present, after controlling for age, 
gender, tribe, total kcal intake and activity. In a study conducted in South African 
adolescents, rs17817449 was also associated with BMI after adjusting for age, gender 
and pubertal stage.26 They showed a 1.9% effect size increase in BMI for each risk 
allele.  The relationship between measures of obesity and FTO variants has been 
contradictory among indigenous African populations.   In West Africans,27 several SNPs 
were associated with BMI, waist circumference and percent fat mass; however, no 
association was found with rs9939609, which is the most replicated SNP in the literature.  
A replication study completed with lean Gambian adults did not show any associations 
between 16 FTO SNPs and measures of body mass, but phenotypic comparisons of 
obesity could not be evaluated since participants that were obese were not part of the 
study.28 
Fat mass and lean mass were associated with rs1121980, rs8050136, and 
rs17817449 with the risk alleles having a higher percentage of fat mass and lower lean 
body mass compared to homozygosity for the non-risk allele.  Adeyemo et al.27 also 
investigated percent body fat in West Africans and showed significant relationships with 
FTO SNPs; however, the investigators did not report significant findings with any of the 
SNPs included in our study.  Although the exact mechanism for the effect of FTO on 
weight is unknown, it is hypothesized that it may affect food intake and energy 
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expenditure.29 FTO is highly expressed in the hypothalamus region of the brain, where 
food intake is controlled.16 In several studies, rs9939609 was shown to be associated 
with higher food intake in children and adults.30-33  Greater levels of FTO mRNA have 
also been found in the adipose tissue of obese persons.34-35 Although, FTO may regulate 
adiposity, factors that influence mobilization of adipose tissue such as leptin, have not 
been consistently demonstrated.   
This is the first study that examined FTO SNPs in HIV+ adults in Africa.  
Botswana is known to be a heterogeneous population with many ethnic groups.36  All of 
the SNPs were in Hardy Weinberg equilibrium, except for rs1421085, which also had a 
minor allele frequency of less than 5% in this sample.  The SNP rs1421085 was 
excluded from the analyses; however, similar genotype frequencies for this SNP were 
also seen in the reference population of the Yoruba tribe from Africa.37 The 
heterogeneity present in this population may also be a limitation for this study.  
Studies have shown that obesity may be protective of further HIV disease 
progression.4,38  We showed in this same cohort that higher fat mass was associated with 
a decreased risk of AIDS defining conditions and CD4 cell count <250 cells/µL 
(unpublished data).  This protection provided by fat may be explained partially through 
its association with leptin, an adipokine secreted by adipose tissue.   Higher fat mass is 
associated with higher levels of leptin, which has been shown to be associated with 
proliferation and reduced apoptosis of immune cells such as CD4+ T-cells.41,42 In the 
current analysis, we did not find any significant effects of FTO variants on laboratory 
markers of HIV infection and disease progression over time.   However, our findings 
suggest that FTO SNPs may indirectly influence HIV disease progression through their 
effect on fat mass before ART initiation.  
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Based on our analyses, further studies should include a larger sample size to be 
able to examine the associations with the SNPs of the FTO gene, BMI and HIV disease 
progression with greater statistical power. A larger sample size would have allowed for 
the examination of the relationship of the FTO variants and body mass in further 
stratified subgroups of overweight and obese separately.  Including other candidate 
SNPs of the FTO gene would also provide a better understanding of the role of the 
variants in the FTO gene on BMI or obesity in this population. Controlling for other 
variable that might affect BMI such as medications, time of HIV diagnosis, and co-
morbidities may also provide a better grasp on the effect of the gene on the phenotypic 
outcomes. 
 The FTO still remains the gene most consistently associated with obesity in 
various populations,43 but its associations have not been replicated in many African 
populations.  GWAS studies in African populations are lacking, and identifying SNPs that 
are relevant to this population is of importance since the SNPs showing associations in 
European and Asian populations may be different from SNPs that will show associations 
in African populations.  In this study, the SNPs chosen were based on those most 
associated with BMI in the literature; however, only rs17817449 had a significant 
relationships with BMI.  Significant associations were seen with percent body fat mass 
and lean mass which have been essential factors in HIV disease progression.44,45  A 
recent publication by Monda et al.46 identified new loci within the FTO gene that was 
associated with BMI in individuals of African ancestry; however, the authors concluded 
that SNPs were not likely to contribute to population differences in obesity, highlighting 
the importance of further studies.   
 This preliminary study did have limitations which may affect the interpretation of 
our findings.  Our study only included 215 participants and may not have had sufficient 
 90 
 
statistical power, as genetic association studies usually require a large number of 
participants.  This study was retrospective in design.  No underweight participants were 
included in the parent study and only a few cases of morbid obesity were present, which 
did not allow for the full spectrum of BMI to be examined and lowered the statistical 
power.  The findings of this study are pertinent to this specific population and not 
generalizable to all African populations.   
 In summary, our data indicate that FTO SNPs may contribute to the variation in 
body fat mass and lean mass in adults in Botswana.  FTO SNPs were not directly 
associated with a protective effect on HIV disease progression. Additional loci within the 
FTO gene should be examined in African populations to enhance our comprehension of 
their influence on obesity and its benefits and risk factors.  
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Table 1: FTO SNP Allele and Genotype Frequencies in HIV+ Adults in Botswana 
 
 Major allele 
Minor 
allele 
Genotype  
frequencies Allele frequencies 
dbSNP ID (A) (B) (AA) (AB) (BB) Major Minor 
rs1121980 T C 0.241 0.474 0.274 0.516 0.484 
rs1421085 T C 0.917 0.056 0.019 0.953 0.047 
rs8050136 A C 0.239 0.452 0.300 0.530 0.470 
rs9939609 A T 0.247 0.493 0.252 0.502 0.498 
rs17817449 T G 0.366 0.412 0.213 0.577 0.423 
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Table 2:  Demographic Characteristics by BMI Group (N=215) 
Variable Normal BMI 
(N=137) 
Overweight/ 
Obese BMI (N=78) 
P-
value 
Age (years) 31.00 (28.00-38.00) 35.00 (30.00-43.00) .004b 
Gender a 
     Male 
     Female 
 
42 (30.70) 
95 (69.30) 
 
10 (12.80) 
68 (87.20) 
 
.003b 
Waist (inches) 30.71 (29.13-32.28) 37.64 (34.84-39.27) <.001b 
Waist-to-hip ratio .80 (.78-.85) .85 (.79-.88) <.013b 
Lean mass (%) 74.90 (70.40-80.00) 65.10 (62.10-67.50) <.001b 
Fat mass (%) 25.10 (20.00-25.10) 34.90 (32.50-37.90) <.001b 
CD4 cell count (cells/µL) 415.87 (324.02-
546.99) 
401.10 (331.24-
545.24) 
.935 
 
CD4 % 27.02 (20.19-31.19) 23.66 (18.88-30.07) .151 
CD8 cell count (cells/µL) 797.05 (588.47-
1225.48) 
891.36 (669.20-
1177.81) 
 
 
CD8 % 52.24 (44.18-58.29) 49.92 (43.40-59.28) .228 
CD4/CD8 Ratio .54 (.37-.67) .49 (.32-.71) .624 
HIV viral load (Log10 
copies/mL) 
4.33 (3.60-4.82) 4.22 (3.30-4.82) .586 
aReported as n (%); all other variables reported as median (interquartile range) 
bStatistically significant, P<.05  
 93 
 
Table 3: FTO rs1121980: Association with Body Composition and Measures of HIV Disease Progression  
Variable  TT TC CC P-
value 
Age (years) 33 (29-39) 33 (28-39) 32 (28-42) .829 
BMI (kg/m2) 21.60 (28.83-25.95) 23.60 (20.48-27.70) 22.60 (20.70-26.60) .614 
Waist (inches) 31.10 (29.53-34.65) 33.27 (29.92-37.30) 32.28 (29.92-35.04) .425 
Waist-to-hip ratio .84 (.78-.88) .80 (.79-.85) .82 (.78-.88) .146 
Lean mass (%) 72.25 (65.65-77.28) 70.25 (64.28-75.90) 71.10 (65.48-76.03) .273 
Fat mass (%) 27.75 (22.73-34.35) 29.45 (24.10-35.73) 28.90 (23.98-33.53) .278 
CD4 cell count (cells/µL) 409.03 (329.59-566.49) 413.58 (324.17-544.17) 417.66 (325.80-560.00) .901 
CD4% 25.19 (19.32-31.58) 25.68 (16.69-30.56) 26.45 (19.58-30.61) .967 
CD8 cell count (cells/µL) 905.58 (650.25-1297.91) 839.66 (619.65-1159.03) 789.35 (604.56-1110.60) .627 
CD8% 52.45 (44.11-60.19) 51.14 (42.80-58.55) 50.88 (43.50-58.54) .769 
CD4/CD8 ratio .51 (.33-.65) .53 (.34-.72) .51 (.36-.64) .886 
HIV viral load (log10 
copies/mL) 
4.11 (3.28-4.92) 4.34 (3.42-4.81) 4.37 (3.71-4.82) .507 
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Table 4: FTO rs8050136: Association with Body Composition and Measures of HIV Disease Progression  
Variable  AA AC CC P-
value 
Age (years) 34 (29-39) 32 (28-39) 32 (28-43) .343 
BMI (kg/m2) 23.10 (21.30-27.10) 23.65 (20.35-27.33) 22.4 (20.45-25.95) .641 
Waist (inches) 32.09 (29.92-36.81) 33.46 (30.12-36.32) 32.28 (29.52-34.45) .272 
Waist-to-hip ratio .84 (.79-.84) .81 (.79-.85) .82 (.78-.88) .396 
Lean mass (%) 71.40 (66.88-75.55) 70.05 (64.95-75.88) 71.70 (67.50-79.85) .162 
Fat mass (%) 28.60 (24.45-33.13) 29.95 (24.13-35.05) 28.30 (20.15-32.50) .159 
CD4 cell count (cells/µL) 407.53 (325.55-580.64) 403.33 (318.04-532.34) 415.87 (343.72-545.17) .533 
CD4% 26.35 (19.60-31.95) 27.36 (19.58-30.56) 24.80 (19.74-30.24) .794 
CD8 cell count (cells/µL) 845.60 (586.65-1249.86) 773.38 (597.30-1120.43) 960.91 (667.27-1249.21) .280 
CD8% 52.28 (42.66-57.92) 48.59 (42.96-58.55) 53.54 (46.33-59.40) .217 
CD4/CD8 ratio .54 (.36-.71) .56 (.34-.69) .44 (.35-.63) .474 
HIV viral load (log10 
copies/mL) 
4.13 (3.63-4.71) 4.34 (3.23-4.90) 4.35 (3.67-4.78) .577 
 
 
 
 
 
  
 95 
 
Table 5: FTO rs9939609: Association with BMI, Body Composition and Measures of HIV Disease Progression  
Variable  AA AT TT P-
value 
Age (years) 31 (28-43) 33 (28-39) 34 (29-40) .656 
BMI (kg/m2) 22.25 (20.05-25.08) 24.20 (20.83-27.80) 22.80 (21.25-26.60) .105 
Waist (inches) 32.28 (29.53-34.25) 33.27 (29.92-37.30) 31.99 (29.92-35.91) .266 
Waist-to-hip ratio .82 (.79-.88) .81 (.78-.87) .83 (.78-.88) .478 
Lean mass (%) 71.70 (67.50-79.70) 70.55 (65.65-75.90) 70.40 (65.25-76.00) .507 
Fat mass (%) 28.30 (20.30-32.50) 29.45 (24.10-34.35) 29.60 (24.00-34.75) .500 
CD4 cell count (cells/µL) 414.54 (342.38-537.99) 421.13 (319.79-550.40) 397.88 (324.59-537.28) .908 
CD4% 25.21 (19.20-28.68) 27.19 (19.52-31.78) 26.42 (19.65-31.50) .516 
CD8 cell count (cells/µL) 933.94 (613.96-1296.52) 838.63 (629.54-1171.28) 813.47 (586.34-1117.45) .532 
CD8% 54.01 (47.92-60.58) 48.76 (43.91-59.09) 52.57 (42.49-56.23) .187 
CD4/CD8 ratio .48 (.34-.60) .56 (.33-.71) .50 (.36-.71) .349 
HIV viral load (log10 
copies/mL) 
4.39 (3.68-4.80) 4.34 (3.41-4.92) 4.19 (3.35-4.74) .605 
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Table 6: FTO rs17817449: Association with Body Composition and Measures of HIV Disease Progression  
Variable  TT GT GG P-
value 
Age (years) 31 (28-40) 33 (28-39) 35 (29-39) .343 
BMI (kg/m2) 22.20 (20.43-25.83) 23.60 (20.25-27.38) 23.95 (21.58-27.85) .088 
Waist (inches) 31.69 (29.53-34.65) 33.27 (29.92-36.37) 32.29 (30.09-34.93) .222 
Waist-to-hip ratio .82 (.78-.88) .80 (.79-.87) .82 (.77-.88) .808 
Lean mass (%) 73.60 (66.38-80.00) 70.30 (65.40-76.40) 68.75 (65.08-73.70) .085 
Fat mass (%) 26.40 (20.00-33.63) 29.70 (23.60-34.60) 31.25 (26.30-34.93) .088 
CD4 cell count (cells/µL) 407.04 (323.34-532.84) 442.65 (334.44-558.80) 397.94 (330.16-513.81) .517 
CD4% 25.29 (18.92-30.09) 26.59 (19.73-30.88) 25.93 (19.60-31.88) .640 
CD8 cell count (cells/µL) 866.85 (616.07-1115.62) 839.66 (623.67-1263.82) 783.42 (584.47-1150.51) .628 
CD8% 52.33 (46.42-58.45) 51.28 (42.57-59.50) 51.18 (43.37-56.76) .447 
CD4/CD8 ratio .49 (.34-.62) .55 (.34-.68) .55 (.36-.72) .432 
HIV viral load (log10 
copies/mL) 
4.38 (3.66-4.81) 4.35 (3.41-4.950 4.10 (3.46-4.65) .360 
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Table 7:  Association of FTO rs1121980 with Body Composition and HIV disease 
Progression in a Dominant Model*  
Variable ORa 95% CIb P-value 
BMI groups** 1.549 .754, 3.182 .234 
BMI (kg/m2) 1.057 .974, 1.147 .183 
Waist (inches)  1.049 .951, 1.157 .338 
Waist-to-hip ratio .144 .001, 134.902 .574 
Lean mass (%) .939 .889, .991 .022c 
Fat mass (%) 1.065 1.009, 1.125 .021c 
CD4 cell count (cells/µL) 1.001 .999, 1.003 .492 
CD4% 1.006 .963, 1.050 .804 
CD8 cell count (cells/µL)  1.001 .999, 1.001 .397 
CD8% .993 .963, 1.023 .625 
CD4/CD8 ratio 1.443 .463, 4.495 .527 
HIV viral load (log10 copies/mL) .736 .498, 1.087 .124 
**Dominant model: homozygous and heterozygous for the variant were compared to the 
wild-type homozygous. Models adjusted for age, gender, tribes, total kcal dietary intake 
and activity 
**BMI groups: 0=BMI 18.0-24.9 kg/m2 and 1=BMI ≥ 25 kg/m2  
aOR=Odds Ratio 
bCI=Confidence Intervals 
cStatistically significant, P < .05 
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Table 8:  Association of FTO rs8050136 with Body Composition and HIV disease 
Progression in a Dominant Model*  
Variable ORa 95% CIb P-value 
BMI groups** 1.584 .776, 3.231 .207 
BMI (kg/m2)a 1.071 .988, 1.162 .097 
Waist (inches) a 1.084 .980, 1.199 .117 
Waist-to-hip ratio 1.641 .002, 1142.635 .882 
Lean mass (%) .928 .878, .981 .008c 
Fat mass (%) 1.078 1.021, 1.140 .007c 
CD4 cell count (cells/µL) 1.001 .998, 1.002 .825 
CD4% 1.013 .972, 1.057 .534 
CD8 cell count (cells/µL)  1.001 .999, 1.001 .390 
CD8% .981 .952, 1.010 .190 
CD4/CD8 ratio 1.347 .473, 3.835 .577 
HIV viral load (log10 copies/mL) .705 .481, 1.035 .074 
**Dominant model: homozygous and heterozygous for the variant were compared to the 
wild-type homozygous. Models adjusted for age, gender, tribes, total dietary kcal, and 
activity 
**BMI groups: 0=BMI 18.0-24.9 kg/m2 and 1=BMI ≥ 25 kg/m2  
aOR=Odds Ratio 
bCI=Confidence Intervals 
cStatistically significant, P < .05 
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Table 9:  Association of FTO rs9939609 with Body Composition and HIV disease 
Progression in a Dominant Model*  
Variable ORa 95% CIb P-value 
BMI groups** .956 .455, 2.007 .904 
BMI (kg/m2) .991 .918, 1.070 .818 
Waist (inches) 1.501 .056, 39.884 .808 
Waist-to-hip ratio 1.018 .926, 1.118 .716 
Lean mass (%) 1.029 .975, 1.087 .294 
Fat mass (%) .971 .920, 1.025 .290 
CD4 cell count (cells/µL) 1.001 .998, 1.002 .868 
CD4% .982 .940, 1.026 .424 
CD8 cell count (cells/µL) 1.001 1.000, 1.001 .159 
CD8% 1.013 .983, 1.043 .405 
CD4/CD8 ratio .861 .310, 2.394 .774 
HIV viral load (log10 copies/mL) 1.204 .811, 1.788 .357 
**Dominant model: homozygous and heterozygous for the variant were compared to the 
wild-type homozygous. Models adjusted for age, gender, tribes, total dietary kcal and 
activity 
**BMI groups: 0=BMI 18.0-24.9 kg/m2 and 1=BMI ≥ 25 kg/m2  
aOR=Odds Ratio 
bCI=Confidence Intervals 
  
 100 
 
Table 10:  Association of FTO rs17817449 with Body Composition and HIV disease 
Progression in a Dominant Model*  
Variable ORa 95% CIb P-value 
BMI groups** 1.732 .885, 3.388 .109 
BMI (kg/m2) 1.082 1.001, 1.169 .047c 
Waist (inches) 1.093 .954, 1.203 .067 
Waist-to-hip ratio .132 .000, 59.237 .516 
Lean mass (%) .921 .874, .971 .002c 
Fat mass (%) 1.086 1.031, 1.145 .002c 
CD4 cell count (cells/µL) 1.002 1.001, 1.004 .136 
CD4% 1.013 .979, 1.060 .360 
CD8 cell count (cells/µL) 1.001 .999, 1.001 .862 
CD8% .986 .959, 1.013 .290 
CD4/CD8 ratio 1.500 .552, 4.076 .426 
HIV viral load (log10 copies/mL) .781 .550, 1.111 .169 
*Dominant model: homozygous and heterozygous for the variant were compared to the 
wild-type homozygous. Models adjusted for age, gender, tribes, total dietary kcal and 
activity 
**BMI groups: 0=BMI 18.0-24.9 kg/m2 and 1=BMI ≥ 25 kg/m2 
aOR=Odds Ratio 
bCI=Confidence Intervals 
cStatistically significant, P < .05 
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Table 11: Adjusted Hazard Ratios on the Effect of rs1121980 Using the Dominant Model 
on HIV Disease Progression Outcomes in HIV+ Adults in Botswana During a Follow-up 
Period of 18 Months*  
Outcome HRb 95% CIc P-value 
≥ 25% decline in CD4 cell count 1.326 .837, 2.100 .230 
CD4 cell count ≤ 250/μL 1.875 .544, 6.469 .320 
AIDS Defining Conditions** 1.536 .165, 14.264 .706 
CD4 cell count ≤ 250/μL & AIDS 
Defining Conditions   
1.203 .416, 3.475 .733 
*Cox proportional hazards model were used to examine the effect of rs1121980 on 
individual HIV disease progression outcomes. Dominant model used for rs1121980: 
homozygous and heterozygous for the variant were compared to the wild-type 
homozygous. All individual HIV disease progression outcomes were analyzed as 
separate models and adjusted for age, gender, tribe, baseline CD4 count, baseline viral 
load, total dietary kcal, and activity. 
**Models adjusted for age, gender and baseline CD4 cell count, baseline viral load, total 
dietary kcal and activity 
aStatistically significant, P<.05 
bHR=Hazard Ratio 
cCI=Confidence Interval 
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Table 12: Adjusted Hazard Ratios on the Effect of rs8050136 Using the Dominant Model 
on HIV Disease Progression Outcomes in HIV+ Adults in Botswana During a Follow-up 
Period of 18 Months*  
Outcome HRb 95% CIc P-value 
≥ 25% decline in CD4 cell count .946 .610, 1.468 .805 
CD4 cell count ≤ 250/μL 1.269 .394, 4.082 .690 
AIDS Defining Conditions** .279 .042, 1.854 .187 
CD4 cell count ≤ 250/μL & AIDS 
Defining Conditions   
.842 .303, 2.339 .742 
*Cox proportional hazards model were used to examine the effect of rs8050136 on 
individual HIV disease progression outcomes. Dominant model used for rs8050136: 
homozygous and heterozygous for the variant were compared to the wild-type 
homozygous. All individual HIV disease progression outcomes were analyzed as 
separate models and adjusted for age, gender, tribe, baseline CD4 count, baseline viral 
load, total dietary kcal, and activity. 
**Models adjusted for age, gender and baseline CD4 cell count, baseline viral load, total 
dietary kcal, and activity 
aStatistically significant, P<.05 
bHR=Hazard Ratio 
cCI=Confidence Interval 
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Table 13: Adjusted Hazard Ratios on the Effect of rs9939609 Using the Dominant Model 
on HIV Disease Progression Outcomes in HIV+ Adults in Botswana During a Follow-up 
Period of 18 Months* 
Outcome HRb 95% CIc P-value 
≥ 25% decline in CD4 cell count 1.039 .631, 1.709 .881 
CD4 cell count ≤ 250/μL 1.141 .350, 3.712 .827 
AIDS Defining Conditions** - - - 
CD4 cell count ≤ 250/μL & AIDS 
Defining Conditions   
1.399 .443, 4.412 .567 
*Cox proportional hazards model were used to examine the effect of rs9939609 on 
individual HIV disease progression outcomes. Dominant model used for rs9939609: 
homozygous and heterozygous for the variant were compared to the wild-type 
homozygous. All individual HIV disease progression outcomes were analyzed as 
separate models and adjusted for age, gender, tribe, baseline CD4 count, baseline viral 
load, total dietary kcal, and activity. 
**Model did not converge all AIDS defining conditions occurring in group with risk alleles 
aStatistically significant, P<.05 
bHR=Hazard Ratio 
cCI=Confidence Interval 
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Table 14: Adjusted Hazard Ratios on the Effect of rs17817449 Using the Dominant 
Model on HIV Disease Progression Outcomes in HIV+ Adults in Botswana During a 
Follow-up Period of 18 Months*  
Outcome HRb 95% CIc P-value 
≥25% decline in CD4 cell count .977 .641, 1.489 .913 
CD4 cell count ≤ 250/μL 1.517 .520, 4.421 .445 
AIDS Defining Conditions** .387 .060, 2.490 .317 
CD4 cell count ≤ 250/μL & AIDS 
Defining Conditions   
1.205 .468, 3.101 .700 
*Cox proportional hazards model were used to examine the effect of rs17817449 on 
individual HIV disease progression outcomes. Dominant model used for rs17817449: 
homozygous and heterozygous for the variant were compared to the wild-type 
homozygous. All individual HIV disease progression outcomes were analyzed as 
separate models and adjusted for age, gender, tribe, baseline CD4 count, baseline viral 
load, total dietary kcal, and activity. 
**Models adjusted for age, gender and baseline CD4 cell count, baseline viral load, total 
dietary kcal, and activity 
aStatistically significant, P<.05 
bHR=Hazard Ratio 
cCI=Confidence Interval 
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CHAPTER V: ASSOCIATION OF INFLAMMATORY MARKERS WITH HIV DISEASE 
PROGRESSION IN ART NAÏVE HIV+ ADULTS IN BOTSWANA 
 
Abstract 
Objective:   This study evaluated the relationship between inflammatory markers 
including C-reactive protein, leptin, and bacterial endotoxin lipopolysaccharide (LPS) and 
body composition and HIV disease progression in HIV+ asymptomatic adults not on ART 
in Botswana over 18 months. 
Methods:  This is a retrospective analysis of data and specimens from a nutritional 
study, henceforth called parent study. Current study was conducted in 144 HIV+ ART 
naïve adults who were in the early stages of HIV disease in Botswana.  CRP was 
measured by the parent study and plasma leptin and LPS were determined in a subset 
of 60 participants at baseline and 18 months.  Linear and logistic multivariable 
regression analyses were conducted and adjusted for age, gender, smoking and body 
fat mass%.  
Results:  CRP was positively associated with BMI and waist circumference and 
inversely with CD4%.  Leptin had significant relationships with BMI, fat mass%, and 
waist circumference. Higher HIV viral load was significantly associated with lower levels 
of leptin.  LPS was inversely associated with BMI and fat mass%.  Higher levels of LPS 
were also associated with higher viral load.   
Conclusions:  HIV disease progression was predictive of inflammation and found to be 
independent of body fat.  These findings suggest that at least one explanation for the 
obesity paradox may be accounted for by increased LPS and lower leptin among those 
with lower BMI which was associated with higher HIV viral load.  The mechanisms 
 110 
 
affecting HIV disease progression through inflammation are complex and still not entirely 
understood, which warrants further prospective investigation.  
 
Keywords: HIV infection, ART naïve, disease progression, CRP, leptin, LPS, 
inflammation  
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Introduction  
 Chronic inflammation and immune activation are related to HIV disease 
progression as documented in the literature.1-3 Inflammation is also associated with other 
HIV co-morbidities and non-HIV related complications such as cardiovascular and 
metabolically-related diseases/conditions.4-6 Inflammation is involved in the depletion of 
T-cells, and chronic immune activation drives the general and HIV-specific losses of 
immune function.7   Continuous inflammation induces pro-inflammatory cytokines which 
has been shown to produce thymic and T cell progenitor dysfunction.8  It has also been 
shown that triggered or activated CD4 cells are favored targets for viral infection and 
replication.  Inflammation can also set up non-infected CD4 cells and other immune cells 
for death by programmed cell death or apoptosis.9 The biomarkers of inflammation 
examined in this study were C-reactive protein, leptin, and lipopolysaccharide (LPS).   
Obesity is known to be associated with a chronic state of low grade inflammation. 
Inflammation in obesity is due to many mechanisms which include disordered secretion 
of adipokines within adipose tissue, resulting in insulin resistance and metabolic 
disorders.10 There seems to be controversy in the literature regarding obesity and 
inflammation and its relationship to HIV disease, which requires further research. A 
nutrition transition in sub-Saharan Africa is occurring with an increase in obesity,11 along 
with being the most affected region by the HIV epidemic.12  The interplay of body 
composition, inflammation and its effect on HIV disease progression warrant 
investigation to provide relevant clinical treatment for patients.   
C-reactive protein or CRP is considered a sensitive systemic marker of 
inflammation and an acute phase reactant.13    Higher levels of CRP have also been 
associated with obesity and specifically abdominal obesity.14 CRP > 3 mg/dL has been 
associated with a higher risk for inflammation and mortality.15 In HIV, CRP has been 
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shown to be a sensitive marker beyond cardiovascular disease;16 it has been 
demonstrated to be an important predictor of higher risk of AIDS and mortality after ART 
initiation in ART naïve patients.17  
 Leptin is considered to be a pleiotropic molecule, with not only metabolic roles 
but also endocrine and immune regulation.18  In some studies, higher levels of leptin 
were found to be present during infection and inflammation; however, the results in 
human studies have been inconsistent in various diseases, including HIV.18   Leptin is 
involved in the proliferation of T- cells, including CD4 and CD8 cells.19  Higher levels of 
leptin have been found in obese individuals20 which may enhance the immunity through 
its role in proliferation and anti-apoptotic effects on lymphocytes.  Leptin has been 
inversely associated with HIV viral load, independent of adipose tissue.21 
Microbial translocation or bacterial products that crossed the gastrointestinal 
mucosa into circulation, is thought to have a role in persistent immune activation in HIV 
infection and can provoke pro-inflammatory reactions.22  Lipopolysacchride (LPS), an 
endotoxin, is a constituent of Gram-negative bacterial cell walls and known to produce 
proinflammatory responses.23 During HIV, microbial translocations may occur due to 
epithelial damage to the intestine, loss of T-helper-17 cells and a reduced removal of 
microbial products by phagocytes.22  Increased secretion of pro-inflammatory cytokines 
can also contribute to increased T cell activation and specifically can increase CD8 T cell 
activation and depletion of CD4 T cells.22 LPS has also been implicated in obesity and 
insulin resistance and high levels may affect inflammation and promote weight gain.25  
Although microbial translocation is associated with immune activation and disease 
progression in developed countries,26-28 whether it contributes to HIV disease 
progression in African HIV+ individuals is not well understood. Sequestration of LPS by 
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higher circulating lipoproteins in obesity has been suggested as mechanism for the 
obesity paradox29 and warrants further investigation in HIV.  
Most of the studies looking at the relationship between inflammation and HIV 
have been conducted in settings where patients are taking ART, and mostly in 
developed nations. Both of these conditions may confound findings.  Few longitudinal 
studies are available in African populations.  The objective of this study was to evaluate 
over 18 months the relationship of inflammatory markers (C-reactive protein, leptin, and 
LPS) with body composition and laboratory markers of HIV disease infection and 
progression in HIV+ asymptomatic adults who are not receiving ART in Botswana. 
Methods  
Study Design and Participants 
A retrospective study was conducted to examine data and specimens from 144 
HIV-positive men (n=34) and women (n=110) from the placebo group of a multifactorial, 
randomized, double-blinded, placebo-controlled clinical trial in Botswana, which 
investigated whether supplementation with multivitamins and selenium could enhance 
immune function and delay the time to AIDS in ART naïve HIV+ adults.30 The study was 
conducted between December 2004 and July 2009.  This parent study originally 
included 219 participants in the placebo group, however our retrospective study only 
included 144 participants with available data on high sensitivity C-reactive protein (hs-
CRP). The placebo group was used to avoid any confounding effects from the 
micronutrient supplementation on the outcome measures.  Participants were eligible for 
the study with confirmation of HIV status, CD4 cell count >350 cells/µL, BMI >18 kg/m2 
for women and 18.5 kg/m2 for men, age ≥ 18 years, lack of a past history of AIDS-
defining conditions, and were not participating in another blinded clinical trial or taking 
ART. Women were excluded if pregnant or had intention to become pregnant.  All 
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participants provided informed consent and approval to use their stored blood for future 
studies.  Participants were recruited from the Botswana-Harvard AIDS Initiative 
Partnership (BHP) in Gaborone, Botswana.  We obtained approval to use their stored 
blood for leptin and LPS from the Florida International University Institutional Review 
Board (IRB), the Harvard School of Public Health IRB and the Botswana Health 
Research Unit of the National Ministry of Health.  
Clinical Data 
At baseline and every three months, physical examination and medical history 
were performed by a trained nurse or a physician.   Anthropometrics were also obtained 
and body mass index (BMI) was calculated by dividing the participants’ weight in kg by 
their height in meters2. Waist and hip circumference was measured using a non-
stretchable tape measure and following standardized procedures.  Waist circumference 
was measured at the narrowest part of the waist between the lowest rib and the iliac 
crest and the hip circumference at the widest portion of the buttocks.   Bioelectrical 
impedance analysis (BIA) was measured using the Biodynamics body composition 
analyzer (model BIA-310; Biodynamics Corp., Seattle, WA), which provides a print-out of 
measured impedance and calculated body fat and lean mass. Subjects were measured 
without shoes and socks, and electrodes were placed on the participant’s right hand and 
wrist and right foot and ankle. Morbidity information was collected by questionnaires at 
screening, and at every monthly visit, and confirmed by documentation in the medical 
chart. Participants received their medical care in the same facilities to improve retention.  
Laboratory Data 
At baseline and every six months, blood was also drawn to evaluate HIV viral 
load, lipid panel, and blood chemistry. Every three months blood was drawn for CD4 and 
CD8 cell counts.  The remaining plasma was centrifuged, aliquoted into cryovials and 
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stored at -80° C for future studies.  Lymphocyte phenotype was determined with a four-
color immunophenotyping panel of monoclonal antibodies. Differential counts were 
determined using a Coulter MaxM hematology instrument and corroborated with 
cytocentrifuge smears. HIV-viral load was determined using an in-vitro nucleic acid 
amplification test (Amplicor reagents and protocol, Roche-Diagnostics, Branchburg, NJ).   
Inflammatory Markers 
A total of 144 participants had high sensitivity-C reactive protein (hs-CRP) levels 
from the parent study that was analyzed using protein-latex assay (Roche, Basel, 
Switzerland) in the Botswana-Harvard HIV Reference Laboratory in Gaborone, 
Botswana.  A subset of 60 participants were randomly selected with available samples to 
measure plasma leptin and LPS levels at baseline and 18 months.  Plasma leptin levels 
were measured using the Quantikine Human Leptin Immunoassay kit by R&D systems 
(Minneapolis, MN, USA), a sandwich ELISA designed to measure soluble human leptin 
in plasma, according to manufacturer’s instructions.  Plasma LPS or endotoxin levels 
were measured using the Limulus Amebocyte Lysate (LAL) by Lonza (Walksersville, 
MD, USA), a chromogenic quantitation of bacterial endotoxin, according to 
manufacturer’s instructions with the following modifications: Samples were diluted 1:20 
with endotoxin-free water to avoid interference with background color and preheated to 
70°C for 10 minutes prior to analyses to inactivate plasma proteins. Duplicates were 
assessed for each sample, for both leptin and LPS. The coefficient of variation or CV% 
was calculated and CVs greater than 10% were reanalyzed.   
Statistical Analysis 
Laboratory markers of HIV infection and disease progression included in the 
analyses were CD4 cell count, CD4%, CD8 cell count, CD8%, CD4/CD8 ratio and HIV 
viral load. Descriptive statistics such as frequencies, percentages, medians and 
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interquartile ranges were used to characterize the participants at baseline and its relation 
between laboratory markers of HIV infection and inflammatory markers.  Mann Whitney 
U was used to determine differences in laboratory markers of HIV infection and body 
composition between the BMI groups and by inflammatory marker groups. BMI was 
stratified into two groups: Group 1: normal weight (BMI=18.0-24.9 kg/m2) and Group 2: 
overweight/obese (BMI=≥ 25 kg/m2) for the statistical analyses.  Viral load was also 
stratified into <4 log10 copies/mL or 10,000 copies/mL and ≥ 4 log10 copies/mL as a 
measure of further disease progression and infectivity.31, 32  Linear and logistic 
regressions were used to assess the relationship between body composition, laboratory 
markers of HIV infection, and inflammatory markers. The linear multivariable regression 
analysis also included a measure to check for multicollinearity known as variance 
inflation factor (VIF).  All models had a VIF <5, therefore multicollinearity was ruled out.  
Multicollinearity was also checked for the logistic regression models and variables with 
correlations r >.75 were not included.  Models were adjusted for covariates that included 
age, gender, smoking and fat mass%. Logistic regression models included dependent 
inflammatory markers at the following cut-offs: hs-CRP < or ≥ 3mg/L; leptin< or ≥ median 
and LPS < or ≥ median.  Smoking tobacco was used a covariate since it has 
immunomodulatory effects and may affect T-cell activation.33,34  Variables that were not 
normally distributed were natural log transformed, except for CD4 and CD8 cell counts 
that were square-root transformed.  For all analyses, a two sided test was used and 
P<0.05 was considered statistically significant.  Statistical analyses was completed using 
SPSS version 21. 
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Results  
Demographics  
 Table 1 displays the demographics of the population included for the analyses 
conducted below.  In summary, the median age was 33 years with an IQR of 29-39 
years and 76.40% were women.  The median CD4 cell count and HIV viral load were 
409.03 (IQR: 329.79-552.58) and 4.33 (IQR:3.58-4.83), respectively.  The inter-assay 
CV for Leptin was 7.45 and for LPS 4.38%.   The intra-assay CV for leptin ranged 
between 6.76-8.69% and for LPS between 2.41-5.87%.   
Spearman Correlations 
 A positive correlation was seen between hs-CRP and leptin (r=.404, P=.010) 
(Table 2).  Leptin was also correlated with LPS (r=.357, P=.005).  There was no 
significant correlation between hs-CRP and LPS.  Hs-CRP was not correlated with 
measures of body composition and HIV disease progression.  However, trends were 
seen between hs-CRP and BMI, waist circumference, lean body mass and fat mass.  
Strong positive correlations were observed between leptin and BMI (r=.734, P<.001), 
waist circumference (r=.603, p<.001) and fat mass % (r=.838, P<.001). LPS was 
inversely correlated with BMI (r=.288, P=.025), waist circumference (r=.493, P=.003) and 
fat mass % (r=.362, P=.004).   Lean mass % was inversely correlated with leptin (r=-
.836, P<.001) and LPS (r=-.361, P=.005).  No correlations were observed between 
inflammatory markers and laboratory markers of HIV infection.  The correlations 
between LPS and CD8% and viral load were approaching significance at r=.253, P=.052 
and r=.246, P=.060, respectively.  
Relationship between BMI and Inflammatory Markers 
 BMI was categorized into two groups: normal BMI (18.0-24.9 kg/m2) and 
overweight/obese BMI (≥ 25 kg/m2) and its association with inflammatory markers were 
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examined.  Those who were overweight/obese had higher median (IQR) levels of hs-
CRP (P=.028) and leptin (P<.001) compared to the normal BMI group, (Table 3). 
Conversely, lower levels of LPS were seen in the overweight/obese group compared to 
the normal BMI group (P=.001).  
Inflammatory Markers, Body Composition and Laboratory Markers of HIV Infection 
 Table 4 demonstrates that having a CRP at or above 3 mg/L is associated with 
higher median (IQR) of waist circumference (P=.036), and CD8 cell count (P=.030) and 
lower levels of CD4% (P=.013), and CD4/CD8 ratio (P=.015). A trend was observed in 
the relationship of having a hs-CRP ≥ 3 mg/L and higher CD8% (P=.078). As shown on 
Table 5, those who had higher median levels of leptin (≥ 13,304 pg/mL) had higher 
median (IQR) BMI (P<.001), waist circumference (P=.003), and fat mass (P<.001).  
Levels below the median of leptin, were associated with higher lean body mass 
(P<.001).  None of the parameters for HIV disease progression were significantly 
associated with median levels of leptin.   Having LPS levels below the median (<.0582 
EU/mL) were significantly related to higher BMI (P=.001), waist circumference (P=.005), 
and fat mass% (P=.002) (Table 6).  Levels above the median were associated with 
higher viral load (P=.023) and lean body mass % (P=.002).  
Regression Analyses of Inflammatory Markers and Laboratory Markers of HIV 
Infection and Disease Progression  
 Linear regression models were conducted to examine the relationship of body 
composition and HIV disease progression markers with hs-CRP, leptin, and LPS at 
baseline, 18 months and the change over 18 months.  All models were adjusted for age, 
gender, smoking and fat mass%. Log transformed BMI at baseline was the only 
measure of body composition associated with continuous hs-CRP at baseline (β=1.905; 
95% CI= .281, 3.530; P=.022) (Table 7). No markers of HIV infection were associated 
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with continuous hs-CRP at baseline or 18 months.  Log transformed leptin was 
associated with continuous BMI at baseline (β=1.764; 95% CI= .788, 2.739; P=.022) and 
18 months (β=2.739; 95% CI= 1.133, 3.075, P<.001) (Table 8).  Higher leptin was also 
associated with higher fat mass% at baseline (β=.112; 95% CI= .090, .135; P<.001) and 
18 months (β=.403; 95% CI= .017, .069; P=.002).  For every unit increase in 
transformed leptin there was a significant 2.103 unit increase in waist circumference at 
18 months (β=2.103; 95% CI= .806, 3.400; P=.002).  Having a viral load of <4 log10 
copies/mL was associated with higher leptin levels (β= -.305; 95% CI= -.579, -.031; 
P=.030) at baseline.  Only waist circumference at baseline had a significant relationship 
with log transformed LPS (β=-1.940; 95% CI= -3.397, .483; P=.011) (Table 9).  
A separate linear regression analysis stratified by BMI groups was conducted. In 
those who had a BMI ≥ 25kg/m2, higher log transformed leptin was associated with lower 
viral load (β=-.205; 95% CI= -3.94, -.016; P=.035) at baseline. 
Hs-CRP ≥ 3 mg/L was significantly related to higher BMI at baseline 
(OR=60.960; 95% CI= 2.784, 1334.723; P=.009), waist circumference at 18 months 
(OR=98.811; 95% CI= 1.697, 5755.086; P=.027), CD4% at baseline (OR=.949; 95% CI= 
.902, .998; P=.042) (Table 10) and waist circumference over 18 months (OR=65.078; 
95% CI: 1.490, 2842.157; P=.030). Lower CD8 count change over 18 months was 
associated with CRP ≥ 3 mg/L (OR=.906; 95% CI=.831, .988; P=.025). A trend 
association was seen in the relationship between hs-CRP ≥ 3 mg/L and BMI ≥ 25 kg/m2 
(OR=2.407; 95% CI= .941, 6.156; P=.067).  Leptin above the median (13,304 pg/mL) 
was related to several body composition measures at baseline and 18 month; however, 
there were no association with measures of HIV disease progression (Table 11).  Leptin 
above the median was associated with a higher odds of having higher BMI at baseline 
(OR=2.073; 95% CI= 1.194, 3.601; P=.010) and 18 months (OR=1.554; 95% CI= 1.125, 
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2.146; P=.008).  Overweight/obese BMI category was also associated with leptin above 
the median at baseline (OR=58.572, 95% CI= 2.187, 1568.688; P=.015) and 18 months 
(OR=79.634; 95% CI= 4.607, 1376.659; P=.003).  Additionally, a higher odds of having 
more fat mass% was seen in the group that had leptin levels at or above the median at 
baseline (OR=1.580, 95% CI= 1.214, 2.055; P=.001) and 18 months (OR=1.231; 95% 
CI= 1.070, 1.416; P=.004).  The likelihood of higher leptin increased with higher waist 
circumference (OR=1.267; 95 CI= 1.016, 1.580; P=.036).  Leptin above the median was 
also associated with having an increase in CD4% over 18 months (OR1.456;  95% 
CI=1.456, 1.025, 2.069; P=.036). Lastly, Table 12 displays the relationships between 
body composition and laboratory markers of HIV infection and disease progression for 
those at or above the median of LPS (.0582 EU/mL).  BMI and having BMI ≥ 25 kg/m2 
was protective of having LPS above the median at baseline (OR=.790, 95% CI= .630, 
.990; P=.041; and OR=.035, 95% CI= .004, .283; P=.002, respectively) and BMI at 18 
months (OR=.799, 95% CI= .655, .976; P=.028). Fat mass% was also shown to be 
protective of having higher LPS at baseline (OR=.852, 95% CI= .757, .958; P=.007).  At 
baseline LPS at or above the median was associated with higher viral load (OR=2.608, 
95% CI= 1.111, 6.124; P=.028) and having a viral load ≥ 4 log10 copies/mL (OR=8.005, 
95% CI= 1.762, 36.357; P=.007).   The relationships between LPS as a continuous 
variable and viral load ≥ 4 log10 copies/mL was approaching significance (OR=3.776, 
95% CI= .959, 14.869; P=.057). 
Discussion 
 The results presented here suggest a strong association between inflammatory 
markers and body composition and HIV disease progression in ART naïve adult 
participants in Botswana.  To our knowledge, no study has assessed leptin or LPS in a 
population from Botswana with or without HIV infection.  
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CRP has previously been shown to be associated with CD4 cell count and HIV 
viral load in ART naïve HIV+ adults.35-37 Our study did not confirm these associations 
with measures of HIV disease progression, except for CD4%.   CRP levels ≥ 3 mg/L 
were associated with lower CD4%.  CD4% is considered to be a more stable measure 
than absolute CD4 cell counts and is thought to provide a better prognostic information 
before ART is initiated in HIV infection.38,39  Thus, this study showed that CD4%, as a 
measure of HIV disease progression, was an independent predictor of higher CRP levels 
after adjusting for age, gender, smoking and fat mass%.  
CRP and its association with mortality were investigated in HIV+ populations in 
Botswana;40,41  however, these previous reports did not asses its relationship with 
parameters of disease progression such as CD4 cell count or viral load.  CRP levels 
were found to be higher 4 weeks after initiation of ART in patients who died compared to 
those who survived, in another HIV+ adult cohort in Botswana.40 Baseline levels of CRP 
were also higher in those who died after ART initiation compared to matched controls in 
Botswana.41  
 Azzoni et al.21 was the first to show that leptin levels were inversely associated 
with viral replication independent of the amount of adipose tissue.  Their cohort of 
exclusively ART naïve women from South Africa also demonstrated an association 
between viral load and immune activation.  We confirmed an inverse relationship 
between leptin levels and viral load at baseline, independent of body fat.  These 
associations were found in HIV+ male and female participants.  These results are in 
agreement with those of Azzoni and colleagues21 who hypothesized that high viral 
replication and immune activation could result in chronic inflammation that would cause 
lipoatrophy, therefore, lowering leptin levels.  
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 Leptin is involved in the proliferation of CD4 and CD8 cells,42 however, we did not 
find any significant relationships between leptin and CD4 or CD8 cell counts, even while 
adjusting for fat mass%.  However, leptin above the median was associated with a 
greater increase in CD4% over 18 months.  Other researchers21,43,44 examining leptin in 
HIV+ ART naïve individuals did not find significant relationship with CD4 cell counts.  
The lack of an association of CD4 cell count and leptin may be due to the early stage of 
the disease and healthier status in these participants.  The parent study’s enrollment 
criteria included having CD4 ≥ 350 cells/µL and BMI >18 kg/m2, which may have 
precluded the chance of examining the associations with lower levels of CD4 counts and 
BMI in the range of undernutrition at baseline. Additionally, ART-naïve participants 
usually present uncontrolled viral loads. 
 Previous studies evaluating LPS and HIV disease progression in ART naïve 
HIV+ adults have shown conflicting findings.  In a cohort of HIV-positive, ART-naïve 
adults, Marchetti el al. 28 reported a significant relationship between LPS and disease 
progression as a composite outcome that included, AIDS defining conditions, death, 
CD4 cell counts < 200 cells/µL, or start of ART in HIV+ ART naïve adults, who were 
followed for approximately 3 years. This relationship was independent of CD4 cell counts 
and HIV viral load.  Conversely, a study examining LPS and HIV disease progression in 
ART naïve Ugandans and Americans was not able to detect sufficient LPS levels in their 
samples for analyses.45  A recent study conducted in Kenyan women demonstrated that 
LPS levels were associated with chronic HIV infection, whether treated or not with ART; 
however, no direct associations with CD4 cell count or viral load was found.46  This 
present study did not find a significant association between LPS and CD4 cell count, but 
LPS was significantly and inversely associated with viral load.  LPS levels above the 
median were associated with higher viral load and those with LPS levels ≥ the median 
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were 8 times more likely to have  viral load > 4log10 copies/mL or 10,000 copies/mL.  
Interestingly, LPS was also inversely associated with measures of body composition, 
therefore being overweight or obese was protective of having higher levels of LPS. 
Timmons et al.47 did not show significant association between LPS and body 
composition; however, they did report relationship with sCD14.  Soluble CD14 is a 
measure of microbial translocation, which is freed from monocytes by LPS stimulation.48 
There was an inverse association between sCD14 and limb and trunk fat in 178 HIV+ 
adults that included ART treated and non-treated patients.  The authors suggest that 
microbial translocation may be involved in muscle and fat loss during HIV disease. 
Unfortunately, the result could not be separated from the effect of ART treatment since 
the analyses included both ART treated and non-treated.  In animals, it has been 
demonstrated that the quality of diet, rather than weight, was a better predictor of the 
composition of intestinal bacteria.49 A high fat diet has been shown to be associated with 
higher LPS levels.50 Diet composition of those with a higher BMI may have affected 
inflammation and should be researched further.   
A possible explanation for the lower levels of LPS observed in those with higher 
BMI might be the endotoxin lipoprotein hypothesis. Rauchhaus et al.29 were the first to 
describe the endotoxin-lipoprotein hypothesis as a way to explain the paradox of higher 
cholesterol levels being beneficial in congestive heart failure.  Higher circulating 
lipoproteins may modulate inflammation by binding to lipopolyssachrides and reduce 
their effect on release of proinflammatory cytokines.  LPS is sequestered during micelle 
creation under the direction of lipoproteins.  Since higher BMI is associated with higher 
risk of elevated cholesterol, triglycerides and LDL,51,52 more circulating lipoproteins may 
be available to capture LPS.  
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 The limitations of our study include the study design, which was retrospective 
and observational.  A larger sample size may have also showed significant relationships 
between inflammatory markers and disease progression.   A selection bias may also 
have been present since we chose to complete leptin and LPS in a random subset that 
had samples available at baseline and 18 months. In HIV, bioimpedance (BIA) has been 
shown to be an effective method for detecting fat mass;53 however, BIA has limitations, 
since its values can be influenced by body arrangement, hydration, ingestion of food and 
drinks, air and body temperature and exercise.54  Our BIA measurement protocol 
countered these limitations by giving detailed instructions to the participants on their 
preparation for their visit, and standardizing the measurement parameters. 
Conclusions 
 Body composition and HIV disease progression affected inflammation in this 
HIV+ adult population in Botswana, early in their disease.  Laboratory markers of HIV 
infection and disease progression was predictive of inflammation, independent of body 
fat.  Higher LPS was associated with lower BMI and higher viral load, while higher leptin 
was associated with higher fat mass and lower viral load. These are new and thought-
provoking findings that might help explain the obesity paradox often observed in HIV+ 
ART adults. The mechanisms affecting HIV disease progression through inflammation 
are complex and still not entirely understood, which warrants further prospective 
investigation before and after initiation of ART.  
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Table 1: General Characteristics of the Sample Population  
Variable Total  
(N=144) 
Age (years) 33.00 (29.00-39.00) 
Gender a 
     Male (%) 
     Female (%) 
 
34 (23.60) 
110 (76.40) 
BMI (kg/m2) 22.70 (20.70-26.93) 
Waist (inches) 32.28 (29.92-35.81) 
Waist to hip ratio .82 (.79-.88) 
Lean mass (%) 71.30 (66.30-76.00) 
Fat mass (%) 28.70 (24.00-33.70) 
CD4 cell count (cells/µL) 409.03 (329.79-552.58) 
CD4 % 26.35 (19.64-31.04) 
CD8 cell count (cells/µL) 844.35 (621.96-1189.17) 
CD8 % 51.70 (43.58-58.30) 
CD4/CD8 Ratio .53 (.36-.68) 
HIV viral load (Log10 copies/mL) 4.33 (3.58-4.83) 
CRP (mg/L) 1.69 (.80-4.74) 
Leptin (pg/mL)b 13,304.75 (5649.13-24,430.50) 
LPS (EU/mL) b .058 (.053, .068) 
aReported as n (%); all other variables reported as median (interquartile range) 
bCompleted in a subset of 60 participants  
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Table 2: Baseline Spearman Correlation Coefficients and P-values   
 
Variables CRP Leptina LPSa 
CRP (mg/L) - r=.404 
p=.010** 
r=-.042 
p=.796 
Leptin (pg/mL) r=.404 
p=.010** 
- r=-.357 
p=.005** 
LPS (EU/mL) r=-.042 
p=.796 
r=-.357 
p=.005** 
- 
BMI (kg/m2) r=.150 
p=.073 
r=.734 
p<.001** 
r=-.288 
p=.025* 
Waist (inches) r=.179 
p=.072 
r=.603 
p<.001** 
r=-.493 
p=.003** 
Waist-to-hip ratio r=.151 
p=.129 
r=-.023 
p=.895 
r=.082 
p=.638 
Lean body mass (%) r=-.154 
p=.066 
r=-.836 
p<.001** 
r=.361 
p=.005** 
Fat mass (%) r=.155 
p=.065 
r=.838 
p<.001** 
r=-.362 
p=.004** 
CD4 cell count (cells/µL) r=-.083 
p=.647 
r=.005 
p=.969 
r=.015 
p=.912 
CD4% r=-.144 
p=.175 
r=-.044 
p=.740 
r=-.134 
p=.308 
CD8 cell count (cells/µL) r=.088 
p=.294 
r=-.090 
p=.496 
r=.157 
p=.232 
CD8% r=.076 
p=.365 
r=-.240 
p=.065 
r=.253 
p=.052 
CD4/CD8 Ratio r=-.104 
p=.216 
r=.096 
p=.464 
r=-.134 
p=.308 
HIV viral load (log10 copies/mL) r=.092 
p=.271 
r=-.145 
p=.273 
r=.246 
p=.060 
aCompleted in a subset of 60 participants 
*P<0.05, **P<0.01 
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Table 3:  Relationship Between BMI Groups and Measures of Inflammatory Markers at 
Baseline* 
 
Inflammatory 
Markers 
BMI (18-24.9 kg/m2) BMI >25kg/m2 P-value 
CRP (mg/L)a 1.41 (.70-4.15) 2.37 (1.20-5.89) .028c 
Leptin (pg/mL) b 5,687.05 (2,799.63-
11,366.73) 
22,894.90 (14,147.43-
33,943.33) 
<.001c 
LPS (EU/mL)b .068 (.061-.079) .055 (.053-.058) .001c 
*Data reported as median (interquartile range) 
aBMI group; BMI (18-24.9 kg/m2) included 95 participants and BMI group >25kg/m2 
included 49 
bBMI group; BMI (18-24.9 kg/m2) included 30 participants and BMI group >25kg/m2 
included 30 
cStatistically significant, P<.05 
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Table 4:  Relationship Between CRP Groups and Body Composition and Measures of 
Inflammatory Markers at Baseline* 
 
Variables  CRP<3 mg/L CRP ≥3 mg/L P-value 
BMI (kg/m2) 22.40 (20.50-25.90)  24.40 (20.70-28.95) .094 
Waist (inches) 31.79 (29.92-34.44) 33.86 (30.71-38.29) .036a 
Waist to hip ratio .81 (.78-.88) .83 (.80-.89) .139 
Lean mass (%) 71.70 (67.20-75.90) 69.25 (64.25-79.53) .254 
Fat mass (%) 28.30 (24.10-32.80) 30.75 (20.48-35.78) .248 
CD4 cell count 
(cells/µL) 
419.05 (332.48-553.63) 401.30 (323.92-555.39) .591 
CD4 % 27.56 (22.02-31.56) 22.95 (18.42-29.85) .013a 
CD8 cell count 
(cells/µL) 
773.28 (586.65-1163.89) 925.36 (712.48-
1213.74) 
.030a 
CD8 % 48.98 (42.91-57.64) 54.67 (44.68-61.18) .078 
CD4/CD8 Ratio .56 (.39-.71) .41 (.29-.62) .015a 
HIV viral load 
(Log10 copies/mL) 
4.14 (3.47-4.82) 
 
4.57 (3.66-5.08) .141 
*Data reported as median (interquartile range) 
aStatistically significant, P<.05 
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Table 5:  Relationship Between Median Groups of Leptin and Body Composition and 
Measures of Inflammatory Markers at Baseline* 
 
Variables  Leptin<13,304 pg/mL Leptin ≥13,304 pg/mL P-value 
BMI (kg/m2) 21.30 (20.00-23.60) 27.10 (25.60-31.10) <.001a 
Waist (inches) 30.51 (29.82-35.04) 36.24 (32.87-38.39) .003a 
Waist to hip ratio .83 (.79-.90) 35.24 (32.87-38.39) .804 
Lean mass (%) 75.50 (69.85-80.40) 64.40 (62.40-66.00) <.001a 
Fat mass (%) 24.50 (19.60-29.75) 35.60 (32.00-37.60) <.001a 
CD4 cell count 
(cells/µL) 
394.41 (318.82-478.95) 393.17 (316.36-543.87) .842 
CD4 % 24.74 (19.22-28.60) 23.60 (18.92-30.04) .988 
CD8 cell count 
(cells/µL) 
941.90 (677.67-1255.15) 889.52 (693.89-1271.36) .912 
CD8 % 54.75 (47.93-61.33) 48.37 (41.06-61.06) .108 
CD4/CD8 Ratio .44 (.32-.57) .47 (.30-.75) .589 
HIV viral load 
(Log10 copies/mL) 
4.31 (3.64-4.87) 4.06 (3.50-4.60) .275 
*Data reported as median (interquartile range) 
aStatistically significant, P<.05  
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Table 6:  Relationship Between Median Groups of LPS and Body Composition and 
Measures of Inflammatory Markers at Baseline* 
 
Variables  LPS<.0582 EU/mL LPS ≥.0582 EU/mL P-value 
BMI (kg/m2) 26.70 (25.05-31.15) 22.40 (20.70-25.00) .001a 
Waist (inches) 36.32 (34.35-39.37) 31.50 (29.92-35.42) .005a 
Waist to hip ratio .80 (.79-.87) .82 (.78-.90) .748 
Lean mass (%) 64.70 (62.55-70.08) 71.90 (67.03-80.03) .002a 
Fat mass (%) 35.30 (29.93-37.45) 28.10 (19.98-32.98) .002a 
CD4 cell count 
(cells/µL) 
424.03 (336.23-545.24) 392.09 (311.12-459.95) .301 
CD4 % 24.14 (19.16-30.34) 23.75 (18.49-28.42) .433 
CD8 cell count 
(cells/µL) 
848.30 (688.51-1276.73) 961.51 (685.78-
1253.53) 
.412 
CD8 % 48.13 (42.73-59.26) 54.81 (47.65-62.10) .089 
CD4/CD8 Ratio .53 (.32-.67) .44 (.31-.61) .375 
HIV viral load 
(Log10 copies/mL) 
3.93 (3.15-4.46) 4.36 (3.92-4.82) .023a 
*Data reported as median (interquartile range) 
aStatistically significant, P<.05 
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Table 7: Linear Regression at Baseline, 18 Months and the Change Over 18 Months by CRP* 
 Baseline 18 Months Change Over 18 Months 
Variable β 95% CI P-value β 95% CI P-value β 95% CI P-value 
BMIb 1.905 .281, 3.530 .022d .646 -1.839, 3.131 .603 .949 -2.579, 4.477 .983 
BMI > 25 kg/m2 .398 -.143, 939 .148 .665 -.353, 1.683 .195 - - - 
Fat mass%a .020 -.009, .050 .177 .010 -.043, .062 .709 .014 -.030, .057 .536 
Waistb -.175 -2.316, 1.965 .871 2.491 -1.108, 6.090 .170 1.736 -.145, 3.617 .070 
CD4 cell countc -.002 -.057, .053 .947 .016 -.078, .111 .730 -.027 -.114, .060 .536 
CD4% -.013 -.041, .015 .368 -.016 -.066, .034 .520 .035 -.024, .093 .243 
HIV viral loadb .084 -.151, .320 .480 .296 -.165, .756 .203 .103 -.226, .432 .620 
HIV viral load         
≥ 4log10 copies/mL 
.091 -.342, .523 .679 .709 -.111, 1.529 .089 - - - 
CD8 cell countc .008 -.019, .034 .565 .025 -.027, .077 .335 -.037 -.085, .012 .137 
CD8% .004 -.017, .024 .709 .008 -.029, .046 .650 -.046 -.098, .006 .085 
CD4/CD8 Ratio -.169 -.952, .613 .669 -.581 -2.080, .917 .438 .737 -1.214, 2.688 .455 
*Models adjusted for age, gender, smoking, and fat mass percentage 
aModel adjusted for age, gender, and smoking 
bLog transformed 
cSquare root transformed 
dStatistically significant, P<.05 
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Table 8: Linear Regression at Baseline, 18 Months, and the Change Over 18 Months by Leptin* 
 Baseline 18 Months Change Over 18 Months 
Variable β 95% CI P-value β 95% CI P-value β 95% CI P-value
BMIb 1.764 .788, 2.739 .001d 2.104 1.133, 3.075 <.001d .493 -1.463, 2.450 .615 
BMI > 25 kg/m2 .584 .260, .908 .001d .864 .498, 1.230 <.001d - - - 
Fat mass%a .112 .090, .135 <.001d .043 .017, .069 .002d -.016 -.057, .025 .437 
Waistb .394 -1.546, 2.333 .681 2.103 .806, 3.400 .002d .247 -1.073, 1.567 .704 
CD4 cell countc .027 -.010, .065 .151 -.016 -.062, .030 .495 .026 -.036, .089 .402 
CD4% .006 -.014, .026 .551 -.003 -.028, .022 .816 .020 -.010, .049 .194 
HIV viral loadb -.145 -.311, .022 .087 -.129 -.335, .078 .217 .107 -.177, .331 .344 
HIV viral load       
≥ 4log10 copies/mL 
-.305 -.579, -.031 .030d -.173 -.541, .194 .348 - - - 
CD8 cell countc .005 -.014, .024 .599 -.008 -.031, .014 .459 -.010 -.040, .019 .493 
CD8% -.002 -.015, .010 .685 .001 -.017, .017 .990 -.019 -.044, .006 .140 
CD4/CD8 Ratio .156 -.429, .740 .595 -.117 -.950, .716 .780 .509 -.451, 1.470 .292 
*Models adjusted for age, gender, smoking, and fat mass percentage 
aModel adjusted for age, gender, and smoking 
bLog transformed 
cSquare root transformed 
dStatistically significant, P<.05 
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Table 9: Linear Regression at Baseline, 18 Months, and the Change Over 18 Months by LPS* 
 Baseline 18 Months           Change Over 18 Months 
Variable β 95% CI P-value β 95% CI P-value β 95% CI P-value 
BMIb -.483 -1.208, .243 .188 -.023 -.399. .354 .904 -2.979 -1.771, .822 .466 
BMI < 25 kg/m2 -.273 -.506, -.040 .022d -.017 -.160, .127 .818 - - - 
Fat mass%a .001 -.014, .016 .892 .001 -.008, .009 .950 .004 -.013, .020 .673 
Waistb -1.940 -3.397, -.483 .011d -.005 -.477, .467 .982 .051 -1.088, 1.190 .927 
CD4 cell countc .009 -.017, .034 .509 -.004 -.019, .011 .569 .003 -.038, .045 .876 
CD4% .003 -.011, .017 .648 -.006 -.014, .002 .165 -.010 -.030, .010 .319 
HIV viral loadb .054 -.059, .168 .337 .047 -.020, .113 .168 .012 -.135, .159 .869 
HIV viral load       
≥ 4log10 copies/mL 
.121 -.067, .309 .201 .064 -.056, .183 .289 - - - 
CD8 cell countc .003 -.010, .016 .660 .004 -.003, .011 .290 .006 -.013, .026 .512 
CD8% .003 -.005, .011 .432 .001 -.004, .007 .643 -.002 -.019, .015 .809 
CD4/CD8 Ratio .019 -.377, .415 .924 -.193 -.458, .072 .150 -.115 -.757, .526 .719 
*Models adjusted for age, gender, smoking, and fat mass percentage 
aModel adjusted for age, gender, and smoking 
bLog transformed 
cSquare root transformed 
dStatitically significant, P<.05 
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Table 10:  Logistic Regression at Baseline, 18 Months, and Change Over 18 Months by CRP Groups (< and ≥ 3 mg/L)* 
 Baseline 18 Months Change Over 18 Months 
Variable OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value 
BMIb 60.960 2.784, 
1334.723 
.009d 8.685 .550, 137.236 .125 1.012 .002, 213.705 .599 
BMI ≥ 25 
kg/m2 
2.407 .941, 6.156 .067 1.719 .623, 4.746 .296 - - - 
Fat mass%a 1.023 .973, 1.076 .366 1.010 .960, 1.063 .697 1.006 .935, 1.083 .868 
Waistb .223 .006, 7.968 .411 98.811 1.697, 
5755.086 
.027d 65.078 1.490, 
2842.157 
.030d 
CD4 cell 
countc 
.971 .881, 1.071 .560 .976 .874, 1.090 .976 .909 .786, 1.052 .201 
CD4% .949 .902, .998 .042d .990 .937, 1.047 .732 1.066 .965, 1.179 .209 
HIV viral 
loadb 
1.289 .851, 1.951 .231 1.231 .785, 1.999 .400 1.100 .630  
HIV viral load  
≥ 4log10 
copies/mL 
1.568 .732, 3.359 .247 1.681 
 
.652, 4.334 .282 - - - 
CD8 cell 
countc 
1.030 .984, 1.078 .207 .993 .935, 1.054 .811 .906 .831, .988 .025d 
CD8% 1.023 .988, 1.060 .203 1.010 .970, 1.052 .633 .933 .852, 1.022 .137 
CD4/CD8 
Ratio 
.292 .063, 1.363 .117 .621 .102, 3.787 .605 3.544 .142, 88.638 .441 
*Models adjusted for age, gender, smoking, and fat mass percentage 
aModel adjusted for age, gender, and smoking 
bLog transformed 
cSquare root transformed 
dStatistically significant, P<.05
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Table 11:  Logistic Regression at Baseline, 18 Months, and the Change Over 18 Months by Leptin Groups (< and ≥ Median)* 
 Baseline 18 Months Change Over 18 Months 
Variable OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value 
BMI 2.073 1.194, 3.601 .010d 1.554 1.125, 
2.146 
.008d 1.438 .819, 2.524 .206 
BMI ≥ 25 
kg/m2 
58.572 2.187, 
1568.688 
.015d 79.634 4.607, 
1376.659 
.003d - - - 
Fat mass%a 1.580 1.214, 2.055 .001d 1.231 1.070, 
1.416 
.004d .985 .887, 1.093 .775 
Waist <.001 <.001,<.001 .998 1.267 1.016, 
1.580 
.036d .967 .000, - 1.000 
CD4 cell 
countb 
1.074 .833, 1.385 .581 1.168 .864, 1.581 .313 1.279 .837, 1.956 .256 
CD4% 1.022 .902, 1.157 .737 1.110 .971, 1.270 .127 1.456 1.025, 2.069 .036d 
HIV viral loadc .654 .231, 1.850 .424 .615 .209, 1.812 .378 .855 .186, 3.928 .840 
HIV viral load   
≥ 4log10 
copies/mL 
.308 .039, 2.408 .261 .180 .018, 1.816 .146 - - - 
CD8 cell 
countb 
1.013 .878, 1.169 .861 .960 .848, 1.088 .522 .872 .698, 1.089 .228 
CD8% .982 .913, 1.057 .628 .961 .886, 1.042 .338 .867 .709, 1.061 .165 
CD4/CD8 
Ratio 
5.405 .124, 
235.292 
.381 73.701 .393, 
13808.169 
.107 133.567 .116, 
154108.571 
.174 
*Models adjusted for age, smoking, and fat mass percentage 
aModel adjusted for age and smoking 
bSquare root transformed 
cLog transformed 
dStatistically significant, P<.05
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Table 12:  Logistic Regression at Baseline, 18 Months, and the Change Over 18 Months by LPS Groups (< and ≥ Median)* 
 Baseline 18 Months Change Over 18 Months 
Variable OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value 
BMI .790 .630, .990 .041d .799 .655, .976 .028d .875 .603, 1.270 .482 
BMI ≥ 25 
kg/m2 
.035 .004, .283 .002d .321 .076, 1.351 .121 - - - 
Fat mass%a .852 .757, .958 .007d .932 .854, 1.017 .113 1.046 .944, 1.158 .391 
Waist .727 .446, 1.187 .203 .907 .778, 1.056 .209 .795 .555, 1.140 .212 
CD4 cell 
countb 
.915 .763, 1.098 .339 .915 .763, 1.098 .339 1.092 .825, 1.444 .538 
CD4% .971 .888, 1.061 .971 .942 .861, 1.029 .185 .905 .784, 1.045 .173 
HIV viral loadc 2.608 1.111, 6.124 .028d 1.691 .782, 3.656 .182 .637 .247, 1.638 .349 
HIV viral load   
≥ 4log10 
copies/mL 
8.005 1.762, 
36.357 
.007d 3.776 .959, 14.869 .057 - - - 
CD8 cell 
countb 
1.003 .925, 1.087 .941 1.038 .956, 1.126 .376 1.124 .982, 1.266 .089 
CD8% 1.025 .972, 1.081 .362 1.038 .977, 1.103 .228 1.061 .941, 1.197 .330 
CD4/CD8 
Ratio 
.630 .051, 7.857 .720 .120 .005, 2.860 .190 .032 .000, 3.912 .161 
*Models adjusted for age, gender, smoking, and fat mass percentage 
aModel adjusted for age, gender, and smoking 
bSquare root transformed 
cLog transformed 
dStatistically significant, P<.05 
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CHAPTER VI:  SUMMARY AND CONCLUSIONS 
This study investigated the obesity paradox in HIV+ ART naïve adults who were 
in early stage of HIV disease in Botswana.  The impact of obesity on HIV disease 
progression over time was explored.  An obesity paradox has been documented in many 
conditions including HIV, where those who are obese may have a survival advantage or 
improved disease outcomes.1  The genetic propensity for being overweight or obese was 
examined using SNPs of the FTO gene, which is reported to be most associated with 
BMI, and its association to HIV disease progression.  In addition, inflammatory markers 
and their relationship to body composition and HIV disease progression were 
investigated.   
Studies on HIV and obesity are mainly conducted in settings where the patients 
are treated with ART, which may confound some of the findings and interpretations, as 
ART has been associated with lipodystrophy and obesity.2  Rising rates of obesity have 
been documented in countries with limited resources;3 however, studies conducted in 
African settings on the relationship between HIV and obesity are lacking. Studies 
conducted to investigate obesity and its effect on HIV disease progression have so far 
been inconclusive, with some studies reporting an association and others reporting no 
association between CD4 cell counts and obesity.1, 4-7  Studies on the relationship 
between BMI and body composition on HIV disease progression are needed to reveal 
possible mechanisms for the obesity paradox in HIV.  The examination of such 
interrelationships is important for translation of results into clinically relevant 
recommendations for people living with HIV.   
Our results demonstrated a protective effect of BMI and fat mass in delaying the 
time to the first AIDS defining condition in HIV+ ART naïve adults in Botswana during 18 
months of follow-up. Higher BMI was also associated with a higher CD4%, another 
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marker of HIV disease progression over 18 months.  In addition, higher fat mass was 
also associated with the combined outcome of CD4 cell count ≤ 250/μL and AIDS 
defining conditions.  Survival analysis showed a positive trend with the outcome of a 
decline in the CD4 cell count of 25% or greater and association with fat mass and 
negative association with lean body mass.   Findings from these analyses indicate that 
higher fat may provide protection from advanced HIV disease. The fat stores would have 
provided the extra energy needed to maintain the innate immune system responding to 
protect against opportunistic infections and delaying wasting.  Extra available energy for 
use in times of emergency during the HIV disease may reduce the use of protein for 
energy8 and also assist to conserve the immune system, especially the innate immunity 
that is not directly affected by the infection.9,10   
This study provides preliminary data on the genetic association between FTO 
SNPs on the genetic risk of being overweight/obese and HIV disease progression in 
HIV+ adults in Botswana.  There were no significant findings between the FTO SNPs 
and markers of HIV disease progression; however, a trend between the risk allele for 
rs8050136 was protective of having higher HIV viral load.  The variant rs17817449 had a 
significant association with BMI, showing a greater odds of having higher BMI when the 
risk allele was present.  The risk alleles for rs1121980, rs8050136, and rs17817449 
were associated with fat mass and lean mass. A higher percentage of fat mass and 
lower lean body mass were associated with these risk alleles compared to homozygosity 
for the non-risk allele.  Although the exact mechanism for the effect of FTO on weight is 
unknown, it is hypothesized that it may affect food intake and energy expenditure.11 FTO 
is highly expressed in the hypothalamus region of the brain, where food intake is 
controlled.12,13  The FTO still remains the gene most consistently associated with obesity 
in various populations,14 but its associations have not been replicated in many African 
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populations.  GWAS studies in African populations are lacking, and identifying SNPs that 
are relevant to this population is of importance since the SNPs showing associations in 
European and Asian populations may be different from SNPs that will show associations 
in African populations.   
The relationship of inflammatory markers such as C-reactive protein, leptin, and 
bacterial endotoxin lipopolysaccharide (LPS) with body composition and HIV disease 
progression in HIV+ asymptomatic adults not on ART in Botswana over 18 months was 
also evaluated.  To our knowledge, no study has assessed leptin or LPS in a population 
from Botswana with or without HIV infection. The results from this study suggest a strong 
association of inflammation markers with body composition and HIV disease progression 
in ART naïve adult participants in Botswana.  Higher levels of inflammation as measured 
was associated with a more progressed state of the disease.  The relationships were 
found to be independent of body fat.  Our findings support the hypotheses in the 
literature that high viral replication and immune activation could result in chronic 
inflammation that would cause lipoatrophy, therefore, lowering leptin levels.15 LPS levels 
above the median were associated with higher viral load and those with LPS levels ≥ the 
median were 8 times more likely to have viral load > 4log10 copies/mL or 10,000 
copies/mL.  In addition, LPS was also inversely associated with measures of body 
composition, therefore being overweight or obese was protective of having higher levels 
of LPS. The endotoxin lipoprotein hypothesis or theory may provide a possible 
explanation for the lower levels of LPS observed in those with higher BMI.  Higher 
circulating lipoproteins may modulate inflammation by binding to lipopolyssachrides and 
reduce their effect on release of proinflammatory cytokines.16   
Current study demonstrated that an obesity paradox may be present in early HIV 
infection. We investigated and suggest several mechanisms for this paradox.  Fat 
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accumulation was found to be protective against further HIV disease progression in HIV+ 
adults who were early in the disease state and ART naïve.  Higher levels of leptin and 
lower levels of LPS were associated with being overweight/obese and higher amounts of 
body fat mass percentage.  Concurrently, lower leptin and higher LPS levels had 
significant relationships to higher HIV viral load, a marker of HIV disease progression.  
Additionally, a trend association was demonstrated with one of the FTO SNPs and HIV 
viral load.  The risk allele was associated with lower HIV viral load, therefore having a 
protective effect.  Establishment of mechanisms for this paradox are needed in order to 
allow for translation of results into meaningful clinical recommendations and care 
guidelines for resource limited settings.  
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Table 1: Study Hypotheses and Results 
Hypothesis # Hypothesis Study Results 
1a (Primary outcome) The overweight/obese group will 
present less clinically significant CD4 cell count 
decline from Baseline (≥ 25%) over 18 months than 
the normal weight group. 
There were no significant differences between BMI 
groups in the main outcome ≥ 25% decline in CD4 cell 
count over 18 months (HR= .744; 95% CI= .489, 1.131; 
P=.166) after controlling for age, gender, marital status 
children (yes/no), baseline CD4 cell count and baseline 
HIV viral load. 
1b The overweight/obese will have significantly lower 
levels of HIV viral load over 18 months than the 
normal weight group. 
BMI groups at baseline, 18 months and the change 
over 18 months were not statistically associated with 
HIV viral load. 
1c Significantly less AIDS defining conditions will occur 
over 18 months in the overweight/obese group 
compared to the normal weight group. 
There were no significant differences between BMI 
groups in the outcome of AIDS defining conditions 
(HR= .500; 95% CI= .047, 4.465; P=.500) after 
controlling for age, gender, marital status, children 
(yes/no), baseline CD4 cell count and baseline HIV viral 
load. However, continuous BMI was associated with 
AIDS defining conditions (HR=.218, 95% CI=.068, .701, 
P=.011). 
2a The FTO gene SNPs will be associated with being 
overweight/obese. 
The FTO SNP rs17817449 was associated with BMI 
(OR=1.082; 95%CI= 1.001, 1.169; P=.047).   
2b1 The FTO gene SNPs will be associated with 
significantly higher CD4 cell count. 
There were no significant associations with between 
FTO SNPs and CD4 cell count. 
2b2 The FTO gene SNPs will be associated with 
significantly lower HIV viral load. 
None of the FTO SNPs were significantly associated 
with HIV viral load.  However, there was a trend 
towards significance with rs8050136 and HIV viral load 
in a dominant model (OR=.705; 95% CI=.481, 1.035; 
P=.074) after controlling for age, gender, tribes, total 
dietary kcal, and activity. 
2b3 The FTO gene SNPs will be associated with 
significantly less AIDS-defining conditions. 
There were no significant associations between FTO 
SNPs and AIDS-defining conditions. 
3a1 Higher levels of inflammatory markers will be There were no significant associations with between 
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associated with lower levels of CD4 cell count. inflammatory markers and CD4 cell count. 
3a2 Higher levels of inflammatory markers will be 
associated with higher HIV viral load. 
Leptin was associated with HIV viral load >4 log10 
copies/mL (OR=-.305; 95%CI=-.579, -.031; P=.030) at 
baseline.  LPS above the median was associated with 
HIV viral load (OR=2.608, 95% CI=1.111, 6.124, 
P=.028) and HIV viral load >4 log10 copies/mL (OR=-
8.005; 95%CI= 1.762, 36.357; P=.007) at baseline and 
HIV viral load >4 log10 copies/mL (OR=-3.776; 95%CI= 
.959, 14.869; P=.057) at 18 months. 
3a3 Higher levels of inflammatory markers will be 
associated with greater AIDS-defining conditions.   
There were no significant associations with between 
inflammatory markers and AIDS-defining conditions. 
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CHAPTER VII:  STRENGTHS AND LIMITATIONS 
The results from this study could be translated into clinically relevant nutrition and 
care recommendations for HIV+ adults who are antiretroviral (ART) naïve in limited 
resource settings. This is the first study to examine the effect of the genetic propensity to 
become overweight/obese and inflammatory markers on HIV disease progression in an 
HIV+ population in Botswana early in their disease.  Both inflammatory markers, leptin 
and LPS, have not previously been investigated in Botswana, with or without HIV. 
Additionally, the FTO gene has never been genotyped in an HIV -infected population 
and its association to HIV disease progression examined.   
The strengths of this study consists of capturing and analyzing longitudinal data 
from HIV+ participants in Botswana, that was collected from the early asymptomatic 
stage through later stages with well-defined health outcomes.  This type of information is 
lacking in African populations.  Considering that most of the HIV+ cases are within sub 
Saharan Africa,1 more research in this area is warranted.  This was also the first known 
study to assess the role of FTO in the obesity paradox that often occurs in HIV+ adults.  
Trends were noted in the relationship of some of the FTO SNPs with markers of HIV 
disease progression, which may suggest a role in the obesity paradox and needs further 
investigation in a larger cohort with adequate sample size.    
Sample Size 
The limitations of this study may have contributed to some of the null findings 
observed.  The sample size was insufficient to be able to examine differences between 
overweight and obese groups separately. A larger sample size would have allowed for 
the examination of the relationship of the FTO SNPs and body mass in further stratified 
subgroups of overweight and obese separately. BMI in the range of underweight 
category was not studied since underweight individuals were excluded from participation 
 152 
 
in the parent study, as those ranges are strong prognostic of AIDS.2 Inadequate sample 
size may have also contributed to find non-significant associations between 
inflammatory markers and CD4 cell count.  In addition, there was a predominance of 
women among the participants. Botswana is known to be a heterogeneous population 
with many ethnic groups.3 The heterogeneity present in this population may also be a 
limitation for this study.  
Study Design 
Study limitations also include a weaker study design, which was retrospective 
and observational.  The exact time since HIV diagnosis or infection were not available; 
however, it was known that the participants were asymptomatic, never had a diagnosis 
of AIDS and did not qualify for ART. The majority were referred from the clinics where 
they were diagnosed. This HIV population was in the early stage of the disease and its 
finding cannot be generalized to all HIV patients, and may be one of the reasons why we 
did not see a significant decline of CD4 as a main outcome. Findings from this study 
cannot be generalized to other HIV+ populations, including ART-treated patients, but 
may be used in resource limited settings were ART is being slowly rolled out.  
Methods 
In HIV, bioimpedance (BIA) has been shown to be an effective method for 
detecting fat mass; however, BIA have limitations, since its values can be influenced by 
body arrangement, hydration, ingestion of food and drinks, air and body temperature and 
exercise.4 Our BIA measurement protocol minimized the potential for variability by 
providing detailed instructions to the participants on their preparation for their visit, and 
standardizing the measurement parameters.  
Selection bias may have contributed to null findings since we chose to complete 
leptin and LPS in a subset that had samples available at baseline and 18 months. 
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Participants who had both samples were those who maintained their CD4 cell counts 
above the cut-off for eligibility for ART and were still followed by the parent study. 
Therefore, those excluded may have been rapid progressors, with different genetic 
makeup.  Interestingly, despite these limitations, we had findings with CD4% and CRP 
and leptin and LPS with viral load.  
LPS measured by the Limulus amebocyte lysate (LAL) method is the most widely 
used method; however, it may be affected by inhibition or interference of other 
compounds.5 To prevent interference, dilution and heating methods were incorporated 
into the LPS assay methodology for this study.  The LAL method for measuring LPS is 
currently only recommended for research purposes and not for a clinical setting.   
The obesity paradox is present in the literature in a variety of diseases that 
include HIV.6   Controversies exist on both sides of the dispute on whether this paradox 
is real, a query that has implications for HIV management and public health efforts.  
Equipoise in the literature regarding obesity paradoxes should drive the need for more 
research to provide the appropriate care and advice for patients.  The results from this 
study may be used as preliminary data for future research in this topic.   
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CHAPTER VIII:  FUTURE RESEARCH 
 The results from this study demonstrated that fat may provide protection against 
further HIV disease progression in HIV+ adults who are early in the disease and ART 
naïve.  Higher levels of leptin and lower levels of LPS were associated with being 
overweight/obese and higher amounts of body fat mass percentage.  At the same time, 
higher leptin and lower LPS levels had significant relationships to higher HIV viral load, a 
marker of HIV disease progression.  There was a trend association with one of the FTO 
SNPs and HIV viral load.  However, genetic association studies generally require large 
sample sizes.1 It seems there is an obesity paradox present in the HIV+ ART naïve 
cohort we investigated.  An obesity paradox is present in several diseases and 
conditions2 and mechanistic studies are needed in this area of obesity and HIV to 
establish the nature and cause for this paradox in order to develop clinical 
recommendations. The preliminary results from the analyses conducted with FTO SNPs, 
inflammatory markers, and measures of HIV disease progression will be useful to 
calculate sample size for future studies.  Further examination of the mechanisms and 
best approaches for translation of findings into recommendations into care of people 
living with HIV are needed.  
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